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Abstract 
 
 
Peripheral nerve injury commonly results in loss of neuromuscular function, often resulting 
in significant impact upon both quality of life and cost of care for patients. One promising target 
for improving patient outcomes is the use of a peripheral nerve specific extracellular matrix 
hydrogel (PNM) as an injectable, regenerative support. It has been long understood that the 
extracellular matrix (ECM) not only provides structural support but also regulates cell growth, 
survival, maturation, differentiation, and development of resident cells. The objective of this 
dissertation was to develop and characterize a decellularized peripheral nerve hydrogel, investigate 
its effect on key properties of peripheral nerve regeneration, and finally assess its ability to enhance 
return to function in several peripheral nerve injury models. We found that PNM provides a tissue-
specific microenvironment which is conducive to nerve repair, including: nerve specific growth 
factors that are chemotactic signals for Schwann cells, promote neurite outgrowth, as well as 
factors that modulate the macrophage inflammatory response to injury. When employed as a lumen 
filler for conduit repair of peripheral nerve defects, a switch in the ratio of M1:M2 phenotype 
macrophages was observed, a phenomenon associated with improved nerve growth and promotion 
of Schwann cell migration across a gap defect. This was associated with improved function over 
time in non-critical common peroneal and sciatic nerve defects. Furthermore, we provided proof-
of-concept for the use of PNM in treating nerve crush injuries. The injection of the PNM hydrogel 
directly into the nerve injury was found to be safe with no impact on downstream function. The 
Development of a Peripheral Nerve Specific Extracellular Matrix-based Hydrogel and 
its Use in Augmenting Peripheral Nerve Injury and Repair 
Travis A Prest, Ph.D. 
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application of PNM to the crush injury resulted in enhanced return to function and a more robust 
axon regrowth across the injury.  
In conclusion, we developed an injectable material that provides a regeneration promoting, 
tissue-specific microenvironment at the site of injury. The material has shown the ability to 
promotes recruitment of alternately activated, M2 macrophages, enhance Schwann cell migration, 
and axon extension. Finally, the use of PNM has enhanced recovery and return to function in 
numerous peripheral nerve injury models. PNM shows promise in augmenting current surgical 
practices for peripheral nerve injury and repair and has the potential to significantly improve 
quality of life for affected patients. 
 
 vi 
Table of Contents 
 
1.0 Introduction ...................................................................................................................1 
1.1 Peripheral Nervous System ..........................................................................1 
1.1.1 Anatomy and Physiology ..............................................................................1 
1.1.2 Peripheral Nerve Injury ...............................................................................5 
1.2 Clinical Repair of Nerve Injuries and Current Research ......................... 10 
1.2.1 Significance ................................................................................................. 10 
1.2.2 Clinical Approaches .................................................................................... 11 
1.2.3 Current Research ........................................................................................ 17 
1.3 Extracellular Matrix .................................................................................. 20 
1.4 ECM Scaffolds in Soft Tissue Repair ........................................................ 21 
1.5 Specific Aims of Dissertation ..................................................................... 25 
1.5.1 Specific Aim 1: Characterize a PNM Hydrogel and Determine if PNM 
Hydrogels Provide a Preferred Microenvironment for Peripheral Nerve 
Repair as Compared to Non-Nerve-specific ECM (SIS and UBM) 
Hydrogels. ................................................................................................... 26 
1.5.2 Specific Aim 2: Determine if PNM Generates Enhanced Recovery Via 
Mechanisms Beyond Simple Structural Support by Assessing PNM’s 
Effect on the Regenerative Response in a Peripheral Nerve Defect Injury 
Model .......................................................................................................... 27 
 vii 
1.5.3 Specific Aim 3: Determine the Translational Potential of PNM by 
Investigating Functional Recovery Outcomes After a Critical Length 
Sciatic Nerve Defect Injury. ....................................................................... 28 
2.0 Development and Characterization of a PNM Scaffold and Hydrogel for Peripheral 
Nerve Repair ................................................................................................................ 29 
2.1 Introduction ................................................................................................ 29 
2.2 Methods ...................................................................................................... 44 
2.2.1 Preparation of Peripheral Nerve ECM ...................................................... 44 
2.2.2 Formation of Hydrogel from Enzymatic Degradation Products............... 47 
2.2.3 Confirmation of Decellularization .............................................................. 47 
2.2.4 Assessment of Extracellular Matrix Ultrastructure and Components ..... 48 
2.2.5 Mechanical and Morphologic Aspects of the Resultant Hydrogels........... 50 
2.3 Results ......................................................................................................... 50 
2.3.1 Confirmation of Decellularization .............................................................. 50 
2.3.2 Maintenance of Extracellular Matrix Ultrastructure and Components ... 56 
2.3.3 Canine Sciatic Nerve Decellularization ...................................................... 58 
2.3.4 Maintenance of Extracellular Matrix Ultrastructure and Components ... 65 
2.3.5 Assessment of Mechanical and Morphometric Characteristics of Resultant 
PNM Hydrogel............................................................................................ 65 
2.3.6 Defining Best Practices for Injectable Hydrogel ........................................ 69 
2.4 Discussion ................................................................................................... 72 
3.0 PNM hydrogel Enhances Recovery Through Increase in Axon Extension, Schwann 
Cell Recruitment, and Phenotypic Changes in Macrophages .................................... 76 
 viii 
3.1 Introduction ................................................................................................ 76 
3.2 Methods ...................................................................................................... 80 
3.2.1 Evaluation of Effects of Enzymatic Degradation Products Upon Neurite 
Outgrowth .................................................................................................. 80 
3.2.2 Evaluation of Enzymatic Degradation Products of Porcine PNM Upon 
Schwann Cell Migration ............................................................................ 81 
3.2.3 Assessment of Macrophage Phenotype in Vitro Using a NanoString's 
nCounter Technology ................................................................................. 82 
3.2.4 Assessment of Macrophage Response and Schwann Cell Migration in an 
Animal Model of Sciatic Nerve Defect Injury ........................................... 83 
3.2.5 Immunolabeling and Quantitative Analysis .............................................. 84 
3.3 Results ......................................................................................................... 86 
3.3.1 Bioactivity of Degradation Products .......................................................... 86 
3.3.2 Assessment of Macrophage Phenotype ...................................................... 91 
3.3.3 In Vivo Test of Macrophage and Schwann Cell Response to PNM Hydrogel
 ..................................................................................................................... 93 
3.4 Discussion ................................................................................................... 96 
4.0 PNM Can be Utilized in Both Crush and Nerve Defect Injuries to Increase Axon 
Growth and Functional Recovery ............................................................................... 99 
4.1 Introduction ................................................................................................ 99 
4.2 Methods .................................................................................................... 103 
4.2.1 Pilot Study of Critical-length Gap Defect of Rat Sciatic Nerve Surgical 
Procedure.................................................................................................. 104 
 ix 
4.2.2 Pilot Non-critical Gap Defect of Rat Common Peroneal Nerve Surgical 
Procedure.................................................................................................. 105 
4.2.3 Surgical Model of a 1cm Gap Defect Injury of Rat Sciatic Nerve .......... 105 
4.2.4 Surgical Model of Sciatic Nerve Crush Injury ........................................ 106 
4.2.5 Large Animal Model of Recurrent Laryngeal Nerve Reconstruction .... 108 
4.2.6 Common Peroneal Functional Index and Sciatic Functional Index ....... 111 
4.2.7 Kinematics Collection and Analysis ......................................................... 113 
4.2.8 Nociception Testing with Von Frey Fibers............................................... 116 
4.2.9 Electrophysiologic Analysis of Evoked CMAP ........................................ 116 
4.2.10 Staining of NF200 to Analysis Axon Growth Across Injury ................... 117 
4.2.11 Histologic Analysis of Downstream Muscles ............................................ 118 
4.3 Results ....................................................................................................... 120 
4.3.1 Improvement of Function with a Sciatic Nerve Defect Model ................ 120 
4.3.2 Improvement of Function with a Common Peroneal Defect ................... 122 
4.3.3 Assessment of Functional Recovery in a Rodent Sciatic Nerve Gap Defect 
Model ........................................................................................................ 124 
4.3.4 Assessing Functional Recovery in a Rat Model of Sciatic Nerve Crush . 133 
4.3.5 Electrophysiology of Downstream Muscle ............................................... 140 
4.3.6 Sex Base Variance in Compound Motor Action Potential Measures of 
Recovery ................................................................................................... 142 
4.3.7 Restoration of Nerve Function Following Reconstruction of the RLn in 
Canine Model ........................................................................................... 143 
4.4 Discussion ................................................................................................. 147 
 x 
5.0 PNM Increases the Effectiveness of an Engineered Nerve Guidance Conduit 
Containing Cell-secreted Neurotrophic Factors ....................................................... 157 
5.1 Introduction .............................................................................................. 157 
5.2 Materials and Methods ............................................................................ 159 
5.2.1 Fabrication of Cell-seeded PCL/GelMA Nerve Conduits ....................... 159 
5.2.2 ECM Hydrogel Preparation ..................................................................... 160 
5.2.3 Scaffold Implantation ............................................................................... 160 
5.2.4 Explanation and Immunohistochemical Analysis .................................... 162 
5.2.5 Rat Sciatic Functional Index Testing ....................................................... 162 
5.2.6 Statistical Analysis .................................................................................... 163 
5.2.7 Immunohistochemistry of Nerve Conduit Sections and Analysis ........... 163 
5.3 Results ....................................................................................................... 164 
5.3.1 Multilayered Nanofibrous Nerve Conduits Possess Suitable Physical 
Properties for in Vivo Implantation ......................................................... 164 
5.3.2 Conduits with Wall-encapsulated Cells Improve Peripheral Nerve 
Regeneration ............................................................................................. 166 
5.4 Discussion ................................................................................................. 172 
6.0 Overall Summary and Conclusions .......................................................................... 174 
Appendix A. Abbreviations Used ......................................................................................... 179 
Appendix B. Programing Code ............................................................................................. 181 
B.1 Matlab Code ............................................................................................. 181 
B.1.1 MatLab Code Used to Process SFI from Photographs of Ink Footprint 
Impressions. .............................................................................................. 181 
 xi 
B.1.2 MS Amplitude from CMAP Analysis RMS Amplitude from CMAP 
Analysis ..................................................................................................... 183 
Bibliography .......................................................................................................................... 185 
 
 xii 
List of Tables 
Table 1: Nerve fiber types and properties ....................................................................................4 
Table 2: Partial list of available nerves for autograft repairs ...................................................... 13 
Table 3: Clinically available nerve repair products and alternatives to the nerve autograft ......... 16 
Table 4: Review of current research on lumen fillers for nerve conduits .................................... 18 
Table 5: Partial list of commercially available extracellular matrix-based scaffolds ................... 22 
Table 6: Summary of decellularization agents and techniques ................................................... 31 
Table 7: Partial list of decellularization methods for peripheral nervous system......................... 34 
Table 8: List of antibodies used ................................................................................................. 85 
Table 9: Diagram of Pre-clinical studies and experiments used................................................ 103 
 xiii 
List of Figures 
Figure 1: Relative expected outcome of peripheral nerve injury based on severity of injury ........6 
Figure 2: Depiction of nerve structure and repair. ........................................................................8 
Figure 3: Confirmation of decellularization for an equine sciatic nerve...................................... 51 
Figure 4: Confirmation of decellularization of a canine sciatic nerve ......................................... 53 
Figure 5: Conformation of decellularization of a porcine sciatic nerve....................................... 54 
Figure 6: Composition analysis of equine sciatic nerve .............................................................. 57 
Figure 7: Characterization of remaining content within canine sciatic nerve after decellularization
 ................................................................................................................................ 60 
Figure 8: Structural ECM components of porcine sciatic nerve.................................................. 63 
Figure 9: Bioactive components in porcine PNM ...................................................................... 64 
Figure 10: Mechanical and morphometric properties of canine PNM hydrogel .......................... 67 
Figure 11: Varying salt concentration changes mechanical properties of porcine PNM hydrogel
 ................................................................................................................................ 68 
Figure 12: Porcine PNM hydrogel shows a maximal storage modulus ....................................... 69 
Figure 13: Testing different protocols for in vivo injection of PNM hydrogel into a silicone conduit
 ................................................................................................................................ 71 
Figure 14: PNM digestion products promote neurite outgrowth and can be formed into a stable 
hydrogel .................................................................................................................. 88 
Figure 15: Porcine PNM effect on primary spinal cord neurite outgrowth.................................. 89 
Figure 16: Porcine PNM effect on Schwann cell migration in vitro ........................................... 91 
 xiv 
Figure 17: A nanostring assay for gene expression using mouse bone marrow derived macrophages 
looking at macrophage phenotype promoted by the nerve specific extracellular matrix.
 ................................................................................................................................ 92 
Figure 18: Representative longitudinal sections of regenerative nerve bridge stained for M1 and 
M2 macrophage markers .......................................................................................... 94 
Figure 19: Macrophage recruitment and Schwann cell migration into nerve bridge ................... 95 
Figure 20: Representative surgical images of sciatic nerve defect model ................................. 106 
Figure 21: Representative surgical images of sciatic nerve crush model .................................. 107 
Figure 22: Anatomy of the recurrent laryngeal nerve ............................................................... 109 
Figure 23: SFI measurements in a rat model of sciatic nerve defect injury ............................... 113 
Figure 24: Representative still of kinematic analysis videos from TSE Motorater .................... 115 
Figure 25: Representation of SFI walking track analysis using inked paw prints ...................... 121 
Figure 26: SFI for PNM in a pilot rat critical length sciatic nerve defect .................................. 122 
Figure 27: Common Peroneal Nerve Functional Index (PFI) ................................................... 123 
Figure 28: Functional metrics for a rat model of sciatic nerve defect ....................................... 125 
Figure 29: Assessment of SFI and ankle angle at 4 and 24 weeks ............................................ 127 
Figure 30: Representative compound motor action potential traces of the sciatic nerve measured 
at the tibialis anterior ............................................................................................. 129 
Figure 31: Compound motor action potential of the sciatic nerve at the tibialis anterior muscle
 .............................................................................................................................. 130 
Figure 32: Axon count across sciatic nerve defect injury ......................................................... 132 
Figure 33: Safety of PNM hydrogel injection into nervous tissue ............................................ 134 
Figure 34: Intraneural injection of PNM as a treatment for peripheral nerve injury .................. 136 
 xv 
Figure 35: Axon growth across injury in sciatic nerve crush injury .......................................... 138 
Figure 36: Atrophy of gastrocnemius muscle after sciatic nerve crush injury ........................... 139 
Figure 37: Electrophysiology of tibialus anterior muscle after sciatic nerve crush injury ......... 141 
Figure 38: Sex base variance in compound motor action potential measures of recovery ......... 143 
Figure 39: Functional recovery of RLn in a canine model........................................................ 146 
Figure 40: Equations for calculating Sciatic Functional Index ................................................. 148 
Figure 41: Diagram of groups used to test engineered conduit with PNM as lumen filler ......... 161 
Figure 42: Implant and explant of nerve conduits .................................................................... 165 
Figure 43: Masson Trichrome staining of 6 week nerve conduit explants. (Top, Bottom) ........ 168 
Figure 44: Combination of centrally located wall-encapsulated ASCs and PNM improve functional 
return ..................................................................................................................... 169 
Figure 45: Conduits with centrally located wall-encapsulated ASCs improve axon myelination
 .............................................................................................................................. 171 
Figure 46: Graphical abstract of the use of PNM in augmenting peripheral nerve injury response
 .............................................................................................................................. 175
  1 
1.0  Introduction 
1.1 Peripheral Nervous System 
1.1.1 Anatomy and Physiology 
The peripheral nervous system encompasses all nerves outside of the central nervous 
system (CNS), including cranial nerves, spinal roots, and all other nerves of the extremities. The 
peripheral nervous system contains three types of cells: neuronal cells, glial cells, and stromal 
cells. The peripheral nervous system is also comprised of a combination of motor, sensory and 
autonomic neurons. Efferent neurons (motor and autonomic) deliver signals from the CNS to 
effectors, such as the musculature. Afferent neurons (sensory) relay sensory information back to 
the brain or interneurons in the spinal cord, generating a reflex response [1, 2]. 
The sensory division of the peripheral nervous system is made up of specialized sensory 
receptors that collect a variety of stimuli information and relay it back to central nervous system. 
Sensory neurons are made up of a receptor, an axon back to the cell body that resides in the dorsal 
ganglia of the spinal cord, and an axon that communicates the signal to the CNS. Sensory receptors 
can be classified by the type of stimulus, their location in the body and their structural complexity. 
Classifications for receptors based on stimulus type include mechanoreceptors, thermoreceptors, 
photoreceptors, chemoreceptors, and nociceptors (pain receptors). Three receptor classes are 
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recognized according to either their location or the location of the activating stimulus: 
exteroceptors (external stimuli), interoceptors (internal stimuli), proprioceptors (internal stimuli 
on body movement.)  Sensory receptors can also be divided by structure broadly into 
unencapsulated (free nerve endings, Merkel discs, hair follicle receptors) and encapsulated 
(Meissner’s and Pacinian corpuscles, Ruffini endings, muscle spindles, Golgi tendon organs, and 
joint kinesthetic receptor) [1, 2]. 
Somatic motor neurons originate in the central nervous system and project their axons to 
skeletal muscles. Three types of motor neurons exist: alpha (α), beta (β), and gamma (γ) neurons. 
Alpha neurons stimulate skeletal muscle to cause contraction and movement. Beta and gamma 
neurons have supporting roles of adjusting the sensitivity of muscle spindles, a specialized sensory 
receptor in muscles that allow for the detection of proprioception and limb movement speed. The 
autonomic nervous system unconsciously controls internal systems such as heart rate, digest ion, 
respiratory rate, pupillary response, among others [1, 2]. 
Nerve tissue is highly responsive to stimuli. When adequately stimulated, an action 
potential is generated, an electrical impulse that is conducted along the length of its axon. This is 
either a sensory response generated by a receptor or a motor response from the CNS. This response 
is always the same regardless of the source or type of stimulus. Generation of the action potential 
involve three main changes in the membrane permeability resulting in the depolarization of the 
axon membrane. These changes involve the transient increase in Na+ permeability, followed by 
restoration of Na+ impermeability and then a short duration increase in K+ permeability. If the 
initial stimulus surpasses a threshold, these changes is propagated along the axon’s entire length 
[1, 2]. 
  3 
The main glial cell within the peripheral nervous system is the Schwann cell. It plays an 
important role in the maintenance and function of peripheral nerves. Schwann cells ensheath 
nerves in a layer of myelin and provide trophic support. Myelin aids in the conduction velocity of 
action potentials by limiting the sites of ionic transfer along the axon to only nodes of Ranvier [1, 
2]. The nodes of Ranvier being gaps in the myelin sheath between adjacent Schwann cells. This 
results in a faster action potential propagation down the axon. The most heavily myelinated fibers 
are large motor neurons (Type Aα), next followed by afferent muscle spindles (Type Aβ). Nerve 
conduction velocities in Type Aα and Aβ are approximately 30-120 m/s. In contrast, unmyelinated 
neurons (Type C), including sensory and sympathetic neurons conduct action potentials at 
approximately 1-2 m/s [3]. Nerve types are described in Table 1. Schwann cells synthesize and 
release a wide range of growth factors, such as neurotrophins, neurgulatory cytokines, TGF-Βs, 
glial cell line-derived neurotrophic factor (GDNF), epidermal growth factors (EGFs), and platelet-
derived growth factor (PDGF) [4]. Peripheral nerve injury stimulates distinct changes in growth 
factor expression including increased production of nerve growth factor (NGF), brain-derived 
neurotrophic factor (BDNF) and neurotrophin-4 and decreased expression of neurotrophin-3 [4].  
Other non-neuronal cells and connective tissues surrounding the neuronal axons provide a 
complex stromal tissue and extracellular matrix. Surrounding individual axons is the endoneurium. 
Axons are bundled into fascicles by a dense connective tissue layer called the perineurium. Finally, 
the outermost layer of the nerve surrounding the nerve trunk is the epineurium. Micro-vessels exist 
in all layers providing blood supply to neuronal and non-neuronal cell populations. Injury to the 
various layers of this structure define the degree of injury and are the major determinate to recovery 
potential. 
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Table 1: Nerve fiber types and properties 
Modified from: Berde CB & Strichartz GR. Local Anesthetics. Miller:Miller's Anesthesia, 7th ed. 
Lars (eds) Eriksson I, Fleisher LA, Wiener-Kronish JP, Young WL. 2009. And Menorca, R. M., 
Fussell, T. S., & Elfar, J. C. (2013). Nerve physiology: mechanisms of injury and recovery. Hand 
clinics, 29(3), 317-30.[5] 
 
Fiber 
Class 
Diameter 
(mm) 
Conduction 
Velocity (m/s) 
Myelin Location Function 
Aα 6-22 30-120 + Efferent to muscles Motor control 
Aβ 6-22 30-120 + Afferent from skin and 
joints 
Tactile, 
proprioception 
Aδ 1-4 5-30 + Afferent sensory nerves Pain, cold, 
temperature, touch 
B 1-3 3-15 + Preganglionic 
sympathetic 
Various autonomic 
functions 
sC 0.3-1.3 0.7-1.3 - Postganglionic 
sympathetic 
Various autonomic 
functions 
dC 0.4-1.2 0.1-2.0 - Afferent sensory nerves Various autonomic 
functions, pain, 
warm, temperature, 
touch 
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1.1.2 Peripheral Nerve Injury 
 Every nerve can be injured by blunt or sharp trauma, and the resultant injury can be partial 
or complete, transient or permanent (Figure 1). Peripheral nerve injury exists on a spectrum and 
can be graded from 1st - 5th  using the Sunderland grading system [6]. In a Sunderland type 1 injury, 
local myelin is disrupted but the axons are preserved, and no degeneration occurs. This injury type, 
also referred to as neuropraxia is not marked by any real pathological changes and is instead a 
block in conduction alone without any need for significant regeneration. Beyond neuropraxia, the 
axon continuity is disrupted, and prognosis depends on how much of the nerve structure is 
damaged: only the axons (2nd degree), endoneurium (3rd degree), perineurium (4th degree), or 
complete transection (5th degree). In all of these cases, the nerves must undergo two major 
processes before regeneration can occur: neuronal survival and reaction, and Wallerian 
degeneration ( 2) [7, 8]. 
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Figure 1: Relative expected outcome of peripheral nerve injury based on severity of injury 
 
 
 
These two processes provide the peripheral nervous system with a superior regenerative 
potential compared to injuries of the central nervous system and ultimately stems from the 
supportive environment generated after nerve injury [9]. Neuronal cell bodies of the PNS within 
the CNS and dorsal root ganglion (DRG) possess the ability to shift from a transmitting state to a 
pro-repair phenotype to regrow after injury. This neuronal reaction represents the metabolic 
changes necessary for regeneration and axonal elongation. Underlying this process are prominent 
changes in gene expression, which lead to a decrease in the synthesis of neurotransmission-
related products and an increased synthesis of growth-associated proteins and structural 
components of the membrane. This process is triggered and maintained by signals integrated at 
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the injury site/growth cone[10]. In contrast, where the environment inhibits recovery after CNS 
injury, the PNS has complex mechanisms that support regeneration at the site of injury [11-15].   
Axonotmesis and neurotmesis injuries to the peripheral nervous system elicit a response 
from multiple cell types both at the site of injury and distally to support regenerating axons 
towards their original targets [16, 17]. Denervated axons distal to the injury are degraded by 
local Schwann cells followed by the infiltration of macrophages in a process known as Wallerian 
degeneration [18]. Myelin sheaths are also degraded as they contain regeneration-inhibitory 
factors, mainly myelin-associated glycoprotein. This process creates a microenvironment distal 
to the injury site that is favorable for the axonal regrowth of surviving neurons [16, 19, 20]. This 
process begins within 2 days of the injury, lasting approximately 2 weeks [20]; however, the 
macrophage population does not peak until 2-3 weeks post-injury. The presence of macrophages 
plays an additional role of supporting Schwann cells, fibroblasts and promoting angiogenesis 
through the release of cytokines and mitogenic signals [7, 16, 21, 22].  Triggered by 
inflammatory macrophages during the first few days after injury, Schwann cells de-differentiate 
and take on a repair-supportive phenotype [7, 9, 13]. Beyond phagocytosing myelin and axonal 
debris, these de-differentiated Schwann cells proliferate and secrete neurotrophic factors, 
including NGF and BDNF to support axon regeneration [7, 9, 23] [7, 9, 13]. Ultimately, the de-
differentiated Schwann cells migrate along new, axially aligned vasculature promoted by 
macrophages guiding axons towards their distal targets [7, 16, 21, 22]. 
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Figure 2: Depiction of nerve structure and repair. 
 
 
 
Nerves undergo neuronal survival at the cell body and Wallerian degeneration at the injury 
site and distally immediately after injury. Schwann cells dedifferentiate, proliferate, and line up to 
form bands of Büngner. Axon sprouts produce a growth cone that follow signals produced by 
Schwann cells. After the axon has reached its target, Schwann cells mature and begin to 
remyelinate the axon. 
Despite these mechanisms for PNS regeneration, actual patient outcomes after peripheral 
nerve injury remain varied, with factors such as severity and location of the injury impacting 
functional outcomes. Mild axonotmesis injuries recover better than more severe axonotmesis and 
neurotmesis injuries [14]These injuries are subject to misalignment of motor and sensory nerves 
as they regrow randomly towards distal targets [24, 25]. Large distances from injury to the end 
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organ also plays a large role in poor outcomes [14, 26]. The rate of axon growth is limited to 
around 1mm/day [8, 24]. However, phenotypic changes favoring repair in neurons and Schwann 
cells are not static and decline with prolonged axotomization and denervation [13, 26]. 
Functional recovery is rare if reinnervation is not established within a window of 12-18 months, 
largely due to atrophy of the target muscle and neuromuscular junctions [8]. 
Blunt force trauma usually results in neurapraxia or minor axonotmesis injuries, 
Sunderland’s first and second-degree injuries [5]. These types of injuries often fully recover in 
most patients. In cases of minor neurapraxia injuries, full recovery occurs within days, but for 
more severe neurapraxia or axonotmesis injuries recovery can take weeks to months. Sharp trauma 
such as glass or knife lacerations are common causes of significant, traumatic nerve injury. Thin 
shards of glass and knife blades can penetrate deeply while leaving a minor skin laceration and 
can involve vascular and/or tendon lacerations. These factors can lead to undetected nerve 
lacerations unless a thorough examination is done. Even when the neurotmesis is found and 
repaired, these nerve injuries often have disappointing outcomes in adults especially in terms of 
recovering fine sensory function [27, 28]. 
Entrapment neuropathies are a type of chronic compression or crush injury that present 
commonly in six different peripheral nerves. The medial nerve can be compressed at the wrist and 
is called carpal tunnel syndrome. This is the most prevalent entrapment neuropathy effecting 3-
6% of the adult population to some degree, with 118,000 procedures performed annually [29]. 
Carpal tunnel syndrome presents as numbness or tingling involving one of more of the first four 
digits. It also appears as weakness and atrophy of the thenar muscles, particularly abductor pollicis 
brevis [30]. The ulnar and radial nerves can also be entrapped causing significant deficits. The 
ulnar nerve can be compressed in the cubital tunnel at the elbow causing paresthesias and pain in 
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the fifth digit and the medial half of the fourth, as well as difficulty spreading the fingers. 
Compression of the radial nerve results in wrist drop and sensory loss of the dorsal aspect of the 
hand [30]. Presentation of radial nerve compression can be caused at multiple points along the 
upper extremity, including at the level of the axilla (“Saturday night palsy”), the spinal groove, or 
in the forearm (posterior interosseous neuropathy.) Lower extremity neuropathies include meralgia 
paresthetica, femoral neuropathy, and peroneal neuropathy. Meralgia paresthitica stems from an 
entrapment of the lateral femoral cutaneous nerve near the inguinal ligament and causes a burning 
sensation and variable loss of sensation over the anterolateral thigh [30]. Femoral neuropathy 
causes overall leg weakness, especially when attempting to stand or walk and are usually caused 
by trauma from surgery, stretch injury, diabetes mellitus, and other inflammatory processes. 
Entrapment of the peroneal nerve between the neck of the fibula and the insertion of the peroneus 
longus muscle causes peroneal neuropathy predominantly presenting as foot drop [30]. 
1.2 Clinical Repair of Nerve Injuries and Current Research 
1.2.1 Significance 
Axons of the peripheral nervous system retain the capacity for regrowth. However, repair 
and reconstruction of nerves in many peripheral nerve injuries is challenging and often leave 
patients with life-long deficits. In the United States, an estimated 20 million people live with the 
long-term effects of peripheral nerve injury resulting in a high economic burden of $150 billion 
[31]. Even the injuries with the best prognosis must go through the same complex repair and 
recovery process described in Section 1.1. This process can be restricted by slow nerve 
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regeneration, tissue adhesion, scar tissue formation, muscle atrophy, neuromuscular junction 
degradation, and other limiting factors. As a result, current re-innervation practices rarely show 
complete recovery of function with only a 51.6% rate of satisfactory motor recovery and 42.6% 
rate of satisfactory sensory recovery [32]. 
1.2.2 Clinical Approaches 
Neuropraxia and axonotmesis injuries have favorable functional recovery and as such little 
to no interventions are undertaken at the time of injury. In most cases, these patients are observed 
for the first 3-6 months before surgical repair is considered [30]. While most of these patients begin 
to show recovery within this time-period, lack of recovery signals either a more serious injury or 
complications necessitating a surgical intervention. Even for those that begin to recover in 3-6 
months, axonotmesis injuries can take months to even years to fully recover. Currently, surgeons 
prefer not to take initial action with these types of injuries because there are no therapies that 
provide significant improvement without running the risk of affecting the already healthy recovery 
rates. 
For transection injuries where a tensionless repair is not possible by direct anastomosis, the 
gold standard is the use of a nerve autograft. The sural nerve is the most common nerve graft, 
especially when a larger amount of graft material is required. Although sural nerve donor site 
morbidity is minimal, it does involve a second operation site that results in numbness of the lateral 
foot. This second operation site can increase operative time especially when the original nerve 
injury is in a different extremity to the sural nerve. The sural nerve is not the only available nerve 
graft. Several upper-extremity sources for nerve autograft also exist which pose several potential 
advantages when repairing upper-extremity nerve injuries, including confining donor morbidity to 
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the affect limb, limiting additional incisions, and simplifying harvest. In addition to the common 
Sural nerve graft, several upper-extremity nerve grafts are described in Table 2 (adapted from 
previously published work[33]. 
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Table 2: Partial list of available nerves for autograft repairs  
Modified from: Drislane, F. W., et al. (2014). Blueprints Neurology. Philadelphia, PA, 
Wolters Kluwer Health. 
 
Donor nerve Harvestable 
length 
Cross-
sectional area 
Disadvantage 
Medial antebrachial 
cutaneous nerve 
Up to 28 cm 2-3.15 mm2 Medial arm scar 
Lateral antebrachial 
cutaneous nerve 
5-8 cm 1.3-1.8 mm2 Visible forearm scar 
Third webspace 
branch of median 
nerve 
24.5 cm 4.4 mm2 Sensory loss in hand (non-critical) 
Palmar cutaneous 
branch of median 
nerve 
5 cm 2.4 mm2 Sensory loss in palm 
Dorsal cutaneous 
branch of ulnar nerve 
Up to 28 cm 2.4 mm2 Sensory loss to dorsal-ulnar hand 
and digits 
Posterior interosseous 
nerve 
2.5 cm 0.5-0.8 mm2 Visible dorsal incision 
Small diameter graft 
Sural 30-50 cm 2.5-4 mm2 Positioning difficult 
Requires second extremity 
Obturator 11.5 cm 3 mm2 Loss of gracilis as possible future 
free functional flap 
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While donor nerve alternatives exist to the sural nerve graft, they still possess similar 
disadvantages including either a need for a second surgery, a loss of sensation, or limited 
availability. A variety of nerve repair products have been approved as alternatives to the nerve 
autograft (Table 3). These products range from hollow tube conduits and wraps to decellularized 
allografts. These products are compared on metrics including tissue specificity, persistence in the 
body, mechanical support for regenerating axons, possible carrier for small molecules or cells, and 
their appropriate use in compression, transection, and short (<3cm) and large (>3cm) gap defect 
injuries. Green denotes high affinity or accepted use for the category. Yellow denotes a moderate 
or neutral affinity. Red represents a negative quality. 
Hollow tube conduits are nonneural, tubular structures designed to bridge the gap of a 
sectioned nerve while protecting the nerve from scar infiltration and guiding the regenerative fibers 
towards the distal nerve stump. Available conduits and nerve connectors includes the Axoguard 
connector (Axogen), Neuragen (Integra), Neuroflex (Styker), Neurotube (Synovis), and 
Hydrosheath (Salubridge). These products are made from a variety of materials including small 
intestinal submucosal ECM (SIS), collagen I, poly-glycolic acid (PGA), and polyvinyl alcohol 
(PVA). Clinical use of the hollow tube conduits is limited predominately to only short gaps and 
does not produce outcomes that match the nerve autograft repair [34-38]. Wraps made from ECM 
including Axogen (Axoguard protector), Integra (Neurawrap), and Styker (Neuromend) exist on 
the market. Wraps are flat or rolled sheets made from SIS or collagen I that can be approximated 
around an injury. Most commonly these products are employed around anastomoses of transected 
nerves to protect the site from scar infiltration and to add mechanical support to the suture site. 
Axogen’s Avance nerve graft is alone in its category and is regulated under HCT/P (Human 
Cellular and Tissue-based Product). The Avance is a decellularized human nerve that is available 
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in a range of lengths and diameters. Avance is currently the only nerve extracellular matrix (ECM) 
scaffold available to the market to bridge nerve discontinuities. The Avance graft has been 
successful in repairing nerve gaps and is a viable alternative to the nerve autograft but is limited 
to nerve gap injuries [38-40].  
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Table 3: Clinically available nerve repair products and alternatives to the nerve autograft 
 
 
  
Hollow Tubes/Conduits 
  
 Wraps  
Decell 
Allograft 
 Axogen 
Axoguard 
Connector 
Integra 
Neuragen 
Stryker 
Neuroflex 
Synovis 
Neurotube 
Axogen 
Axoguard 
Protector 
Integra 
Neurawrap 
Stryker 
Neuromend 
Axogen 
Avance 
Graft 
Material 
Small 
intestinal 
submucosa 
(SIS) 
Collagen 
type I 
Collagen 
type I 
Woven 
poly-
glycolic 
acid (PGA) 
SIS matrix 
Collagen 
Type I 
Collagen 
Type I 
Nerve 
matrix 
Form Solid sheet Gel tube Gel tube Solid mesh 
Solid 
sheet 
Gel sheet Gel sheet 
Solid 
sponge 
Cost $700  
$1470-
1670 
$1,838   -- 
$1400-
1725 
$1470-2000 $1828-2000 
$1300-
3000 
Tissue 
specificity 
                
Persistence 4-8wks 6-12mos 4-8mos 6-12mos 4-8wks  6-12mos 4-8mos  4-8wks 
Mechanical 
support for 
regenerating 
axons 
                
Carrier for 
small 
molecules or 
cells 
                
Compression 
injury 
                
Transection                 
Transection 
w/ short gap 
                
Transection 
w/ long gap 
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While many alternatives exist, some with outcomes that come close or match the nerve 
autograft, many surgeons still prefer the traditional gold-standard over any alternative solutions. 
Surgeons that routinely repair peripheral nerve injuries have a high barrier of entry for new 
products and require alternatives that not only match but exceed current practices. Therefore, 
current research has explored new ways of improving current repair practices.  
1.2.3 Current Research  
Numerous approaches for delivery of matrix components, immunomodulatory or growth 
factors, and cells to the site of nerve repair have been used. The majority of studies have 
investigated single or combinations of a small number of additives to common hollow tube nerve 
guidance conduits with the goal of altering the local environment and improving recovery 
through the addition of growth factors such as Brain Derived Neurotrophic Factor (BDNF), Glial 
Derived Neurotrophic Factor (GDNF), Nerve Growth Factor (NGF), Neurotrophibn-3 (NT-3) or 
accessory cells into a supportive matrix [41-50]. A review of current research on lumen filler for 
nerve conduits can be found in Table 4. While many of these studies have reported positive 
outcomes, limitations include tailoring growth factor release profiles, optimizing the mechanical 
environment of the substrate used at the site of repair, and maintaining cell viability after 
transfer [51]. One alternative to engineering a complex microenvironment is to mimic the native 
microenvironment of healthy peripheral nerve using a decellularized tissue-based hydrogel. This 
strategy may be able to compete with both the Avance graft and the gold-standard nerve 
autograft. 
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Table 4: Review of current research on lumen fillers for nerve conduits 
Reused with permission (4546560968632). [52] 
 
 
Growth 
Factor/ 
Cell 
Matrix Conduit 
material 
Animal 
model 
Conclusions Ref 
BDNF 
Collagen Collagen Rabbit facial 
nerve; 15 
mm, n = 10 
BDNF did not appear to promote better 
regeneration than collagen matrix only. 
[53] 
GDNF 
Fibrin Silicone Rat sciatic 
nerve; 13 
mm, n = 12 
GDNF delivery system generated significantly 
less nerve fibers at middle line of conduit than 
isograft but fibers were more mature. 
[54] 
EVA/BSA EVA Rat sciatic 
nerve; 15 
mm, n = 10 
GDNF promoted approximately 20% and 35% 
regeneration of motor and sensory neurons 
respectively. 
[43] 
Fibrin Silicone Rat femoral 
nerve; 5 mm, 
n = 7 
Controlled delivery of GDNF led to enhanced 
nerve regeneration that was not significantly 
different then isograft control. 
[46] 
NGF 
Fibrin Silicone Rat sciatic 
nerve; 13 
mm, n = 6 
NGF was not significantly different from the 
isograft control including showing similar nerve 
maturity and density. 
[44] 
EVA/BSA EVA Rat sciatic 
nerve; 15 
mm, n = 10 
Only 5% of the total number of motor and 
sensory neurons regenerated with treatment of 
NGF after 6 weeks. 
[43] 
NT-3 
Collagen PHEMA- 
MMA 
Rat sciatic 
nerve; 10mm, 
n = 6 
The introduction of a high dose of fibroblast 
growth factor (FBF-1) was comparable to 
isograft and was significantly better than NT-3, 
BDNF, and matrix alone. 
[45] 
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Table 4 (continued) 
 
 
Schwann 
Cells 
Collagen PLGA Rat sciatic 
nerve; 12 
mm, n = 9 
The bone marrow stromal cell derived Schwann 
cells produced better histologic and functional 
outcomes than matrix alone but did not match 
autograft control. 
[47, 
55] 
Alginate/ 
fibronectin 
PHB Rat sciatic 
nerve; 10 
mm, n = 6 
Transplanted Schwann cells and fibronectin had an 
additive effect on regeneration over negative 
controls. 
[47] 
Gelatin PLGA Rat sciatic 
nerve; 10 
mm, n = 6 
The addition of Ginkgo biloba extract with 
Schwann cells increased motor unit action potential 
at 6 weeks after injury over autograft control. 
[56] 
Matrigel Collagen Mouse 
sciatic 
nerve 6 
mm, n = 9 
Allogeneic Schwann cells did not provide a benefit 
over matrix only control but the addition of FK506, 
an immunosuppressant, improved results over 
negative control. 
[49] 
Matrix 
Alone 
Keratin Silastic Mouse 
tibial nerve; 
4 mm, n = 5 
Keratin increase histologic and electrophysiologic 
measures of recovery over autograft, however these 
results did not translate to muscle function recovery 
after 6 weeks. 
[48] 
Keratin Silicone Mouse 
tibial nerve 
5 mm, n = 6 
Keratin hydrogel improved electrophysiologic and 
histologic measurement of recovery over empty 
conduits and autograft controls. 
[41] 
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1.3 Extracellular Matrix  
Tissues are not solely comprised of cells, instead a substantial volume is made up of 
extracellular matrix (ECM). The ECM is an intricate network of macromolecules including 
proteoglycans and fibrous proteins [57, 58]. Proteoglycans fill the majority of the extracellular and 
interstitial space in tissues creating a hydrated gel [58]. Collagen is the most abundant fibrous 
protein but other fibrillar proteins of the ECM include elastins, fibronectins, and laminins [59]. 
The composition of the ECM of tissues is quite complex with hundreds of possible ECM molecules 
described today [58, 60, 61]. It has been long understood that the extracellular matrix (ECM) not 
only provides structural support but also regulates cell growth [62, 63], survival, maturation, 
differentiation [64, 65], and development [66] of resident cells [67]. ECM is not a static scaffold 
but subject to dynamic reciprocity with its host cells [68] responsive to and responsible for the 
changing structure, mechanical, metabolic, and functional needs of these cells. Components of 
ECM such as thrombospondin-1, thrombospondin-2, SPARC, tenascin-C and osteospontin all do 
not function as structural proteins but modulate cell-matrix interactions and cell function [69, 70]. 
Peripheral nerve tissue also has its own unique extracellular matrix. The ECM of peripheral 
nerves are made up of macromolecules including collagen (I, II, IV, and V), laminin, fibronectin, 
and chondroitin sulfate proteoglycans[71]. The predominant component in peripheral nerve ECM 
is collagen I, making up about 90% of the composition [71, 72]. Collagen has been seen throughout 
the three layers of the peripheral nerve; epineurium, perineurium, and endoneurium[73]. Laminin 
is another common component of peripheral nerve ECM. Laminin is mainly produced by Schwann 
cells and is found in the basement membranes in a tight network with glycoproteins, collagen IV, 
and proteoglycans [73]. Laminin can also be found in the perineurium. Along with collagen, 
laminin has been shown to play an essential role in enhancing axonal growth [71, 73]. Fibronectin 
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is found around the perineurium and within the epineurium. Both laminin and fibronectin are 
important constituents of peripheral nerve development. Fibronectin has been shown to play a role 
in migration and differentiation in neural crest cells while laminin maturation through Schwann 
cell myelination of axons [73].  
1.4 ECM Scaffolds in Soft Tissue Repair 
ECM scaffolds are derived from the removal of cellular components within whole tissue 
and retain the micro- and macro-scale structural components and functional ECM proteins. These 
components include collagen molecules (e.g. types I, III, IV, among others), laminin, fibronectin, 
and glycosaminoglycans (GAGs) as well as a variety of growth factors (e.g. vascular endothelial 
growth factor (VEGF), basic fibroblast growth factor (bFGF), transforming growth factor β 
(TGFβ)) [67, 74-78]. The ECM of urinary bladder, small intestine, dermis, pericardium, and 
nervous tissue are all examples of FDA approved or clinically available scaffolds for soft tissue 
repair (Table 5), adapted and updated from [79]) [80]. These ECM scaffolds have been used in a 
number of different configurations to meet the exact clinical needs. These configurations include 
two-dimensional sheets, powders, multi-laminate sheets, tubular structures, powder pillow 
devices, and whole organs [81]. Recently, a method for fabricating ECM scaffold degradation 
products into injectable, temperature responsive, hydrogels has been described [36, 37], enabling 
delivery in multiple settings without prior fabrication of solid matrices into specific shapes and 
sizes. 
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Table 5: Partial list of commercially available extracellular matrix-based scaffolds 
Modified from Swinehart, I. T., & Badylak, S. F. (2016). Extracellular matrix bioscaffolds 
in tissue remodeling and morphogenesis. Developmental dynamics : an official publication of the 
American Association of Anatomists, 245(3), 351-60. [82] 
 
Product Vendor Scaffold Source 
MatriStem® ACell Inc. Porcine urinary bladder matrix (UBM) 
AxoGuard® Nerve 
Connector 
AxoGen Porcine small intestinal submucosa (SIS) 
AxoGuard® Nerve 
Protector 
AxoGen Porcine small intestinal submucosa (SIS) 
Oasis® Wound matrix Smith&nephew Porcine small intestinal submucosa (SIS) 
Biodesign® Cook Medical Porcine small intestinal submucosa (SIS) 
AlloDerm Biohorizons Human dermis 
ArthroFLEX ® Arthrex Human dermis 
AlloMax ™ BD (C. R. Bard) Porcine dermis 
Permacol™ Covidien Porcine dermis 
XenMatrix  
Surgical graft 
BD (C. R. Bard) Porcine dermis 
Zimmer Collagen Patch® Zimmer  Porcine dermis 
PriMatrix™ Integra LifeScience Fetal bovine dermis 
SurgiMend™ Integra LifeScience Fetal bovine dermis 
TissueMend® Integra LifeScience Fetal bovine dermis 
Dura-Guard® Baxter Bovine pericardium 
Peri-Guard® Baxter Bovine pericardium 
Vascu-Guard® Baxter Bovine pericardium 
Veritas® Baxter Bovine pericardium 
Avance® Nerve graft AxoGen Human peripheral nerve (HCT/P) 
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These ECM scaffolds have been successfully used in a range of applications to support 
constructive remodeling, or the deposition of site-appropriate tissue. The precise mechanisms that 
drive the process of ECM mediated constructive remodeling are only partially understood. 
However, it has been shown that scaffold degradation, recruitment of endogenous stem cells, and 
modulation of the innate immune system are important determinants of outcome. ECM scaffolds 
are rapidly infiltrated by host cells, especially macrophages which degrade the matrix via matrix 
metalloproteinases (MMPs) and other proteases. This degradation of the scaffold releases 
bioactive molecules such as growth factors and cytokines. Furthermore, bioactive cryptic peptides 
can be created by cleavage of molecules such as collagen, fibronectin and laminin [83, 84]. These 
bioactive molecules in combination with scaffold degradation initiate a robust remodeling activity 
that includes immunomodulatory, chemotactic, proliferative, and differentiation activity for a 
variety of cell types. Macrophages are an important cell population altered by the interaction with 
ECM scaffolds. Macrophages exist on a phenotypic and functional spectrum (i.e., M1, M2a, M2b, 
M2c). ECM scaffolds have been shown to promote a shift towards a regulatory, anti-inflammatory 
macrophage phenotype (M2) and this shift is strongly correlated to downstream constructive 
remodeling response. 
Within the peripheral nervous system, macrophages play an important role in injury 
recovery. After injury, macrophage arrive to the site within 24 h and their population peaks by 14-
21 day [85]. They account for the bulk of phagocytosis within these days and play critical roles in 
scavenging debris, growth factor production such as NGF and IL-6 [86, 87], and remodeling of 
the ECM of the distal nerve [24, 88]. It has been shown that modulating macrophages within the 
peripheral nerve injury towards an M2 like phenotype results in enhanced Schwann cell infiltration 
and substantially quicker axonal growth in rodent animal models [89]. Furthermore the ratio of 
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pro-remodeling (M2) macrophages to pro-inflammatory (M1) macrophages has been shown to 
have a linear relationship with the number of axons that are found at the distal end of nerve 
scaffolds [89]. 
While individual ECM components have been isolated from native tissues and 
investigated, whole ECM is a highly complex milieu that is not fully understood. This prevents 
the creation of artificially engineered scaffolds with the same ECM composition and distribution. 
Collagen type 1 is the most abundant ECM protein in many adult tissues and is easily extracted. 
Collagen can be formed into sheets, hydrogels, and sponges and has been used in applications that 
include peripheral nerve conduits and lumen fillers (Table 3, Table 4). However, in many 
applications the response of simple collagen scaffolds does not match that of a comparable whole 
ECM scaffold.  
While many components of the ECM are conserved across several tissue types, each tissue 
is believed to possess a unique composition and mechanical and ultrastructural characteristics [90, 
91]. Recently, scaffolds have been derived from ECM sourced from a variety of tissues including 
skin, fat, pericardium, heart, skeletal muscle, and liver for both in vivo and in vitro experiments to 
examine the effects of using application specific ECM  sources [67, 92-95]. These scaffolds have 
been observed to assist with constructive remodeling or the formation of site-appropriate tissue 
when used as a biomaterial in vivo [96] and in some cases these ECM scaffolds have tissue-specific 
effects on cellular behavior [83, 84, 93, 97-101]. In these cases, a homologous ECM source has 
maintained tissue-specific cell phenotypes [84, 99-101], promoted cell proliferation [93, 100], 
induced tissue-specific differentiation [98], and enhanced the chemotaxis of stem cells [97, 102, 
103]. While a preference or necessity for tissue-specific ECM has not been shown for all  
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therapeutic applications [102, 104, 105], research suggests that the peripheral nerve system is a 
candidate for a peripheral nerve specific ECM scaffold over non-nerve specific sources [97, 106, 
107]. 
1.5 Specific Aims of Dissertation 
Through decellularization, whole nerve-specific ECM scaffolds can be created that would 
contain the same structural and functional molecules found within the autologous nerve graft. 
These components have been shown to enhance the natural regenerative response. Key elements 
found within the peripheral nerve ECM (PNM) such as laminin, fibronectin, and collagen have 
been shown to enhance the Schwann cell response with the greatest results where proteins were 
combined [108]. Further research has shown that the presence of laminin in co-cultures of 
Schwann cells and NG108-15 cells activated transcription factors in Schwann cells which in turn 
promoted growth of longer neurites by the neuronal cells [108]. In addition, ECM scaffolds have 
been shown to promote a shift in infiltrating macrophage phenotype towards M2, an anti-
inflammatory and tissue repair phenotype.  It has been demonstrated that M2 polarized 
macrophages play a neuroprotective role and as such, shifting the neurodegeneration-induced 
immune responses towards an M2 response could be an important therapeutic strategy [22]. As 
the hydrogel degrades, these components, among others, are released into the surrounding area 
and we believe that they will cause a cascade of effects including Schwann cell migration and a 
shift towards anti-inflammatory M2 macrophages [109, 110] and will have positive effects on 
axonal outgrowth and functional outcomes. 
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This dissertation investigates the use of a novel extracellular matrix hydrogel derived from 
peripheral nerve tissue as a lumen filler for nerve guidance conduits and more broadly in enhancing 
peripheral nerve regeneration after injury. The methods and techniques developed in this 
dissertation provide a better understanding of PNM, characterization of a novel lumen filler, and 
possible new therapies for peripheral nerve injuries. Furthermore, the results of this dissertation 
provide insight into the phenotypic role of macrophages during the nerve healing response and 
correlations between benchtop metrics and functional outcomes of nerve repair. 
The objective of this dissertation was to investigate the effects and mechanisms of action 
of a peripheral nerve specific ECM in the regeneration of peripheral nerve injury.  The specific 
aims of this proposal are designed to answer the following questions: 
Does a peripheral nerve specific ECM hydrogel provide a preferred microenvironment over 
non-nerve specific ECM hydrogels for peripheral nerve repair? 
Does PNM generate enhanced recovery through mechanisms beyond simple structural 
support in a critical length sciatic nerve defect injury model?  
Does PNM generate improved functional recovery after a critical length sciatic nerve 
defect injury as compared to the gold standard, the autologous nerve graft? 
 
1.5.1 SPECIFIC AIM 1: Characterize a PNM Hydrogel and Determine if PNM Hydrogels 
Provide a Preferred Microenvironment for Peripheral Nerve Repair as Compared to Non-
Nerve-specific ECM (SIS and UBM) Hydrogels. 
Because the extracellular matrix is generated by the resident cells of each tissue and organ, 
scaffolds derived from different tissues will logically vary in structure and composition. This 
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complex structure and composition cannot be artificially engineered, thus decellularization 
represents an ideal approach to the generation of tissue specific substrates. Previous studies have 
suggested scaffolds derived from a site specific tissue may be better suited for constructive tissue 
remodeling than non-site specific tissue sources [107]. We hypothesized that PNM would be a 
better scaffold for peripheral nerve repair than non-nerve ECM. This included that ECM derived 
from peripheral nerves would contain important nerve associated structural and functional 
constituents. PNM would have a greater effect on neurite outgrowth and Schwann cell migration 
than a non-nerve-specific ECM (sub-intestinal submucosa ECM and porcine dermis ECM). 
Furthermore, PNM was expected to promote a macrophage phenotype similar to M2. 
1.5.2 SPECIFIC AIM 2: Determine if PNM Generates Enhanced Recovery Via 
Mechanisms Beyond Simple Structural Support by Assessing PNM’s Effect on the 
Regenerative Response in a Peripheral Nerve Defect Injury Model 
ECM scaffolds have been shown to promote a process of new, site-appropriate, functional 
tissue formation.  These studies have also demonstrated that ECM scaffold materials play a 
bioactive role and promote a shift in the macrophage response from M1 (proinflammatory) to M2 
(anti-inflammatory). M2 macrophages have been shown to have a positive effect on the Schwann 
cell response to injury [22]. PNM was expected to have a bioactive response on Schwann cells, 
axons and macrophages. The corollary hypothesis was that use of PNM when repairing a sciatic 
nerve defect injury of rat sciatic nerves will increase the rate of axonal growth, Schwann cell 
migration and presence of M2 polarized, anti-inflammatory macrophages. 
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1.5.3 SPECIFIC AIM 3: Determine the Translational Potential of PNM by Investigating 
Functional Recovery Outcomes After a Critical Length Sciatic Nerve Defect Injury. 
Even when successful regeneration of axons across the injury site occurs, reinnervation of 
the target tissue does not always follow. Misdirected axons which do not distally reconnect will 
ultimately undergo progressive withdrawal [111]. These axons will also likely not undergo 
maturation (myelin sheath formation). Since axon misdirection is believed to play a significant 
role in poor functional recovery, this proposal seeks to investigate the link between nerve fiber 
maturity following PNM application and function outcomes [112]. To test this PNM will be 
compared to the autograft procedure (gold standard), conduit without lumen filler, and no repair 
controls (negative control). Our hypothesis was that the PNM enhanced regenerative response 
during acute timepoints would lead to enhance electrophysiological measurements and functional 
dynamic and static parameters of downstream function. 
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2.0  Development and Characterization of a PNM Scaffold and Hydrogel for Peripheral 
Nerve Repair 
2.1 Introduction 
ECM scaffolds are an attractive material that have not been fully investigated for possible 
benefits in the peripheral nervous system. ECM based scaffolds that have been appropriately 
decellularized have been shown to promote constructive remodeling following injury [79, 106, 
107, 109, 110, 113, 114]. However, over or under decellularizing tissue results in poor outcomes. 
The insufficient removal of DNA and other immunogenic materials leads to an increased 
inflammatory response and possible rejection of the implanted scaffold [1, 2]. The use of overly 
harsh decellularization methods can successfully remove unwanted native constituents of the tissue 
but can also damage structural and signaling proteins [115-117]. While many methods for 
decellularization of tissues have been described and are accepted to work, no methods is broadly 
accepted as optimal for all tissues and organs due to variability in tissue composition and structure 
[1, 2]. Even for decellularization of peripheral nerve tissue, a wide range of protocols exist [116-
140]. A summary of these methods can be found in Table 7. The goals of decellularization are the 
removal of cells, elimination of genetic material, preservation of ECM components, and the 
retention of mechanical properties. Decellularization methods described have used mechanical, 
chemical, and enzymatic techniques to remove cellular debris while limiting the disruption to the 
ECM. These methods have been previously described [141] and have been summarized and 
expanded upon in the table below (Table 6). 
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These methods all have their own advantages and disadvantages as described (Table 6) and 
as such several techniques are often combined to complement each other with the goal of 
maintaining the desired tissue characteristics. This can involve all categories, chemical, enzymatic, 
and mechanical and each constituent’s parameters need to be optimized to suit a particular tissue.  
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Table 6: Summary of decellularization agents and techniques 
 
Category 
Examples Advantages and Disadvantages Tissue Types 
References 
PNS 
Detergent 
Class 
Ionic 
Sodium 
dodecyl sulfate 
(SDS) 
(-) Cytotoxic: requires 
extensive wash process [142] 
(-) Alters microstructure (i.e., 
collagen fibers)[143]  
 
sciatic nerve, tibial 
nerve, femoral 
nerve, median 
nerve, caudia 
equine 
[34, 133, 136, 
139, 144, 145] 
Sodium 
deoxycholate 
(SDC) 
(-) Causes agglutination of 
DNA when used without 
DNase [146] 
sciatic nerve, tibial 
nerve, femoral 
nerve, caudia 
equine 
[52, 115, 117, 
120, 121, 132, 
147, 148] 
Triton X-200 
(-) Discontinued sciatic nerve, tibial 
nerve, femoral 
nerve, human 
peripheral nerve 
[38-40, 116, 
120, 122, 123, 
138, 144, 149, 
150]  
Nonionic Triton X-100 
(-) Less damaging to structure 
of tissue than ionic surfactants 
[83, 92] 
 
sciatic nerve, tibial 
nerve, femoral 
nerve, median 
nerve, caudia 
equine 
[52, 115, 117, 
121, 130, 132, 
136, 147, 151, 
152] 
Zwitterionic 
Sulfobetaine-10 
(SB-10) 
(+) Solubilization of oleosins  
(+) works over a broad pH 
range (+) effectively removes 
cells with mild disruption of 
ultrastructure in thin tissues 
[149] 
sciatic nerve, tibial 
nerve, femoral 
nerve, human 
peripheral nerve 
[38-40, 116, 
120, 122, 123, 
138, 144, 149, 
150] 
Sulfobetaine-16 
(SB-16) 
(+) solubilizes membrane 
proteins  
(+) works over a broad pH 
range (+) effectively removes 
cells with mild disruption of 
ultrastructure in thin tissues 
[149] 
sciatic nerve, tibial 
nerve, femoral 
nerve, human 
peripheral nerve 
[38-40, 116, 
120, 122, 123, 
138, 144, 149, 
150] 
CHAPS 
(+) Maintains structural ECM 
proteins 
(-) Remnant cytoplasmic 
proteins 
(+) Maintains ultrastructure 
[153] 
sciatic nerve, tibial 
nerve, femoral 
nerve 
[130] 
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Table 6 (continued) 
Chemical 
Peracetic acid 
(-) Insufficient cell removal 
(-) Highly corrosive  
(+) Oftentimes used for sanitization 
(-) Increases stiffness of ECM [142, 154] 
UBM, sciatic 
nerve 
[34, 52, 79, 120, 
121, 132, 135, 
145, 151, 155] 
EDTA 
(-) Commonly used with trypsin but 
ineffective when used alone (-) Decreases 
salt- and acid-soluble ECM proteins [156] 
sciatic nerve [52, 157, 158] 
Enzyme 
Trypsin 
(-) Prolonged exposure can disrupt ECM 
ultrastructure  
(-) Removes ECM constituents such as 
collagen, laminin, fibronectin, elastin, and 
GAG [141] 
Sciatic nerve [52, 157, 158] 
DNase (-) Difficult to remove from the tissue and 
could invoke an immune response [141], 
[153] 
sciatic nerve 
[132, 147, 151, 
152, 157-159] 
RNase sciatic nerve 
[132, 147, 152, 
157, 158] 
Chondroitinase 
ABC 
(-) Prolonged exposure could disrupt ECM 
ultrastructure [118, 137] 
sciatic nerve, 
human peripheral 
nerve 
[38-40, 118, 122, 
137, 138] 
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The majority of application of decellularized ECM towards the PNS have sought to 
improve nerve grafting by generating decellularized allografts [119, 120, 130-132, 145, 147, 152, 
157, 159] or xenografts (Wang et al. 2013). Others have processed decellularized nerve [52, 160] 
or urinary bladder sources[151] to produce hydrogels or wraps to augment existing repair 
procedures. While the methods vary, they often utilize a combination of ionic and non-ionic 
detergents and sometimes enzymatic processes to decellularize the peripheral nerve tissues. 
In order to study PNI, researchers have developed two primary models: Transection or 
Gap Injury and Crush Injury. The transection or gap injury model aims to address the impacts of 
severe PNI, where a segment of the nerve is completely removed, to mimic the physiological 
limit upon which natural nerve regrowth is not possible. The crush injury model represents a 
mild injury prognosis, where the nerve is expected to make a full recovery post injury. Each 
model provides a deeper insight into the critical factors necessary to assist nerve regeneration for 
PNI patients. 
Serious trauma to the peripheral nervous system resulting in a full transection requires 
coaptation surgery and is often further complicated by retraction of the nerve stumps. [161] If 
nerve ends cannot be coapted directly without tension, the current gold standard repair involves 
the use of an autologous nerve graft to bridge the gap. Often using the sural nerve as donor 
tissue, the autologous nerve graft procedure results in donor site morbidity. As an alternative, 
decellularization techniques have been utilized to create acellular nerve grafts from allogeneic 
and xenogeneic sources that emulate the same structure and ECM composition of the autologous 
nerve graft. 
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Table 7: Partial list of decellularization methods for peripheral nervous system 
 
Study 
model 
Source 
Tissue 
Added 
Comp. / 
Post 
Processing 
Method 
Type 
Decellularization Method 
Notable Results Ref 
# Step T rpm 
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Sondell et al. 1998 Method   
The study found that the 
Sondell method of 
decellularization disrupted the 
nerve ECM more than the 
Hudson method. Hudson 
method also produced a greater 
degree of demyelination and 
improved adhesive ratios when 
scaffolds were co-cultured with 
adipose-derived stem cell. The 
study suggests that greater 
ECM disruption in the Sondell 
method could be from 
switching between the tissue 
shrinkage of sodium 
deoxycholate and swelling of 
distilled water. 
[115-
117, 
121, 
123, 
150] 
 
distilled water 7h  
2x 
3% Triton X-100 12h  
4% Sodium deoxycholate 24h yes 
 
distilled water   
Hudson et al. 2004 Method   
 
distilled water 7h  
 
125 mM sulfobetaine-10 15h yes 
 50 mM phosphate and 
100mM sodium 15m  
 
0.14% Triton X-200, 0.6 
mM sulfobetaine-16, 10 
mM phosphate and 50 
mM sodium 24h yes 
3x 
50 mM phosphate and 
100mM sodium 5m  
 
125 mM sulfobetaine-10 7h yes 
 50 mM phosphate and 
100mM sodium 15m  
 
0.14% Triton X-200, 0.6 
mM sulfobetaine-16, 10 
mM phosphate and 50 
mM sodium 15h  
3x 
50 mM phosphate and 
100mM sodium 15m  
1
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Distilled water 7h yes 
This method decellularized the 
nerve to a similar degree to the 
Hudson T. method but 
displayed better ECM 
preservation. In a rat sciatic 
nerve gap model, the detergent 
less method outperformed the 
Hudson T. method in nerve 
histomorphometry and muscle 
mass but did not outperform the 
nerve autograft controls.  
[130] 
 
1 M Sodium chloride 15h yes 
 
2.5 nM Triton X-100 24h yes 
 
1X PBS 15m yes 
 
Distilled water 7h yes 
 
1 M Sodium chloride 15h yes 
 
100 nM CHAPS 24h yes 
5x 1X PBS 5m yes 
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  distilled water 7h  Testing showed that the method 
effectively decellularized the 
tissue and significantly 
increased pore size and created 
axially aligned channels. In vivo 
work has not been published but 
in vitro work showed enhanced 
PC12 cell migration both in 
number and depth into the graft.  
[132] 
2x 
3% Triton X-100 12h yes 
2% deoxycholic acid in 
50nM Trizma base 24h yes 
 
DNase and RNase (5 
U/ml) in 10nM 
magnesium chloride 12h  
 
0.1% peracetic acid 1h  
3
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 DMEM 10% FBS 2% 
pen/strep/amph 2wk yes 
In a rat sciatic nerve gap model, 
histologic results indicated that 
nerve autograft outperformed 
both the detergent free and 
detergent decellularized grafts. 
Only nerve autograft and 
detergent free grafts showed 
functional recovery inn muscle 
force testing  
[131] 
 
PBS 1wk yes 
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DMEM with 
camptothecin (5 or 
10uM) 37°C 
1-
3d 14 
The apoptosis decellularization 
method was able to decellularize 
the tissue while maintaining 
basal lamina microarchitecture 
while being less cytotoxic then 
detergent decellularization 
methods. The apoptosis-assisted 
method also produced less 
inflammatory infiltrate and 
stromal remodeling compared to 
autograft control. More work 
will need to be done to look at 
downstream outcomes for nerve 
regeneration.  
[159] 
 
4X PBS 24h  
 
2X PBS 30m  
3x 1X PBS 30m  
 
75 U/mL DNase 36h  
2x 
1X PBS 30m  
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2x 
10 mM TRIS-HCl; pH 
8.0  yes 
Decellularization method 
reduced DNA content by greater 
than 95% but preserved 
collagen, laminin, and 
fibronectin.  
[145] 
0.1% SDS with 10 
kIU/mL Aprotinin and 
0.1% EDTA  yes 
3x 1X PBS 30m yes 
 
1 U/mL Benzonase 3h yes 
 
1.5 M NaCl  yes 
 0.1% peracetic acid in 
PBS 3h yes 
3x 1X PBS at 4C 30m yes 
 
1X PBS at 4C 48h yes 
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1X PBS   
Decellularization method was 
performed on both an 
allogeneic and xenogeneic 
tissue source and were 
compared in vivo to isograft 
control. Function, 
electrophysiological, and 
histomorphological analyses 
were performed after 24 
weeks. Limited macrophage 
infiltration was observed but a 
large number of axons and 
Schwann cells were shown 
migrating into the bridge. 
Testing showed no difference 
between allo- and xenogeneic 
sources of decellularized 
nerve graft. However, both 
were inferior to isograft 
control. This was different 
than previous results from the 
group in Wakimura et al. 
2015, where isograft and 
decellularization allograft was 
found to have similar 
outcomes in the same model 
and tests. 
[136, 
152] 
 
1% SDS 24h yes 
 
Distilled water 30m  
 
1% Triton X-100 1h yes 
 
Distilled water 30m  
 
100 U/mL penicillin-
G, 100 ug/mL 
streptomycin, 0.25 
ug/mL amphotericin B 7d  
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2x 
50 nM Tris buffer 12h  
Methods developed were 
compared to Sondell et al. and 
Hudson et al. methods. 
Method proposed by Roosens 
et al. showed a better removal 
of DNA content and 
preservation of ECM 
components. 
[116, 
121, 157, 
158] 
1% Triton X-100 in 50 
nM Tris buffer at 4°C 24h  
HBSS 24h 24 
2x 
40,000 U/L DNase, 20 
mg/L RNase, 100 
mg/L Trypsin at 37C 45m yes 
 1% Triton X-100 in 50 
nM Tris buffer at 4°C 12h  
3x HBSS at 4°C   
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distilled water 7h  
The goal of the study was to 
generate an alternative to human 
decellularized nerve allograft by 
decellularizing a porcine sciatic 
nerve. This was tested as a solid 
scaffold as well as an ECM 
hydrogel filler for a polymer 
conduit. The decellularization 
method closely resembles the 
Sondell method but the authors 
found that repeated detergent 
washes stripped to much ECM 
for effective gelation formation. 
This study found that repeated 
detergent washes was not 
necessary to produce a scaffold 
with significant residual DNA 
removal. In vivo the peripheral 
nerve ECM was able to augment 
a conduit with similar 
electrophysiology results to 
xenograft. However, both were 
inferior to autograft control for 
electrophysiology and sciatic 
functional index testing. 
[127] 
 3% Triton X-100 12h  
4% Sodium deoxycholate 24h yes 
3x distilled water 15m yes 
 
Ethanol:Dichloromethane 
(1:2) 24h  
 
distilled water 
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Distilled water 6h  
New decellularization method 
developed by altering Hudson et 
al. method while still using 
similar detergent combinations 
(sulfobetaine-10, sulfobetaine-
16, Triton X-200, and sodium 
deoxycholate). Method sought 
to reduce residual myelin 
present in the original Hudson et 
al. method. The modified 
method did produce a higher 
degree of demyelination than the 
Hudson method. Comparing 
these two methods to the nerve 
autograft, the modified method 
had a reduce immune response 
in vivo and had remyelination 
that was more similar to 
autograft than the Hudson 
method. However, morphologic 
assessment of axon regrowth 
showed no difference between 
the two methods. 
[120] 
 
125mM sulfobetaine-10 12h yes 
3x 1X PBS 10m  
 0.14% Triton X-200, 0.6 
mM sulfobetaine-16 24h yes 
 
1X PBS 10m  
 
Distilled water 10m  
 
125mM sulfobetaine-10 12h yes 
 
4% Sodium deoxycholate 24h yes 
3x 1X PBS 2h  
 
0.1% Peracetic acid 3h  
3x 
1X PBS 1h  
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Method 1: Hudson Method (control) 
The main goal of the study was 
to develop a protocol that 
limited the hands-on time 
necessary to decellularize 
peripheral nerve in order to 
avoid postprocessing 
sterilization steps. Results 
suggested that both method 2 
and 3 were less harsh than the 
Hudson method with small 
amount of DNA fragments and 
Schwann cells still present after 
decellularization. Furthermore, 
method 2 produced a more 
prominent uneven 
decellularization towards the 
center of the graft. The Triton 
X-100 and SDS method did 
remove most of the myelin 
sheets, axons and DNA residue 
to a satisfactory degree and 
maintained the nerve ECM 
well. 
[144] 
2x 
125 mM SB-10, 10 mM 
phosphate, 50 mM 
sodium 15h yes 
0.14% Triton X-200, 0.6 
mM SB-16, 10 mM 
phosphate, 50 mM 
sodium 24h yes 
Method 2: Triton X-100 based Method 
 
125 mM SB-10, 0.2% 
Triton X-100, 1% 
penicillin-streptomycin 
48h yes 
 Sonication at 40 Hz 2m  
Method 3: Triton X-100 and 
SDS method 
  
 
125 mM SB-10, 0.2% 
Triton X-100, 1% 
penicillin-streptomycin 
48h  
 
freeze-thaw cycle 
  
3x 1X PBS 30m 
 
 
0.25% SDS and sonicated 
for 5m every 30m at 40 
Hz 
3h  
ra
t 
tr
ig
em
in
al
, 
in
tr
ao
rb
it
ra
l 
sc
ia
ti
c 
n
er
v
e 
tr
an
se
ct
io
n
 m
o
d
el
 
P
o
rc
in
e 
fe
ta
l 
u
ri
n
ar
y
 b
la
d
d
er
 m
at
ri
x
 
P
re
ss
ed
 a
n
d
 l
y
o
p
h
il
iz
ed
 i
n
to
 a
 s
h
ee
t.
 
E
T
O
 s
te
ri
li
ze
d
 
M
ec
h
an
ic
al
 a
n
d
 D
et
er
g
en
t 
8x 
Nanopure water 30m  
The method was done under a 
vacuum in a specially designed 
pressure chamber that cycled 
between ambient pressure and 0 
psi at a rate of 1min/cycle. This 
wrap enhanced epi- and 
endoneurial organization and 
increased angiogenesis and 
growth associated protein-43 
expression at peripheral nerve 
repair sites at 28 d post-surgery. 
However, the number of axons, 
myelination, and whisker-
evoked functional responses 
were unaltered. 
[151] 
3% Triton X-100 30m  
3 M NaCl 30m  
 
DNAse 1h  
 0.1% Peracetic acid/ 4% 
ethanol 1h  
 
1X PBS   
3x 
Nanopure water   
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Method 1: Sondell method 
(control)   
Histology showed lower 
immunogenicity for all three 
decellularized groups compared 
to native control, however the 
freeze-thaw combined with 
enzymatic degradation showed 
the lowest inflammatory 
response. This was marked by 
fewer inflammatory cells and 
less necrosis at the downstream 
muscle. In addition, the native 
and first two methods displayed 
expression of MHC-II antigen 
in the neural scaffolds while the 
freeze-thaw enzyme method did 
not. Furthermore, all three 
decellularization techniques had 
similar mechanical properties to 
the native nerve. 
[147] 
 
distilled water 12h yes 
2x 
3% Triton X-100 12h  
4% Sodium 
deoxycholate 24h  
Method 2: Low detergent 
method   
 
ultrapure water 1h yes 
 
0.5% Triton X-100 48h yes 
 
ultrapure water 48h  
 DNase and RNase at 
37°C 12h  
Method 3: Freeze-thaw 
method   
 hypotonic solution at 
4°C 12h  
 hypotonic solution at -
80°C 6h  
 hypotonic solution at 
37°C 30m  
 
0.05% pancreatin 6h  
 DNase and RNase at 
37°C 12h  
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3x 1X PBS   
Caudia equine does not possess 
an epineurium which the study 
hypothesized would allow for 
less harsh decellularization 
methods. The paper found that 
the caudia equine tissue 
required half the time (12h) in 
SDS to achieve similar 
decellularization results. This 
was combined with a 
chondroitin conduit and 
compared in vivo to conduit 
alone, acellular sciatic nerve, 
and autograft. Acellular sciatic 
nerve inferior to the acellular 
caudia equine embedded 
conduit in histologic, 
electrophysiologic, and 
functional metrics. The caudia 
equine conduit device 
performed similarly to the 
autologous nerve graft. 
[139] 
 
0.5% SDS at 16°C 12h 40 
10x 
penicillin (100 U/mL) 
and streptomycin (0.1 
mg/mL) in PBS   
R
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1X PBS 12h  
10x 1X PBS 
  
  40 
Table 7 (continued) 
In
 v
it
ro
 a
n
al
y
si
s 
P
o
rc
in
e 
ca
u
d
ia
 e
q
u
in
e 
H
o
m
o
g
en
iz
ed
 c
au
d
ia
 e
q
u
in
e 
E
C
M
 c
o
m
b
in
ed
 w
it
h
 P
L
G
A
 t
o
 
fo
rm
 a
n
 e
le
ct
ro
sp
u
n
 s
ca
ff
o
ld
 
D
et
e
rg
en
t 
 
distilled water   
Method successfully 
removed genetic material and 
differential centrifugation 
was able to incorporate 
insoluble proteins of the 
caudia equine ECM into an 
aligned, electrospun PLGA 
material. This incorporation 
of ECM proteins enhanced 
neurite outgrowth of dorsal 
root ganglion cells compared 
to PLGA material alone. 
[148] 
 
3% Triton X-100 2h yes 
 4% Sodium 
deoxycholate 2h yes 
 
1X PBS rinse   
 
Homogenized   
 
Centrifugation steps to 
isolate ECM 
precipitate   
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distilled water 15m  
Polydopamine (PDA) was 
coated onto polycaprolactone 
(PCL) conduits to 
successfully increase 
attachment of peripheral 
nerve ECM as a surface 
modification. This was 
shown to have potentially 
beneficial changes in 
Schwann cell behavior when 
cultured on the material in 
vitro. 
[34] 
 
0.5% Triton X-100 in 
1M NaCl distilled 
water 2h yes 
 
1% SDS in 1M NaCl 
distilled water, solution 
changed daily 2d yes 
 
0.1% peracetic acid 
and 4% EtOH in 1M 
NaCl 4h  
 
distilled water 4h  
 
lyophilized   
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3x 
Liquid nitrogen 2m  
This study compared the 
chondroitinase ABC treated 
acellular nerve grafts to those 
imbibed with NGF or GDNF. 
In vivo results showed that 
NGF significantly enhanced 
motor axon outgrowth into 
the graft during the first week 
and the number of 
myelinated axons present at 8 
weeks. However, sensory 
nerve outgrowth was 
significantly stunted 
compared to control and 
GNDF groups. In vitro 
experiments with dorsal root 
ganglion outgrowth in the 
presence of chondroitinase 
ABC and NGF showed no 
effect on sensory neurite 
outgrowth. Authors suggest 
that NGF in the presence of 
chondroitinase ABC might 
promote apoptosis of the 
measured IB4-positive 
sensory neurons. 
[118, 
137] 
Thawed in water bath 
at 37°C 2m  
 2 U/mL chondroitinase 
ABC in PBS at 37°C 16h  
 Rinsed in lactated 
Ringer solution   
 
Incubated with NGF 
(10ug/mL) or GDNF 
(20 ug/mL) solution 1h  
2x 
Rinsed in lactated 
Ringer solution   
  41 
Table 7 (continued) 
C
li
n
ic
al
 s
tu
d
y
 o
f 
d
ig
it
al
 
n
er
v
e 
g
ap
s 
>
2
.5
cm
 
H
u
m
an
 p
er
ip
h
er
al
 n
er
v
e 
g
am
m
a 
ir
ra
d
ia
te
d
 
D
et
er
g
en
t 
an
d
 E
n
zy
m
at
ic
 
 
distilled water 7h  
Rinker et al., 2017 reviewed 
28 patients with digital nerve 
injuries that were treated with 
the Avance nerve graft from 
Axogen. Of these, 86% 
recovered meaningful 
function which matched 
historic data of autograft 
repair (60-80%). Isaacs & 
Safa, 2017 looked at a small 
number of patients that 
required large diameter 
repairs. If repaired with 
autograft, these 4-5 mm wide 
nerves might require a cabled 
repair to avoid limitations of 
large diameter grafts. This 
study examined clinical data 
to see if similar concerns 
exist when using the largest 
diameter Avance nerve 
allografts. The study suggests 
that the acellular graft does 
not have this same limitation 
as autograft, presenting 
similar motor and sensory 
recovery as the gold-
standard. Finally, 
Yampolsky, Ziccardi, & 
Chuang, 2017 reviewed the 
data of the Avance graft 
being used in the 
reconstruction of <2 cm 
trigeminal nerve injuries. In 
this case, 15 of 16 patients 
regained sensory function. 
[38, 
39, 122, 
138] 
 125 mM sulfobetaine-
10 15h yes 
 
50 mM phosphate and 
100mM sodium 15m  
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0.14% Triton X-200, 
0.6 mM sulfobetaine-
16, 10 mM phosphate 
and 50 mM sodium 24h yes 
3x 
50 mM phosphate and 
100mM sodium 5m  
 125 mM sulfobetaine-
10 7h yes 
C
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r  50 mM phosphate and 
100mM sodium 15m  
 
0.14% Triton X-200, 
0.6 mM sulfobetaine-
16, 10 mM phosphate 
and 50 mM sodium 15h  
3x 
50 mM phosphate and 
100mM sodium 15m  
 
Chondroitinase ABC 
37°C   
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Sondell M. et al. was one of the first investigators to decellularize peripheral nerve for 
use as an allograft. [121]Rat sciatic nerves were treated using Triton X-100 and SDC. (Table 3) 
This process was repeated once and then the graft was washed in distilled water and stored in 
PBS. Early understanding of peripheral nerve decellularization was enhanced by Hudson et al., 
who compared the effects of many different detergents on cellular clearance and ECM 
preservation. An anionic detergent, Triton X-200 was found to be the most effective 
decellularization agent and combined with two amphoteric detergents to further increase 
effectiveness  [116, 149]. This method was more effective a decellularizing the peripheral nerve 
tissue while better preserving the ECM when compared to the Sondell et al. method. [115-117, 
149]This foundation led to a wide range of work optimizing the methods, structure, and 
composition of decellularized nerve grafts. 
Despite advantages of the detergents Hudson et al. method identified, variations of the 
Sondell et al. method using Triton X-100 and sodium deoxycholate are still investigated [52, 
132, 148]. Sridharan et al. used a modified Sondell et al. method to decellularize rat sciatic 
nerves but imparted an axially aligned channel structure through controlled freezing [132]. The 
study hypothesized that native pore size of basal laminal tubes was not ideal for nerve 
regeneration and sought to increase the pore size to enhance axon penetration. They showed that 
their methods were able to effectively decellularized the tissue and significantly increased pore 
size and the channels remained axially aligned. Briefly, the sciatic nerves were placed into 
insulating molds and stood upright, perpendicular to the freeze-dryer plate. Freezing rate was 
controlled to a constant rate of 1 °C/min to a final temperature of -30 °C. This was held for 1 hr 
before warming to -10 °C to lyophilize for 24 hr. In vivo work has not been published, however 
in vitro work showed enhanced PC12 cell migration both in number and depth into the graft. 
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Remnant detergents can be cytotoxic to infiltrating cells, so investigators have tried 
reducing or removing the detergent load [118, 130, 131, 137, 147, 159]. Kim et al. devised a 
method that used minimal detergent concentrations to decellularize rat sciatic nerves [130]. This 
method decellularized the nerve to a similar degree to the Hudson method but displayed better 
ECM preservation. In a rat sciatic nerve gap model, the method without the detergents 
outperformed the Hudson method in nerve histomorphometry and muscle mass, but ultimately 
the nerve autograft controls showed greater recovery. Several decellularization methods have 
been developed that use no detergents to create acellular grafts [118, 130, 131, 137, 147, 159]. 
Both Wang et al. 2013 and Boyer et al. 2015 explored the use of mechanical and enzymatic 
decellularization method to replace detergent based methods. Want et al. 2013 performed a 
signal freeze-thaw cycle and used DNase and RNase to finish the decellularization of rat sciatic 
nerves. This method produced less inflammation in vivo compared to the Sondell et al. method 
and a light detergent method which showed expression of MHC-II within the scaffolds [147]. To 
enhance removal of chondroitin sulfate proteoglycans, a known inhibitor of regrowth, Boyer et 
al. 2015 used a method that combined multiple freeze-thaw cycles with chondroitinase ABC. 
The reduction of chondroitin sulfate proteoglycan with chondroitinase ABC was shown to 
increase axon growth into critically long grafts [118]. Boyer et al. 2015 augmented the scaffold 
with NGF and found enhanced motor neuron survival and growth [137]. Cornelison R. C. et al. 
used camptothecin, hypertonic PBS solution, and 75 U/ml DNAse to decellularize sciatic nerves 
without the use of detergents and using the Hudson method as a comparison [159]. Their 
apoptosis-assisted decellularization method was able to successfully decellularize the tissue 
while maintaining basal lamina microarchitecture while being less cytotoxic than detergent 
decellularization methods. The apoptosis-assisted method also produced less inflammatory 
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infiltrate and stromal remodeling compared to the autograft control. Vasudevan S. et al. 
developed a decellularization method that utilized a yet undescribed technique [131]. Rat sciatic 
nerves were cultured in DMEM with 10% fetal bovine serum and 2% 
penicillin/streptomycin/amphotericin for 2 weeks under constant agitation. After the 2-week 
culture period, the nerves were transferred to a new tube containing only PBS and kept for 1 
week under constant agitation. The abrupt termination of nutrient supply was expected to aid in 
decellularization. In a rat sciatic nerve gap model, histologic results indicated that nerve 
autografts outperformed both the detergent-free and detergent decellularized grafts. Only nerve 
autograft and detergent free grafts showed functional recovery in muscle force testing. 
Another approach to replacing the nerve autograft is nerve guidance conduits. While 
outcomes of current nerve guidance conduits are often inferior to the nerve autograft, researchers 
have investigated numerous approaches to improve these devices. The inclusion of ECM is one 
such strategy. This dissertation proposes the inclusion of a hydrogel from a decellularized sciatic 
nerve as a lumen filler for a nerve guidance conduit.  
2.2 Methods 
2.2.1 Preparation of Peripheral Nerve ECM 
As most ECM scaffolds used in clinical settings are of a xenogeneic nature, and due to the 
amount of material required for processing, sciatic nerve tissue was originally harvested from an 
equine source for use in canine experiments. PNM was first developed using equine sciatic nerve 
harvested from healthy, adult horses euthanized for reasons unrelated to nerve injury or 
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neurological disease. These tissues were frozen for at least 16h at -80° C. The outer portion of the 
epineurium of the nerve was stripped by sharp dissection and mechanical delamination, leaving 
the nerve bundles intact. The tissue was then sectioned longitudinally and cut into lengths of less 
than 5 cm and quartered lengthwise prior to treatment.  
Tissues were then processed using a modification of a protocol for spinal cord 
decellularization as previously described [107]. Briefly, the decellularization process consisted of 
a series of agitated washes: water (type 1, ultrapure, Milli-Q® purified water, 14 hours at 4° C), 
0.02% trypsin (HyClone)/0.05% EDTA (Invitrogen, Waltham, MA USA) (60 minutes at 37° C), 
3.0% Triton X-100 (Sigma, 60 min), water rinse (type 1, repeated until agitation no longer 
produced bubbles), 1M sucrose (Thermo Fisher, Waltham, MA USA, 15 min), 4.0% sodium 
deoxycholate (Sigma, St. Louis, MO, USA 60 min), 0.1% peracetic acid/4% ethanol (Sigma, 120 
min), 1X PBS (15 min), water (14 hours), 1X PBS (15 min). Following treatment, samples were 
frozen (-80° C) and then lyophilized. 
Further studies utilized both canine and porcine sciatic nerves also harvested following 
euthanasia of adult animals for reasons unrelated to nerve injury or neurological disease. These 
tissues were also frozen for at least 16 h at -80° C. The epineurium was left intact, but the nerves 
were halved longitudinally and segmented into smaller 0.5 cm sections. The same protocol as 
above was performed with the addition of another water rinse (type 1, repeated until agitation no 
longer produced bubbles) after the 4.0% sodium deoxycholate wash.  
Enzymatic degradation products were generated from the above PNM and UBM scaffold 
materials as previously described [21]. Briefly, lyophilized scaffold materials were powdered and 
solubilized at a concentration of 20 mg/mL in a solution containing 2.0 mg/mL pepsin (Sigma) in 
0.01 N HCl (ACROS organic) at a constant stir rate for 48h and then frozen for future use. 
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Finally, the porcine sciatic nerve was sourced from clinical grade, traceable, market-weight 
pigs (Tissue Source; LLC, Lafayette, IN). The tissue was then frozen for at least 16 h at -80° C. 
The tissue was quartered longitudinally and cut into sections of less than 5 cm. Decellularization 
was performed as previously described [162]. Enzymatic degradation products were produced 
from solid ECM scaffold material as previously described [162]. Enzymatic degradation products 
were aliquoted and lyophilized. Immediately before use, lyophilized degradation products were 
rehydrated using sterile water. Gelation was then initiated by adjusting the pH of the digest to 7.4 
and 0.5X PBS concentration through the addition of 0.2 M NaOH and 10X PBS.  
Comparisons were made with both canine and porcine ECM. Urinary bladder matrix 
(UBM) from a canine source and both UBM and small intestine submucosal matrix (SIS) from 
porcine sources were used as a control for characterization of decellularization and biochemical 
composition. Urinary bladder matrix was chosen as a control as it is a well characterized source 
for tissue decellularization, protocols resulting in effective decellularization have been established. 
Canine urinary bladder matrix was prepared as previously described [163]. Briefly, the tissue was 
bisected into a sheet and mechanically delaminated to remove the outer muscular layers, leaving 
the urothelial basement membrane and underlying connective tissue intact. The delaminated tissue 
was then subjected to washes in 0.1% peracetic acid/4% ethanol (Sigma, 120 min), 1X PBS (15 
min), water (14 hours), 1X PBS (15 min). All tissues were then treated in a manner like that 
described for PNM. Porcine urinary bladder extracellular matrix (UBM) was also prepared using 
the previously described method [164]. 
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2.2.2 Formation of Hydrogel from Enzymatic Degradation Products 
ECM hydrogels were formed from the degradation products as previously described [165]. 
Briefly, gelation was induced by adjusting the pH of the pepsin digest to 7.4 through the addition 
of one-tenth the digest volume of 0.1 M NaOH, one-ninth the digest volume of 10X PBS, and then 
diluting to the desired final ECM concentration in 1X PBS. Dilutions were performed on ice and 
the gel solution was placed in a non-humidified incubator at 37° C and allowed to gel for 1 h for 
benchtop confirmation of gelation. Concentrations between 8 and 15 mg/mL were examined 
visually for their ability to form a hydrogel. Hydrogels were prepared and evaluated under SEM 
using a standard preparation procedure and imaged at 4,000 magnification. 
2.2.3 Confirmation of Decellularization 
Qualitative and quantitative assessments of cellular content was performed on all three tissue 
sources including histologic staining, immunofluorescent labeling, and dsDNA quantification. 
Fixation of lyophilized ECM scaffolds was performed in 10% neutral buffered formalin (Electron 
Microscopy Sciences, Hatfield, PA, USA). Samples were embedded in paraffin, sectioned, and 
stained with hematoxylin and eosin (H&E) or with 4',6-diamidino-2-phenylindole DAPI to verify 
removal of nuclei. Additional samples were stained using Luxol fast blue to determine removal of 
myelin as an additional metric of decellularization.  
Qualitative assessment of DNA content was conducted by digesting the ECM scaffold in 
0.1 mg/mL proteinase K solution (Invitrogen). Protein content was removed from the sample by 
repeated phenol/chloroform/isoamyl alcohol (Thermo Scientific) extraction and centrifugation 
(10,000 G) until no protein precipitate was observed at the interface. The aqueous layer was mixed 
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with 3 M sodium acetate (Fisher Scientific) and 100% ethanol. The solution was frozen using dried 
ice and centrifuged to produce a DNA pellet. The pellet was rinsed with 70% ethanol, centrifuged 
(10,000 G), and dried. Double-stranded DNA was then quantified using Quant-iT™ PicoGreen 
dsDNA assay kit (Life Technologies) following kit instructions. Statistical significance was 
assessed using one-way ANOVA with Tukey post-hoc test. Additionally, agarose gel 
electrophoresis was performed to assess base pair length of any remaining DNA. 
2.2.4 Assessment of Extracellular Matrix Ultrastructure and Components 
Maintenance of tissue-specific extracellular matrix components was assessed using 
histologic staining, immunolabeling, and scanning electron microscopy (SEM). Scaffold materials 
were fixed in 10% neutral buffered formalin, embedded in paraffin and sectioned at 5 µm. 
Immunolabeling was performed with antibodies specific to ECM components (collagen I, III, and 
IV). Briefly, after deparaffination, all slides were subjected to antigen retrieval by immersion in 
95°C–100° C in citric acid solution (Acros Organics, Waltham, MA USA, 10 mM, pH 6.0; 20 
min) followed by rinsing in a 1X Tris buffered saline/Tween-20 solution (0.1% Tween 20, Fisher 
Scientific, v/v, pH 7.4; 3 washes, 5 minutes each). Samples were then washed in PBS and treated 
with a pepsin digestion (0.05% pepsin, Sigma, w/v in 10 mM HCl, 15 minutes at 37° C. solution 
for further antigen retrieval. Samples were blocked against nonspecific binding using a solution 
consisting of 2% horse serum, 1% bovine serum albumin, 0.1% Tween-20, and 0.1% Triton X-
100 in PBS for 30 minutes at room temperature. Primary antibodies for collagen I, III, and IV 
(Sigma, 1:200) were applied to sections overnight at 4° C. Samples were washed in PBS and 
appropriate fluorescently labeled secondary antibodies (AlexaFluor 488, 1:250) were applied for 
60 minutes at room temperature. 
  49 
For SEM, lyophilized samples were fixed in cold 2.5% (v/v) glutaraldehyde and processed 
using an established method [164]. The dried samples were mounted onto aluminum stubs and 
sputter coated with a 3.5 nm layer of gold–palladium alloy prior to imaging 
Quantitative assessment of collagen (hydroxyproline) and GAG content was performed 
through spectrophotometric assays. 100 mg of dry tissue was digested overnight at 60o C in 0.125 
mg/ml papain (Sigma) in phosphate buffer with 0.01 M EDTA and 0.01 M cysteine (Sigma). 
Afterwards, GAG content was assessed by mixing aliquots of the resultant digest with the dye 1,9-
dimethylmethylene blue (Fisher Scientific) and reading the absorption of a 525 nm wavelength. 
Hydroxyproline content was analyzed as per a published protocol [166]. 
The concentrations of nerve growth factor (NGF) and ciliary neurotrophic factor (CNTF) 
in NP40-glycerol extracts (20 mM Tris containing 1.0% NP40, 10% glycerol, and protease 
inhibitors) of native nerve, PNM, and UBM were determined using human β-NGF and human 
CNTF ELISA kits (Sigma). These ELISA assays are cross-reactive with porcine and equine 
growth factors and indicative of concentration but not activity. Assessment of growth factor 
composition was performed only on PNM harvested from equine sources; however, all other 
assessments were performed on both canine and equine PNM samples. 
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2.2.5 Mechanical and Morphologic Aspects of the Resultant Hydrogels  
For scanning electron microscopy (SEM), lyophilized samples were fixed in cold 2.5% 
(v/v) glutaraldehyde and processed using a standard SEM preparation procedure. The dried 
samples were mounted onto aluminum stubs and sputter coated with a 3.5 nm layer of gold–
palladium alloy prior to imaging.  
To test the mechanical properties of the resultant PNM hydrogel an AR2000 dynamic 
rheometer was used to measure gelation time and shear storage (G’) and loss moduli (G’’).  The 
concentration of PNM reconstituted into a hydrogel was varied (8, 10, 15 and 20 mg/mL). 
Measurements were acquired using a time sweep with a frequency of 0.1 Rad and using a 40mm 
plate with a 0.5 mm gap over 2000 sec. A frequency sweep between 5 and 0.1 will also performed. 
 
2.3 Results 
2.3.1 Confirmation of Decellularization 
2.3.1.1 Equine Sciatic Nerve Decellularization 
Following decellularization, Decellularized canine sciatic nerve shows significant removal 
of nuclei through H&E staining (Figure 3A) compared to native sciatic tissue (Figure 3B). o nuclei 
were visible in hematoxylin and eosin (H&E) stained sections under light microscopy (Figure 3A-
B). DAPI stain in decellularized (Figure 3C) and native (Figure 3D) shows similar results with a 
small number of disrupted nuclei remaining In some samples, a small number of nuclei (2-3 
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nuclei/40X field) were observed when labeled with DAPI (Figure 3E-F). When present, retained 
nuclei were observed within the central most nerve fascicles relative to the whole nerve tissue or 
within the dense perineurium of the treated tissues.  
DNA remaining in the scaffold is highly fragmented (< 400bp) (Figure 3E). Quant-iTTM 
PicoGreen assay for dsDNA content shows dsDNA content of the decellularized tissue of PNM 
was significantly decreased as compared to native tissue (p < 0.05, n = 5) ( 4F). dsDNA content 
was decreased by approximately 85% in the decellularized tissue (158.1 ± 34.5 ng/mg) compared 
to native tissue (1,043.6 ± 291.2 ng/mg) (Figure 3F). Error bars denote standard deviation. These 
values are consistent with those reported for multiple FDA approved, commercially available ECM 
scaffold materials [29].  
 
 
 
 
Figure 3: Confirmation of decellularization for an equine sciatic nerve 
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2.3.1.2 Canine sciatic nerve decellularization 
Decellularized canine sciatic nerve shows significant removal of nuclei through H&E 
staining (Figure 4A) compared to native sciatic tissue (Figure 4B). Following decellularization of 
canine sciatic nerve, few nuclei were visible in hematoxylin and eosin (H&E) stained sections 
under light microscopy (Figure 4A–B). DAPI stain in decellularized (Figure 4C) and native 
(Figure 4D) shows similar results with a small number of disrupted nuclei remaining In some 
samples, a small number of nuclei (5–10 nuclei/20X field) were observed when labeled with DAPI 
(Figure 4C–D). When present, retained nuclei were observed within the central most nerve 
fascicles relative to the whole nerve tissue or within the dense perineurium of the treated tissues. 
Luxol Fast Blue staining was used to assess myelin content in decellularized (Figure 4E) and native 
(Figure 4F) sciatic nerve. Myelin, a potentially immunogenic axonal component [167], was 
reduced within the endoneurial tissue compared to dark circles of myelin in native tissue after 
decellularization process (Figure 4E–F). 
 PicoGreen assay for DNA content shows dsDNA content of the decellularized tissue of 
both PNM and urinary bladder matrix was significantly decreased as compared to native tissues (p 
< 0.05, n = 5) (Figure 4G). The dsDNA that remains within PNM was highly fragmented (<400bp) 
compared to dsDNA extracted from native tissue (Figure 4H). The dsDNA content was decreased 
by approximately 85% in the decellularized tissue (158.1 ± 34.5 ng/mg) compared to native tissue 
(1,043.6 ± 291.2 ng/mg) (Figure 4G). These values are consistent with those reported for multiple 
FDA approved, commercially available ECM scaffold materials [168].  
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Figure 4: Confirmation of decellularization of a canine sciatic nerve 
Decellularized canine sciatic nerve shows significant removal of nuclei through H&E staining (A) 
compared to native sciatic tissue (B). DAPI stain in decellularized (C) and native (D) shows similar results 
with a small number of disrupted nuclei remaining. Luxol Fast Blue staining myelin dark blue is reduced 
after decellularization (E) within the endoneurial tissue compared to dark circles of myelin in native tissue 
(F). (G) PicoGreen assay for DNA content shows dsDNA content of the decellularized tissue of both PNM 
and urinary bladder matrix was significantly decreased as compared to native tissues (**, p<0.05, n=5). (H) 
The dsDNA that remains within PNM was highly fragmented (<100bp) compared to dsDNA extracted from 
native tissue. Reused with permission (4546560968632). [52] 
 
2.3.1.3 Porcine sciatic nerve decellularization 
Decellularization was confirmed qualitatively through DAPI staining and SEM imaging 
(Figure 5A-D). DAPI stain for nuclei in native (Figure 5A) and decellularized sections (Figure 5B) 
of sciatic nerve. DAPI staining showed a full reduction in whole nuclei within the solid nerve 
scaffold (Figure 5A, B). SEM images shows dense tissue both between and within individual 
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fascicles before decellularization (Figure 5C). After decellularization, the tissue is porous with 
tubules where the axons previously resided. The original structures, including endoneurium and 
perineurium are well preserved within the scaffold (Figure 5D). Quantitative results showed 
effective removal of cellular content and high degree of fragmentation after decellularization 
(Figure 5E, F). Gel electrophoresis shows highly fragmented remnant DNA after decellularization 
with the majority below 400bp (Figure 5E) Quant-iTTM PicoGreen assay for dsDNA showed a 
statistically significant (p < 0.01) reduction of 84% in residual dsDNA after decellularization 
(Figure 5F). Error bars show standard deviation of a n = 5. 
 
 
 
 
Figure 5: Conformation of decellularization of a porcine sciatic nerve 
Qualitative assessment of decellularization was confirmed through DAPI staining of native 
(A) and decellularized (B) as well as SEM imaging of native (C) and decellularized (D). Gel 
electrophoresis was performed to assess dsDNA fragmentation (E). The dsDNA that remains 
F 
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within PNM was highly fragmented (<100bp) compared to dsDNA extracted from native tissue. 
(F) PicoGreen assay for DNA content shows dsDNA content of the decellularized tissue of PNM 
was significantly decreased as compared to native tissues (**, p<0.05, n=5).  
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2.3.2 Maintenance of Extracellular Matrix Ultrastructure and Components 
2.3.2.1 Equine Sciatic Nerve Decellularization 
Biochemical testing was performed to assess the quantity of basic ECM components 
including hydroxyproline and GAG as well as nerve-specific growth factors including ciliary 
neurotrophic factor (CNTF) and nerve growth factor (NGF). Hydroxyproline content increased 
from 34.9 ± 9.1 µg/mg in native nerve tissue to 65.0 ± 9.4 µg/mg after decellularization (p = 0.027). 
PNM was observed to contain less hydroxyproline than UBM (65.0 ± 9.4 µg/mg) (p = 0.001) 
(Figure 6A). GAG content decreased with decellularization (native 51.3 ± 8.0µg/mg to 31.0 ± 
16.7µg/mg). Homogeneity of variances was violated; therefore, a Games-Howell post-hoc test was 
used to reveal a difference between native nerve and UBM (p = 0.001) but no significant difference 
between PNM and native nerve (p = 0.15) or UBM (p = 0.33) (Figure 6B). Levels of NGF in PNM 
(177.0 ± 33.2 pg/g) were retained at 26% of the native nerve (680.9 ± 160.8 pg/g) after 
decellularization (p < 0.001). Despite a non-nerve tissue origin, UBM was observed to have a 
similar amount of NGF (161.0 ± 38.5 pg/g) as PNM (p = 0.953) (Figure 6C). After 
decellularization, 50% of CNTF was preserved from native nervous tissue (457.5 ± 60.9 pg/g) to 
PNM (228.2 ± 38.4 pg/g) (p < 0.001). A comparable amount of CNTF was found in UBM (301.6 
± 58.3 pg/g) (p =0.953) (Figure 6D). Differing letters denote statistical significance (p < 0.05) and 
error bars show standard deviation. 
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Figure 6: Composition analysis of equine sciatic nerve 
Quantification of hydroxyproline, glycosaminoglycan, nerve growth factor, and ciliary 
neurotrophic factor content in equine sciatic nerves. (A) Relative hydroxyproline content, a proxy 
for collagen content, was found to increase after decellularization. This could be caused by an 
overall reduction of cells within the tissue. PNM was observed to have less hydroxyproline than 
UBM. (B) Glycosaminoglycan content did not change after decellularization and content was  
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greater than seen in UBM. (C-D) Nerve specific growth factors were significantly reduced by 
decellularization and were similar between PNM and UBM. Differing letters denote statistical 
significance (p < 0.05) and error bars show standard deviation. 
2.3.3 Canine Sciatic Nerve Decellularization 
Individual components of the ECM were examined through immunofluorescent staining of 
collagen I, collagen III, and collagen IV before and after decellularization (Figure 7A-F). Collagen 
I was seen both within the endoneurial and epineurial space before decellularization (Figure 7A) 
but was reduced by decellularization (Figure 7B). Little positive staining of collagen III was seen 
in both native (Figure 7C) and decellularized (Figure 7D) sciatic nerve tissue sections. 
Maintenance of the basal lamina was investigated through staining of collagen IV, a major 
constituent of the basal lamina. While immunofluorescent labeling showed that the content and 
organization of collagen I and III was affected by decellularization (Figure 7A–D), collagen IV 
within individual nerve bundles was strongly preserved (Figure 7E–F). Strong positive staining 
within the decellularized samples both within the endoneurial basal lamina and within the 
perineurium (Figure 7E–F) with a similar pattern of staining between the decellularized and native 
samples, suggests a strongly preserved basal lamina structure. The intensity of the staining within 
the endoneurium, however, was less than the perineurium and the architecture was slightly 
disrupted as compared to native tissue. 
 Low (Figure 7G, H) and high (Figure 7I, J) magnification scanning electron microscopy 
(SEM) images of native and decellularized sciatic nerve. Cross-sectioned native (Figure 7G) and 
decellularized (Figure 7H) tissue at 150X magnification shows a dense epineurial space that it is 
largely cleared by decellularization but perineurium and endoneurium structure largely 
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maintained. Enhanced magnification (1000X) of the same samples, native (Figure 7I) and 
decellularized (Figure 7J) endoneurial tissue. Images show the presence (Figure 7I) and removal 
of (Figure 7J) axons within the endoneurium. Biochemical assays for hydroxyproline (Figure 7K) 
and glycosaminoglycans (GAG) (Figure 7L) did not reveal any significant changes to either 
component after peripheral nerve decellularization (p = 0.57 n = 5, p = 0.26 n = 5). These 
components were compared to urinary bladder matrix (UBM) which had significantly more 
hydroxyproline (p = 0.001) (Figure 7K) but significantly less GAG (p = 0.001, Figure 7L) than 
PNM and native nerve. Different letters denote a significant difference (p < 0.05).  
The solubilized PNM can be reconstituted into a stable hydrogel at concentrations as low 
as 8 mg/ml. This was visually confirmed by depositing the neutralized PNM solution within a 
stainless-steel ring and incubating at 37° C for 30 min (Figure 7M). Under SEM, the hydrogel was 
characterized by a highly porous network of fibular proteins (Figure 7N). Image shows 
macroscopic (Figure 7M) and SEM image (Figure 7N) of an 8 mg/ml equine PNM hydrogel 
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Figure 7: Characterization of remaining content within canine sciatic nerve after 
decellularization 
(A–F) Immunofluorescent staining of collagen I, collagen III, and collagen IV before and 
after decellularization. Collagen I was seen both within the endoneurial and epineurial space before 
decellularization (A) but was reduced by decellularization (B). Little positive staining of collagen 
III was seen in both native (C) and decellularized (D) sciatic nerve tissue sections. Collagen IV, a 
major component of the basal lamina had strong staining around the individual nerve fibers, in the 
endoneurial space, and in the perineurium in native nerve (E). The same pattern of collagen IV 
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staining was seen in the decellularized nerve tissue (F) suggesting a preservation of the basal 
lamina. (G, H) Low and (I, J) high magnification scanning electron microscopy (SEM) images of 
native and decellularized sciatic nerve. Cross-sectioned native (G) and decellularized (H) tissue at 
150X magnification shows a dense epineurial space that it is largely cleared by decellularization 
but perineurium and endoneurium structure largely maintained. Enhanced magnification (1000X) 
of the same samples, native (I) and decellularized (J) endoneurial tissue. Images show the presence 
(I) and removal of (J) axons within the endoneurium. Biochemical assays for hydroxyproline (K) 
and glycosaminoglycans (GAG) (L) did not reveal any significant changes to either component 
after peripheral nerve decellularization (p=0.57 n=5, p=0.26 n=5). These components were 
compared to urinary bladder matrix (UBM) which had significantly more hydroxyproline but 
significantly less GAG than PNM and native nerve. Different letters denote a significant difference 
(p<0.05). Image shows macroscopic (E) and SEM image (F) of an 8 mg/ml equine PNS-ECM 
hydrogel. Reused with permission (4546560968632). [52] 
 
2.3.3.1 Porcine sciatic nerve decellularization 
 
The qualitative presence of tissue-specific extracellular matrix components was confirmed 
using immunofluorescent staining methods. Samples were stained with antibodies specific to 
collagen I, III, IV and laminin. Native and decellularized porcine nerve sections on the top and 
bottom rows respectively stained for collagen I (Figure 8A, B), collagen III (Figure 8C, D), 
collagen IV (Figure 8E, F), and laminin (Figure 8G, H). Collagen I was seen predominately within 
the epineurial space around the nerve bundles before decellularization ( 8A) but was completely 
reduced by decellularization (Figure 78B). Little positive staining of collagen III was seen in both 
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native ( 8C) and decellularized ( 8D) sciatic nerve tissue sections. Maintenance of the basal lamina 
was investigated through staining of collagen IV and laminin, a major constituent of the basal 
lamina. While immunofluorescent labeling showed that the content and organization of collagen I 
and III was affected by decellularization ( 8A–D), collagen IV and laminin within individual nerve 
bundles was strongly preserved ( 8E–H). Strong positive staining within the decellularized samples 
both within the endoneurial basal lamina and within the perineurium ( 8E–F) with a similar pattern 
of staining between the decellularized and native samples, suggests a strongly preserved basal 
lamina structure 
Quantitative assessment of ECM components hydroxyproline (Figure 8I) and 
glycosaminoglycans was determined through direct spectrophotometric assays (Figure 8J). No 
significant differences were observed in either hydroxyproline or glycosaminoglycan content 
between native and decellularized porcine sciatic nerve tissues. 
Assessment of nerve specific growth factors including brain derived neurotrophic factor 
(BDNF) ( 9A), neurotrophic factor 3 (NT-3) ( 9B), ciliary neurotrophic factor (CNTF) ( 9C), and 
nerve growth factor (NGF) ( 9D) in PNM as compared to native tissues and decellularized tissues 
from other anatomic locations (UBM- urinary bladder, SIS- small intestine submucosa) was 
assessed using ELISA kits. Some similarities between PNM and both SIS and UBM were 
observed. PNM had similar levels as SIS of BDNF and similar levels to UBM for NGF. In addition 
to these similarities, both SIS and UBM showed significantly higher concentrations of NT-3 (p < 
0.05, n = 5). However, in all four nerve-specific growth factors surveyed PNM most closely 
matched the normal profile of the native nerve source. This suggests that PNM might more closely 
match the overall growth factor profile of normal nerve tissue. 
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Figure 8: Structural ECM components of porcine sciatic nerve 
(A–F) Immunofluorescent staining of collagen I, collagen III, collagen IV, and laminin 
before and after decellularization. Collagen I was seen both within the endoneurial and epineurial 
space before decellularization (A) but was reduced by decellularization (B). Little positive staining 
of collagen III was seen in both native (C) and decellularized (D) sciatic nerve tissue sections. 
Collagen IV, a major component of the basal lamina had strong staining around the individual 
nerve fibers, in the endoneurial space, and in the perineurium in native nerve (E). The same pattern 
of collagen IV and laminin staining was seen in the decellularized nerve tissue (F) suggesting a 
preservation of the basal lamina. Biochemical assays for hydroxyproline (I) and 
glycosaminoglycans (GAG) (J) did not reveal any significant changes to either component after 
peripheral nerve decellularization (p=0.6 n=5, p=0.4 n=5).  
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Figure 9: Bioactive components in porcine PNM 
Assessment of nerve specific growth factors including brain derived neurotrophic factor 
(BDNF)(A), neurotrophic factor 3 (NT-3) (B), ciliary neurotrophic factor (CNTF)(C), and nerve 
growth factor (NGF)(D) in PNM as compared to native tissues and decellularized tissues from 
other anatomic locations (UBM- urinary bladder, SIS- small intestine). PNM was found to have 
similar levels of nerve specific growth factors including brain derived neurotrophic factor 
(BDNF)(A), neurotrophic factor 3 (NT-3)(B), ciliary neurotrophic factor (CNTF)(C), and nerve 
growth factor (NGF)(D) as compared to native tissues, but significantly increased levels as 
compared to decellularized tissues from other anatomic locations (UBM- urinary bladder, SIS- 
small intestine).  
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2.3.4 Maintenance of Extracellular Matrix Ultrastructure and Components 
Maintenance of the basal lamina was investigated through staining of collagen IV, a major 
constituent of the basal lamina. While immunofluorescent labeling showed that the content and 
organization of collagen I and III was affected by decellularization (Figure 8A-D), collagen IV 
within individual nerve bundles was strongly preserved (Figure 8E-H). Strong positive staining 
within the decellularized samples both within the endoneurial basal lamina and within the 
perineurium (Figure 8E-H), suggests a strongly preserved basal lamina structure. The intensity of 
the staining within the endoneurium, however, was less than the perineurium and the architecture 
was slightly disrupted as compared to native tissue. 
PNM was found to have similar levels of nerve specific growth factors including brain 
derived neurotrophic factor (BDNF) (Figure 9A), neurotrophic factor 3 (NT-3) (Figure 9B), ciliary 
neurotrophic factor (CNTF) (Figure 9C), and nerve growth factor (NGF) (Figure 9D) as compared 
to native tissues. In most cases, PNM had significantly increased levels as compared to 
decellularized tissues from other anatomic locations (UBM- urinary bladder, SIS- small intestine) 
except for NT-3 where both native nerve and PNM had significantly less than UBM and SIS.  
2.3.5 Assessment of Mechanical and Morphometric Characteristics of Resultant PNM 
Hydrogel 
The hydrogel was formed by returning the digested ECM to a pH of 7.4 and raising the temperature 
to 37 o C. A time sweep was run showing gelation within 10 minutes and a maximum storage 
modulus of 70 Pa ( 10A, B). Analysis of morphometric properties of the gel showed minimal 
difference in fibrinous connections and porosity with changing concentration ( 10C, D). Examples 
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of the PNM hydrogel at 8, 10, and 15 mg/mL can be seen in  10E. A max of 70 Pa was a very weak 
hydrogel that may not hold up to surgical conditions. However, based on literature nervous tissue 
prefers weaker materials. Study suggest that scaffolds stiffer than 500 Pa limit neurite growth 
[169]. Therefore, our goal was to tailor the PNM hydrogel to a stiffness between 100-200 Pa. This 
would still be a soft matrix that neurons prefer but stable enough for clinical use. 
Based on previously published work on ECM hydrogels, we were able to alter mechanical 
properties of the hydrogel by changing salt concentrations [170]. We found that lowering the ionic 
concentration to 0.5X PBS significantly increased the storage modulus of the PNM hydrogel (*, p 
< 0.05,  11A, B). When the ionic concentration was again tested with multiple concentrations, we 
found that PNM hydrogels at 15 and 20 mg/mL fell within our desired range ( 12A, B). In addition, 
results suggest that the current PNM hydrogel has an upper stiffness of ~150 Pa as increasing 
concentration did not increase stiffness above 15 mg/mL. 
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Figure 10: Mechanical and morphometric properties of canine PNM hydrogel 
(A) Rheometry of PNM hydrogel at 8, 10, and 15 mg/mL. No significant differences were observed 
but batch to batch variable of early samples increased experiment variability (n=5). (B) Sample 
trace of a single rheometry run of the 8, 10, and 15 mg/mL PNM hydrogel. The 10 mg/mL hydrogel 
reaches peak storage modulus by 10 minutes. (C-D) SEM images of the PNM hydrogels were 
assessed for porosity and fibrillar connections but no differences were observed. (E) Sample SEM 
images of the PNM hydrogel at 8, 10, and 15 mg/mL. 
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Figure 11: Varying salt concentration changes mechanical properties of porcine PNM 
hydrogel 
(A) Sample trace of a single rheometry test of a 20 mg/mL porcine PNM hydrogel with varied 
ionic strength. (B) Reducing ionic strength by using 0.5X PBS produced the most stable hydrogel. 
(*, p < 0.05, n = 5) 
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Figure 12: Porcine PNM hydrogel shows a maximal storage modulus 
(A) Sample trace of a single rheometry test using 0.5X PBS at 10, 15, and 20 mg/mL using porcine 
PNM. (B) Storage modulus increases between 10 to 15 mg/mL but did not increase from 15 to 20 
mg/mL. (*, p < 0.05, n = 5) 
 
 
 
2.3.6 Defining Best Practices for Injectable Hydrogel 
PNM was previously observed to form a stable hydrogel in vitro between concentration of 
8-15 mg/mL. PNM was then assessed for the ability to form a hydrogel in vivo. The PNM hydrogel 
was tested in a rat model of sciatic nerve defect and repair. A silicone conduit was filled with the 
PNM hydrogel at 10mg/ml as a lumen filler and removed after 1 hour. Different sized conduits 
were tested as well as different methods of injecting and gelating the PNM to define best practices 
for delivering the hydrogel. A larger conduit with an inner diameter of 2.5 mm, approximately 0.5 
mm larger than the sciatic nerve was tested first. The hydrogel was first injected into the conduit 
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and allowed to gel in a non-humidified incubator at 37o C before implantation ( 13A). Most of gel 
was lost during manipulation of conduit into place. The conduit was not refilled, and the hydrogel 
was not present at all after 1 hour ( 13B). The same conduit was tested but implanted before 
injecting the PNM digest ( 13C). The hydrogel was slowly leaking out and was down to 50% 
during muscle suturing. Only a small gel plug remained after 1 hour ( 13D). The same process was 
repeated with a conduit with an inner diameter comparable to the rat sciatic nerve (1.98 mm inner 
diameter.) Gelling the PNM hydrogel prior to implantation still caused liquid to leak out during 
manipulation of conduit and only 50% remained at muscle closure ( 13E). However, the 50% 
appeared to remain after 1 hour ( 13F). ( 13G, H) The same PNM hydrogel was injected in the 
conduit after placement. ( 13G) Only a very small amount of the hydrogel was observed to exit the 
conduit. ( 13H) The conduit appeared to remain full of the 10 mg/mL PNM hydrogel after 1 hour. 
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Figure 13: Testing different protocols for in vivo injection of PNM hydrogel into a silicone 
conduit 
(A) PNM hydrogel injected into 2.5mm diameter conduit prior to implantation. (B) After 
1 hour, conduit was empty. (C) PNM hydrogel injected into 2.5mm diameter conduit after 
implantation but only a small amount remained after 1 hour (D). (E) PNM hydrogel injected into 
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2.0mm diameter conduit prior to implantation. (F) Some PNM hydrogel was lost during the 
manipulation of implantation. (G) PNM hydrogel injected into 2.0mm diameter conduit after 
implantation. (H) All of the PNM hydrogel remained in the conduit after 1 hour. 
 
 
 
2.4 Discussion 
ECM based scaffold materials such as those used in the present study have been derived 
from a wide variety of tissues and organs through decellularization. These materials have 
subsequently been used in a similarly wide variety of preclinical and clinical studies to promote 
constructive tissue remodeling at the implantation site [171, 172].The majority of the scaffold 
materials which are used clinically are derived from xenograft sources; however, a smaller number 
of decellularized tissue based products are sourced from cadaveric human tissues. In the present 
study, we chose to utilize a xenogeneic scaffold material composed of canine sciatic nerve. All 
three tissue sources used (equine, canine, and porcine) were utilized due to local availability, and 
the necessity of a large animal tissue source to provide sufficient tissue to complete the study. It is 
noted that most of the commercially available products utilize source tissues from porcine and 
bovine sources. Regardless of the tissue source, the development of effective decellularization 
protocols is essential to remove the majority of immunogenic cellular constituents while 
maintaining the tissue-specific structural and functional components intact [97, 109, 173]. For this 
reason, it is generally desirable to use the mildest, least disruptive protocol possible that yields an 
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acellular material with the least interference to the structural and functional components of the 
ECM.  
PNM was developed from three different sciatic nerve sources, equine, canine, and porcine. 
The decellularization process was adapted slightly for each source to account for the different size 
ranges but the predominate process was kept consistent. The three different nerve-specific ECMs 
generated by decellularization in this dissertation was demonstrated to be effectively decellularized 
with an 85-90% decrease in DNA content when compared to native tissue, yielding a material with 
similar or less DNA content than many commercially available ECM-based materials [168]. 
Removal of genetic material from the PNM scaffolds was consistent across animal sources. 
Furthermore, the remaining ECM components of the nerve tissue was also well preserved with 
each of the three PNM scaffolds. The results of this chapter suggest that PNM can be generated 
from multiple animal sources while still producing a highly similar nerve specific ECM scaffold. 
The PNM used in this study retained many of the structural and functional components of 
native nerve following processing to remove cellular content. SEM demonstrated an ultrastructure 
like that of native nerve, with retention of epineural and endoneural architecture including the basal 
lamina. This was confirmed by immunofluorescent labeling that demonstrated preservation of 
large amounts of collagen IV, a component of the basal lamina. Previous studies have 
demonstrated that UBM also maintains tissue-specific structural features including an intact 
basement membrane rich in collagen IV as well as the underlying submucosal connective tissues 
[19]. In the present study, a shift in the balance of hydroxyproline to GAG content was observed 
when comparing PNM and UBM. Likely, UBM contains an increased hydroxyproline content due 
to the maintenance of the underlying submucosal tissues during decellularization, while the PNM 
scaffold materials are enriched in non-fibrillar collagens and laminin, comparatively. ELISA 
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further demonstrated maintenance of nerve specific growth factors such as NGF and CNTF at 
similar levels within both the PNM and UBM scaffold materials. These results are consistent with 
previous studies comparing UBM to central nervous tissue derived materials [17]. 
While differences were observed between PNM and UBM and SIS, many similarities still 
exist between these ECM sources. While exact ratios may differ between ECM sources, PNM still 
share basic ECM constituents with UBM and SIS such as collagen IV and laminin. Furthermore, 
PNM, UBM, and SIS all showed the presence of nerve-specific growth factors. Concentration and 
ratios of exact growth factors were found to differ between sources but the hypothesis that only 
PNM would possess nerve-specific growth factors was found to be false. We still believe that PNM 
was the closest approximation to the peripheral nerve ECM and therefore could provide an 
advantaged benefit when used as a scaffold for peripheral nerve repair and regeneration. Our 
findings, though suggest that UBM and SIS could still provide factors beneficial to nerve 
regeneration. 
The prominent component of most ECM is collagen. Collagen alone has been processed 
into an injectable solution, which can self-assemble under certain conditions into a hydrogel [174, 
175]. It has been shown that the same process can be performed with ECM of multiple sources, 
including peripheral nerve sources [52, 97, 106, 127, 176, 177]. The formation of the collagen into 
fibril within ECM hydrogels is dependent upon electrostatic and hydrophobic interactions [174, 
175]. This provides alternatives to cross-linking agents for manipulating the mechanical properties 
of the hydrogel. Previous literature has shown that altering the ionic salt concentration can increase 
the storage modulus of ECM hydrogels [170, 178] and this was also shown within this dissertation 
for PNM hydrogels. Reducing the ionic salt concentration has the effect of enhancing interactions 
between electrostatically charged amino acid side chains [174, 178]. Using 0.5X PBS has been 
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shown to have little effect on hydrogel swelling but it is not known how infiltrating cells would 
tolerate salt concentration lower than physiologic conditions [170]. It is also yet unknown how 
soon the salt concentration would normalize due to native swelling of the injury. 
ECM hydrogels were found to be a practical solution for supporting nerve repair. Both the 
PNM and UBM degradation products begin to gel within 60 seconds after neutralizing to 7.4 pH 
at body temperature (37° C). The injectable substance was easy to handle and deliver to the site of 
injury. In a clinical setting, ECM hydrogels could be readily injected into an inert or bioactive 
conduit so that the liquid filled the available space before forming a hydrogel. Alternatively, the 
hydrogel could be delivered directly at the site of nerve coaptation. 
In summary, it was shown that an ECM scaffold could be produced from peripheral nerve 
tissue and that this scaffold can be processed into a collagen-based hydrogel. Furthermore, we 
characterize and show the bioefficacy of the PNM hydrogel. The pilot animal study suggests that 
extracellular matrices should play a role in augmenting nerve repair in clinical patients. 
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3.0  PNM hydrogel Enhances Recovery Through Increase in Axon Extension, Schwann 
Cell Recruitment, and Phenotypic Changes in Macrophages 
3.1 Introduction 
Many studies have investigated the use of lumen fillers for nerve guidance conduits to 
affect the local environment and favor better recovery outcomes through the addition of growth 
factors or accessory cells into a supportive matrix [41-50, 53, 55, 56]. While many of these studies 
reported positive results, very few report results nearing those achieved with an autograft 
procedure. Additionally, there are numerous practical problems associated with many approaches 
to nerve conduits and lumen fillers: the addition of growth factors is expensive and the factors are 
not always stable, cells require tissue harvesting and time to culture, and a bulk of donor Schwann 
cells undergo apoptosis and die during the first weeks after introduction [179]. The use of matrix 
fillers that are engineered to last the duration of the recovery are often too dense and impede cell 
growth through the nerve conduits. These studies explore lumen fillers that incorporate single cell 
or growth factor suspensions that were selected based on their roles on nerve regeneration. 
Extended axonal regrowth cannot occur without closely apposed Schwann cells (SC) [180] 
and the specificity of this process is enhanced both by extracellular matrix (ECM) components, 
such as collagen IV or laminin, which provide basement membrane support for SC migration. 
Studies have shown that axon regeneration is severely limited when SC proliferation or migration 
are artificially inhibited. Inversely, the addition of SCs to a nerve defect injury has been shown to 
support improved regrowth. Schwann cells provide a large number of cues to support regeneration 
including classic neurotrophins (NGF, BDNF, NT-3, and NT-4/5), neuropoietic cytokines (CNTF 
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and IL-6), other neurotrophic factors (IGT-1 and Glial Derived Neurotrophic Factor (GDNF)), cell 
adhesion molecules (NCAM, L1, and N-cadherin), and ECM proteins (laminin, tenascin C, 
fibronectin, and heparan sulfate proteoglycan) [4]. These molecules influence the peripheral nerve 
regeneration through endogenous Schwann cell support or supporting axon outgrowth or survival. 
Axon, in turn signal Schwann cell to proliferate upon injury and then myelinate if they can 
reconnect with an appropriate end organ [180, 181]. Axons as well as macrophages responding to 
the injury provide mitogenic molecules to SCs including neuregulins, PDGF-β, TGT-β, and FGFs.  
Macrophages are a key component of the host response to nerve injury [181], providing 
important signaling and support molecules to axons and SCs, clearing cellular debris from the 
injury through phagocytosis, and stimulating neovascularization [180-185]. Macrophages have 
been described as having diverse and plastic phenotypes along a continuum between M1 
(classically activated; proinflammatory) and M2 (alternatively activated; remodeling, 
homeostatic) extremes. M1 macrophages are characterized by the secretion of reactive oxygen 
species and proinflammatory cytokines and chemokines. Persistence of M1 macrophages can lead 
to tissue damage and destruction. In contrast, M2 macrophages secrete anti-inflammatory immune 
modulators and participate in the constructive healing and remodeling phase of the tissue 
remodeling response by promoting tissue deposition and in growth. 
Macrophages are critical for regeneration within the peripheral nervous system. 
Macrophage arrive to the site within 24 h after injury and their population peaks by 14-21 day 
[85]. They play critical roles in scavenging debris, growth factor production such as NGF and IL-
6 [86, 87], and remodeling of the ECM of the distal nerve [24, 88]. In multiple injury models, the 
process of inducing a shift from M1 to M2 like macrophage phenotype has positive benefits on 
downstream healing, including the generation of site appropriate tissue [87, 109, 110]. It has been 
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shown that modulating macrophages within the peripheral nerve injury towards an M2 like 
phenotype results in enhanced Schwann cell infiltration and substantially quicker axonal growth 
in rodent animal models [89]. In addition, the ratio of pro-remodeling (M2) to pro-inflammatory 
(M1) population macrophages in the injured nerve tissue has been shown to have a linear 
relationship with the number of axons at the distal end of nerve scaffolds [89]. 
Scaffolds composed of ECM derived through the decellularization of intact tissues and 
organs have been shown to promote a process of constructive remodeling following injury [172], 
including the formation of new, functionally innervated, site-appropriate host tissue [186, 187]. 
While the exact mechanisms which underlie the ability of these materials to promote such 
remodeling are unknown, a number of studies have now shown that the release of bioactive tissue 
specific molecules and a shift in the local inflammatory response at the site of implantation are 
key occurrences during the remodeling process [172]. A number of ECM scaffolds have been 
demonstrated to be supportive substrates for axonal growth and the degradation products of such 
materials have been demonstrated to be bioactive and chemotactic for SC [96, 186]. 
The native microenvironment of nerve regeneration is a complex mixture of signaling and 
support cues produced by SCs, macrophages, and axons. A limitation of many existing studies is 
the limited scope of growth factor or cellular incorporation. This is partly scientifically motivated 
to fully understand one element at a time. However, artificially engineering a microenvironment 
that approaches the native nerve milieu becomes increase difficult. One alternative to engineering 
a complex microenvironment is to use the natural microenvironment of healthy peripheral nerve 
harvested through decellularization. Scaffolds composed of ECM derived through the 
decellularization of intact tissues and organs have been shown to promote constructive remodeling 
following injury [172] including the formation of new, functionally innervated, site-appropriate 
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host tissue [186]. Studies implanting porcine derived ECM scaffolds into a rat model of abdominal 
wall defect and canine model of esophageal reconstruction found the presence of new nervous 
tissue within the graft area. Mature nerve, immature nerve, and Schwann cells were found within 
the remodeled ECM scaffolds after 28 days in the rat and 91 days in the canine model demonstrated 
that ECM can act as a substrate for the formation of functionally innervated tissue. This dissertation 
also shows that PNM is a friendly substrate for axonal growth and the degradation products of the 
materials have been demonstrated to be bioactive and chemotactic for SC [186]. Furthermore, 
PNM stimulates macrophages to produce PDGF-β possibly enhancing the SC proliferation 
response to injury. While PDGF-β is thought primarily to be a mitogen for mesenchymally derived 
cells, PDGF-β along with other factors (bFBF, neuregulin-1, neurotrophin-3, and IGF-1) have been 
already reported to play a role in the development from Schwann cell precursor cells into early 
Schwann cells [188]. Schwann cells must undergo proliferation after injury and it has been shown 
that PDGF-β is a potent mitogen for Schwann cells and has a neuroprotective action to nerves after 
injury [189, 190]. 
In this chapter, the PNM was examined in vitro and in vivo for its effect on axons, SCs, 
and macrophages. Both macrophages and Schwann cells involvement is critical for peripheral 
nerve regeneration [4, 24, 85, 88, 89, 181]. Macrophages account for the majority of debris 
phagocytosis, produces growth factors, and remodels the ECM of the distal nerve [24, 85, 88, 89]. 
Furthermore macrophages with an M2 like phenotype enhance Schwann cell infiltration and 
improve axonal growth [22]. Schwann cells proliferate upon injury and provide many signaling 
and survival cues to support regeneration [4]. These molecules support axon outgrowth and 
survival. Finally, Schwann cell myelinate axons that are able to reconnect with an appropriate end 
organ [180, 181]. It for these reasons that the chapter focuses on PNM effect on increasing 
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Schwann cell migration into the site of injury and macrophage phenotype and involvement. To test 
this in vivo, canine PNM was used in a rat sciatic nerve critical length defect model and assays 
focused upon two key early events in the remodeling process: modulation of the host macrophage 
response and recruitment of Schwann cells.  
3.2 Methods 
3.2.1 Evaluation of Effects of Enzymatic Degradation Products Upon Neurite Outgrowth 
Neurite outgrowth was tested with ECM produced from both equine and porcine sciatic 
nerve sources. Spinal cord neurons were isolated from embryonic day 14 Sprague–Dawley rat 
pups. Spinal cords were collected in cold Hanks’ buffered salt solution without Ca2+ and Mg2+ 
(Gibco, Carlsbad, CA, USA), minced into pieces and enzymatically dissociated in 2 ml 0.25% 
trypsin solution containing 0.05% collagenase L1 (MP Biomedicals, Solon, OH, USA) at 37° C 
for 20 minutes. Cell digestion was inhibited by adding 2 ml SBTI-DNAse solution (0.52 mg/ml 
soybean trypsin inhibitor; 3.0 mg/ml BSA; 0.04 mg/ml bovine pancreas DNAse, D-4263; Sigma). 
The cell suspension was gently triturated and centrifuged at 800×g for 5 minutes. The resulting 
pellet was then resuspended in plating medium and gently triturated. The plating medium consisted 
of 20% horse serum (Gibco), 5 ml HBSS without Ca2+ and Mg2+ (Gibco) and 9.8 ml Dulbecco’s 
modified Eagle’s medium with L-glutamine (DMEM; Sigma). All non-dispersed tissue was 
discarded. Spinal cord neurons were seeded on poly-L-lysine-coated coverslips (12.5 µg/ml in 
H2O; Sigma) in plating medium with a plating density of 3×105 cells/mL and allowed to adhere 
for 4 h in culture conditions of 5% CO2 and 37° C. After 4 h, the medium was exchanged with 1 
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ml serum-free culture medium containing Neurobasal-A (NBA, Gibco), and 1 mM Glutamax 
(Gibco). ECM degradation products were neutralized by adjusting the pH to 7.4 prior to dilution 
in PBS to the desired concentration. Medium was either supplemented with PNM or UBM 
digestion products (at concentrations of 125, 250, and 500 μg/mL), 1×B27 supplement (Gibco, 
positive control), or with 50 μg/ml pepsin (negative control). Low concentrations were used to 
prevent the digestion products from polymerizing within the cell culture media and to focus 
analysis strictly on ECM component bioactivity. Three images at 20X magnification were taken 
per well on days 1, 2 and 4 post seeding.  Three images at 20X magnification were taken per well. 
The number of cells with neurite extensions and the length of neurite extensions were counted 
using NeuronJ (ImageJ, NIH). Difference in length of neurite extensions between groups (Media 
supplemented with 50 μg/ml pepsin solution, B27 supplement, or the protein digest of PNM or 
UBM at concentrations of 125, 250 and 500 μg/ml) was determined using ANOVA with Tukey’s 
post hoc test.  
3.2.2 Evaluation of Enzymatic Degradation Products of Porcine PNM Upon Schwann 
Cell Migration 
A Schwann cell line (RT4-D6P2T) obtained from ATCC was used. The Schwann cell line 
was cultured in medium containing DMEM, 10% FBS, 100 U/mL penicillin, and 100 µg/ml 
streptomycin and passaged 2-4 times and allowed to reach 70-80% confluence before starving in 
serum-free DMEM for 16 hours. After starvation, cells were trypsinized with 0.25% trypsin and 
0.53 mM EDTA for 2 minutes. Cells were then centrifuged at 1200 RPM for 5 minutes. The 
resultant pellet was re-suspended in serum-free DMEM and incubated (37° C) for 1 hour. 
Polycarbonate PFB filters (8 um pores) was coated on both sides with 0.05 mg/mL collagen type 
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1. Digested ECM peptide fragments were plated in the bottom chamber before assembling and 
sealing the top chamber. Approximately 30,000 cells were placed in to each well followed by 
incubation for 3 hours. Afterwards, cells facing the upper chamber were scraped off and the cells 
facing the lower chamber were fixed in methanol and stained with anti-S-100 antibody (1:100, 
Sigma) and corresponding secondary antibody (1:100, Alexafluor). 
3.2.3 Assessment of Macrophage Phenotype in Vitro Using a NanoString's nCounter 
Technology 
Briefly, murine bone marrow derived macrophages were cultured for 7 days before running 
experiment. Macrophages were exposed to low concentrations of PNM (100, 300, 500, 700 
µg/mL) or IL-4 to promote an M2 like phenotype or IFγ to promote an M1 like phenotype. The 
cells were then lysed, and RNA was isolated with RNeasy microkit (Qiagen). Nanodrop 
spectrophotometer (ND-1000, Saveen Werner) was used to measure RNA concentration, and 100 
ng was applied from each sample for RNA expression analysis, running one strip of 12 samples at 
a time on a nCounter analysis system (Nanostring Technologies). The procedure was performed 
according to the manufacturer´s instructions. The kit used was a fixed codeset for mRNA analysis, 
nCounter GX Human Immunology Kit v2 (Nanostring Technologies). 
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3.2.4 Assessment of Macrophage Response and Schwann Cell Migration in an Animal 
Model of Sciatic Nerve Defect Injury 
To determine the effects of cell PNM on macrophage and Schwann cell migration animals 
underwent creation of a sciatic nerve gap defect followed by repair with a silicone conduit alone 
(n = 7) or a silicone conduit with PNM (n = 7). Rats (Sprague Dawley, females, 200–250 g) were 
pre-medicated with subcutaneous buprenorphine (2 mg/kg), anesthetized with isoflurane and 
maintained under anesthesia with isoflurane/oxygen. The sciatic nerve was exposed and transected 
and a 15 mm critical-length defect [191] was created within a 17 mm silicone nerve conduit (Tuzic, 
Siliclear tubing, 4.6 mm OD, 3.4 mm ID). Proximal and distal nerve stumps were aligned and 
sutured 1 mm into the conduit with 9-0 suture. Conduits were filled with PNM hydrogel at a 
concentration of 8 mg/ml, prepared as described above. The hydrogel was brought to room 
temperature 5 minutes prior to injection into the conduit. The hydrogel was observed to gel within 
the silicone conduit with 5 minutes. Excess gel was removed, and the site irrigated with saline 
solution. Muscular and cutaneous layers were closed routinely. Post-surgical pain control was 
provided by subcutaneous meloxicam (2 mg/kg) injection immediately postoperatively and 12 
hours after surgery. Rats were euthanized with pentobarbital (I.P.) 21 days after implantation and 
the conduit and proximal and distal stumps removed intact. Samples were fixed in Zamboni's 
solution for immunofluorescent labeling as described below. 
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3.2.5 Immunolabeling and Quantitative Analysis 
Samples were embedded in paraffin and sectioned longitudinally at 4 μm for 
immunofluorescent labeling to assess the host macrophage, and Schwann cell response. Complete 
consecutive sections were used for M1, M2 and Schwann cell labeling. Three slides from each rat 
were generated for each label. After deparaffinization and rehydration, antigen retrieval was 
performed by steaming in 10 mM citrate (pH 6.0) for 20 min followed by incubation for 20 min at 
room temperature. Sections were then processed with a MicroProbe System (Fisher Scientific) and 
phosphate buffered saline containing 0.05% Neonate 20 (PBST) was used for washing between 
each of the steps described below. Slides were blocked in a solution of 2x casein and 10% antibody 
host species matched serum for 30 minutes at room temperature. The sections were then incubated 
with a mixture of antibodies specific for markers of M1 macrophages (CD68, CCR7), M2 
macrophages (CD68, CD206), and Schwann cells (GFAP) for 90 minutes at room temperature. 
Incubation in appropriate AlexaFluor 488 and Texas Red conjugated secondary antibodies was 
performed sequentially for 30 minutes each at room temperature. Sections were coverslipped in 
an aqueous mounting media containing DAPI (Vectashield, Vector Laboratories). For negative 
control, the primary antibodies were replaced with a mixture of isotype IgG at equivalent 
concentrations. Antibody species, isotype, dilution, and supplier information are provided in Table 
8. 
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Table 8: List of antibodies used 
Reused with permission (4546560968632). [52] 
 
Antibody Host 
species 
Isotype Dilution Source 
CD206 (C-20) goat IgG, polyclonal 1:50 Santa Cruz 
CCR7 (Y59) rabbit IgG, monoclonal 1:500 Abcam 
CD68 (ED1) mouse IgG1, monoclonal 1:50 BioRad 
GFAP rabbit IgG, whole antiserum 1:500 Abcam 
 
 
High resolution images of the entire proximal stump and regenerative bridge were obtained 
from fluorescently labeled slides (Zeiss 510). The original site of transection was identified in each 
image and a straight line drawn perpendicular to the long axis of the nerve at that level to allow 
identification of individual cells relative to this line (Volocity Image Analysis Software, Perkin 
Elmer). The location of all individual macrophages (M1, CD68+ CCR7+; or M2, CD68+ CD206+) 
and Schwann cells (GFAP+) and their location relative and perpendicular to the transected 
proximal nerve stump were then determined (Volocity) with concealment of group allocation. Cell 
position (M1, M2 macrophage or Schwann cell) relative to the original site of transection was 
binned into 500μm increments, log transformed and treated as a categorical variable to allow for 
non-linear effects. M2:M1 ratio was calculated for each section as the total number of 
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CD68/CD206+ macrophages divided by the total number of CD68/CCR7+ macrophages. The 
distribution of each cell population was analyzed using a mixed effect models, with animal identity 
as a random effect. Linear contrasts were used to make specific comparisons when appropriate. 
3.3 Results 
3.3.1 Bioactivity of Degradation Products 
3.3.1.1 Evaluation of Effects of Enzymatic Degradation Products Upon Neurite Outgrowth 
Degradation products of canine PNM were introduced at different concentrations to 
primary neurons over four days. Bioactivity of degradation products was analyzed through a 
neurite outgrowth assay assessed at 1, 2, and 4 days post-plating using ImageJ. Individual days 
were assessed for statistical significance using a one-way ANOVA followed by a Sidak post-hoc 
test to correct for multiple comparisons. A trend towards increased neurite outgrowth with 
increased ECM concentration was observed for both PNM and UBM groups (Figure 11A). The 
increase in neurite outgrowth for the highest concentration (500 µg/ml) of PNM produced similar 
results to the positive control (p = 0.98) and was significantly greater than the negative control (p 
= 0.03). Images from neurite outgrowth with pepsin (negative) control, b27 supplement (positive) 
control, PNM and UBM at 500 µg/ml. Neurite outgrowth analysis images depict increased growth 
over the four days as well as increase growth over the negative control (Figure 11B). 
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The degradation products were neutralized, diluted to a concentration of 8 mg/ml and the 
hydrogel was allowed to form in a non-humidified incubator at 37° C (Figure 11C). Digested 
decellularized nerve products formed into a stable gel at 8 mg/mL shown both macroscopically 
and under scanning electron microscopy at 4,000X magnification (Figure 11D). 
The same neurite outgrowth performed using primary spinal cord neurons collected from 
E14 embryonic rat pups to test PNM generated from porcine sciatic nerves. Media was 
supplemented with PNM at low concentrations (125, 250, or 500 μg/ml), pepsin (50 μg/ml, 
negative control), or nerve growth factor (NGF 50 pg/ml, positive control) (Figure 15A). Statistical 
analysis of covariance with Sidak post-hoc test performed with statistically similar groups (p < 
0.05) for each separate day shown with matching letters. Primary neurites stained with β-Tubulin 
shows neurites produced after 7 days (Figure 15B) 
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Figure 14: PNM digestion products promote neurite outgrowth and can be formed into a 
stable hydrogel 
 (A) Degradation products of PNM were introduced at different concentrations to primary 
neurons over four days. PNM 500 µg/ml was significantly greater than positive control by 4 days 
(*, p < 0.05, n = 5). (B) Images from neurite outgrowth with pepsin (negative) control, b27 
supplement (positive) control, PNM and UBM at 500 µg/ml. (C-D) Digested decellularized nerve 
products formed into a stable gel at 8 mg/mL. 
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Figure 15: Porcine PNM effect on primary spinal cord neurite outgrowth 
Neurite outgrowth performed using primary spinal cord neurons collected from E14 
embryonic rat pups. Media was supplemented with NS-ECM at low concentrations (125, 250, or 
500 μg/ml), pepsin (50 μg/ml, negative control), or nerve growth factor (NGF 50 pg/ml, positive 
control) (A). Statistical analysis of covariance with Sidak post-hoc test performed with statistically 
similar groups (p < 0.05, n = 5) for each separate day shown with matching letters. Primary neurites 
stained with β-Tubulin shows neurites produced after 7 days (B). 
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3.3.1.2 Evaluation of effects of enzymatic degradation products upon Schwann cell migration 
Schwann cell migration was performed using a boyden chamber. Serum-free media 
supplemented with various concentration of PNM produced similar migration to positive controls 
(serum supplemented media, with 50 ng/ml NGF, and with 100 ng/ml NGF). Because the cells are 
serum starved, serum is an accepted positive control for most Schwann cell migration assays. We 
also included medium supplemented with both 50 and 100 ng/ml of NGF. UBM and SIS was also 
tested at the highest concentration tests (1000 µg/mL). PNM treatment showed enhanced Schwann 
cell migration that was chemoattractant. Poor migration when PNM was added to the cell side of 
the boyden chamber suggests that PNM is not simply chemokinetic or promoting not directed 
migration. Conversely, we found that UBM and SIS promoted greater chemokinetic migration 
rather than chemoattractant migration (16A). Migration stimulated by PNM treatment was 
significantly greater than that of SIS or UBM (p < 0.05, n = 5). PNM treatment was also statistically 
greater than negative controls (pepsin and PNM on cell side only) (p < 0.05, n = 5). The application 
of PNM also had an apparent dose dependent effect of Schwann cell migration (16B). 
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Figure 16: Porcine PNM effect on Schwann cell migration in vitro 
Schwann cell migration was performed using a boyden chamber. PNM digested products 
supplemented to serum-free media at 1 mg/mL produced significantly more migration (p<0.05, 
n=5) than UBM and SIS at the same concentration (A). Serum-free media supplemented with 
various concentration of PNM produced similar migration to positive controls (serum 
supplemented media, with 50 ng/ml NGF, and with 100 ng/ml NGF). Treatment was statistically 
greater than negative controls (pepsin and PNM on cell side only) (*, p < 0.05, n = 5) (B). 
 
 
 
3.3.2 Assessment of Macrophage Phenotype 
A nanostring assay was performed on murine bone derived macrophages. Macrophages 
were exposed to PNM digestive products at dilute concentrations (100, 300, 500, and 700 µg/mL). 
Exposure to PNM digestive products promoted a phenotype that was distinct from resting, pro-
inflammatory, and anti-inflammatory macrophages and the biggest activity we found was the 
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expression of an angiogenesis factor, Platelet derived growth factor β (PDGFβ) (Figure 17). 
Angiogenesis is well known to be essential for nerve regeneration. PNM also promoted M2 
(regenerative) genes including Chi313, Retnla and IL4ra. 
 
 
 
 
Figure 17: A nanostring assay for gene expression using mouse bone marrow derived 
macrophages looking at macrophage phenotype promoted by the nerve specific extracellular 
matrix. 
A nanostring assay for gene expression using mouse bone marrow derived macrophages 
looking at macrophage phenotype promoted by the nerve specific extracellular matrix. PNSECM 
promoted phenotype was distinct from resting, pro-inflammatory, and anti-inflammatory 
macrophages and the biggest activity we found was the expression of an angiogenesis factor,  
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PDGFb – Platelet derived growth factor b – angiogenesis stimulant. Angiogenesis is well known 
to be essential for nerve regeneration. Abbreviations used: PNM 100 µg/mL; PNM 300 µg/mL; 
PNM 500 µg/mL; PNM 700 µg/mL; PDGFb, Platelet derived growth factor β. 
 
 
 
3.3.3 In Vivo Test of Macrophage and Schwann Cell Response to PNM Hydrogel 
3.3.3.1 Macrophage Phenotype in a Sciatic Nerve Defect 
Representative longitudinal sections of regenerative bridges were immunohistolabeled for 
M1 macrophages (18A, CD68+CCR7+) for control (empty conduit) and PNM filled conduits. 
Sections were also immunolabeling for M2 ( 18B, CD68+CD206+) macrophages in empty and 
PNM filled conduits. Macrophages within the remodeling site tended to be distributed on the 
margins of the regenerative bridge (Figure 18) and the number of both M1 and M2 macrophages 
(M1: CD68+ CCR7+; M2: CD68+ CD206+) was found to be increased in the presence of PNM 
within rodent sciatic defects (Figure 19A–B) as compared to conduit alone. Insert demonstrates 
intracellular CD 68 labelling and surface CD206 labelling. No additional extension of proximal 
stump was observed in control sections. The number of M1 macrophages was significantly 
increased in the PNM group at 2.5–3.0 mm from the original site of transection (p = 0.01, linear 
contrast) and M1 macrophages were identified up to 5.5 mm from the original site of transection, 
in contrast to the control (3.5 mm). The number of M2 macrophages was also significantly 
increased in the PNM group at each 500 µm interval from 1.0 to 3.0 mm from the original site of 
transection (all p = 0.001, linear contrast) and M1 macrophages were identified up to 5.5 mm from 
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the original site of transection, in contrast to the control (3.0 mm). The presence of PNM also 
increased the M2:M1 ratio within the conduit (n = 3 slides/label/animal and 7 animals/group) (p = 
0.002,  19C).  
 
 
 
Figure 18: Representative longitudinal sections of regenerative nerve bridge stained for M1 
and M2 macrophage markers 
Representative longitudinal sections of regenerative bridges immunohistolabeled for M1 
macrophages (panel A, CD68+CCR7+) for control (empty conduit) and PNM filled conduits. 
Representative immunolabeling for M2 (panel B, CD68+CD206+) macrophages in empty and 
PNM filled conduits. Insert demonstrates intracellular CD 68 labelling and surface CD206 
labelling. No additional extension of proximal stump was observed in control sections. Reused 
with permission (4546560968632). [52] 
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Figure 19: Macrophage recruitment and Schwann cell migration into nerve bridge 
PNM promotes migration of both M1 (CD68+CCR7+) and M2 (CD68+CD206+) 
macrophage phenotypes, relative to the original site of transection (A, B); an increased M2:M1 
ratio (C) and increased extension of Schwann cells populations relative to the original site of 
transection (D). Data shown are least square (adjusted) mean and standard error (A, B, D) and 
mean and standard error (C). n= 3 slides/ label/animal and 7 animals /group. Reused with 
permission (4546560968632). [52] 
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3.3.3.2 Schwann cell migration in a sciatic nerve defect 
Schwann cells (SC) tended to be distributed on the margins of the regenerative bridge and 
SC numbers were significantly increased in the PNM group at 2.5–3.0 mm from the original site 
of transection (p = 0.02, linear contrast). SC were identified up to 5.5 mm from the original site of 
transection, in contrast to the control (3.5 mm,  19D). Overall, the use of PNM as a lumen filler 
increased extension of Schwann cells populations relative to the original site of transection (Figure 
19D). Data shown are least square (adjusted) mean and standard error (A, B, D) and mean and 
standard error (C). n= 3 slides/ label/animal and 7 animals /group. 
3.4 Discussion 
In this study, we characterized the biological effects of PNM hydrogels upon the early 
progression of peripheral nerve reconstruction across a critical gap defect. We show that PNM 
hydrogels largely maintain matrix structure and several growth factors, promote increased 
macrophage invasion and higher percentages of M2 macrophages and enhance Schwann cell 
migration when transplanted into a rodent model. These effects have all been associated with 
improved nerve regeneration in previous studies [87, 89, 108, 112, 181, 192, 193] 
Neurite outgrowth assays demonstrated that degradation products formed through pepsin 
digestion of the intact materials were bioactive, promoting neurite outgrowth and extension. Both 
UBM and PNM displayed dose dependent effects across the observed time points, showing 
increasing neurite growth with increasing dose. While lower doses of PNM were not significantly 
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increased over positive control, by the last time point (day 4) the highest dose of PNM (500 µg/ml) 
showed significantly better growth than both UBM and B27 positive control. Even at this highest 
dose (500 µg/ml), PNM is still significantly more diluted than when it was (8 mg/ml). These results 
suggest that the resultant PNM hydrogel retained biologically active nerve specific components, 
although native architecture was lost when the hydrogel was formed. 
In the present study, when delivered into a rodent critically sized defect, we observed a 
switch in the ratio of M1:M2 phenotype macrophages, a phenomenon associated with improved 
nerve growth, [22] and promotion of Schwann cell migration across a gap defect. This was 
associated with improved function over time in a non-critical (8 mm) common peroneal defect. 
We selected the common peroneal nerve as our experimental paradigm for functional studies as 
the consequence of axonal misdirection is reduced compared to sciatic nerve injury in which 
inappropriate reinnervation of muscular targets leads to dysfunction after injury [51]. We did not 
evaluate PNM in comparison to other biomaterials or biopolymers. This is the focus of ongoing 
work. 
The present study does not attempt to investigate the mechanisms by which the injectable 
ECM promote these phenomena; however, a recent study has described M2 macrophage mediated 
angiogenesis as a mechanism leading to Schwann cell chemotaxis and downstream regeneration 
[181]. While ECM mediated shifts in macrophage phenotype have been reported in other 
applications, as has increased angiogenesis, further investigation of these phenomena in the 
context of nerve repair is warranted. Similarly, mechanistic studies linking these phenomena to 
improvements in function downstream should be performed. However, though the exact 
mechanisms are not clear, these results provide evidence that PNM is an effective tool for 
improving nerve repair. 
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In this study, we characterized the biological activity of injectable peripheral nerve-specific 
ECM hydrogels, determined the biological effects of these hydrogels using both in vitro and in 
vivo test for neurite extension, Schwann cell migration, macrophage gene expression as well as an 
animal model of critical gap defect sciatic assays. 
Results of the study demonstrated that the ECM hydrogels tested had significant potential 
for promoting increased recovery following surgical reconstruction. The decellularized PNM was 
shown to retain multiple nerve-specific matrix components, including growth factors. Enzymatic 
degradation products of the PNM scaffolds were shown to promote neurite outgrowth in in vitro 
assays. These same degradation products, when assembled into a hydrogel were demonstrated to 
promote a switch in the ratio of M1:M2 phenotype macrophages, a phenomenon associated with 
improved nerve growth [172], and to promote Schwann cell migration across the gap defect. In 
total, these results provide strong evidence that PNM is effective at altering the response of 
Schwann cells and macrophages during peripheral nerve injuries. Results from this chapter show 
that PNM effects important mediators of nerve regeneration, the next step is to investigate if these 
effects lead to improvement in downstream functional recovery. 
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4.0  PNM Can be Utilized in Both Crush and Nerve Defect Injuries to Increase Axon 
Growth and Functional Recovery 
4.1 Introduction 
Previous work has shown that the PNM retains components of the peripheral nerve ECM 
including collagen, laminin, and nerve specific growth factors. Furthermore, PNM was able to 
enhance neurite outgrowth and Schwann cell migration in vitro after post processing for hydrogel 
formation. The PNM hydrogel was also shown to promote a switch in the ratio of M1:M2 
phenotype macrophages and to promote Schwann cell migration across a sciatic nerve gap defect. 
Overall, these results suggest that the PNM hydrogel provides a beneficial microenvironment for 
nerve regeneration during the initial stages of recovery. We hypothesis that the early effects on the 
response of Schwann cells and macrophages during peripheral nerve injuries will lead to lasting 
downstream changes. This involves tracking functional improvements over the full course of 
recovery to test potential for promoting increased recovery following surgical reconstruction in a 
pre-clinical study.  
There are a number of methods for estimating recovery of peripheral nerve repair in 
experimental models, including histological measurements of axon count, neuron cell body count, 
motor endplate count, and motor unit number estimation. However, these metrics are not direct 
measures of function and do not always correlate with actual nerve function. Axon count and 
myelination does not give information about whether the axon has reached its appropriate target 
organ and electrophysiology does not necessarily equate to the function of complex locomotion 
[194-196]. Therefore, a direct measure functional recovery is important for a well-designed study 
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for a new nerve repair therapy. Relatively few methods of assessing functional recovery after 
peripheral nerve injury have been used. These methods have historically focused on behavioral 
tests and include walking track analysis, sensory function, kinematics, and ground reaction force. 
Serial assessment of functional recovery reduces the number of animals required for 
experimentation and reduces some of the variability in testing, as each animal can act as its own 
control. Quantification of peripheral nerve regeneration in animal models of nerve injury and 
repair by purely histologic, morphologic, or electrophysiologic parameters do not directly measure 
the goal of peripheral nerve repair, full functional recovery. These metrics do not necessarily 
correlate with actual nerve function.  
This chapter includes pre-clinical studies that incorporates a wide range of experiments, 
including histologic, electrophysiologic, and functional metrics. This was done to broaden overall 
the understanding of the effect that PNM had on peripheral nerve injury. The predominant focus 
of this dissertation has been on severe fifth degree injuries or neurotmesis resulting in a gap defect. 
These injuries have the worst outcomes but also have the largest focus from the research 
community and have several FDA approved devices directed at improving outcomes. However, as 
discussed previously, peripheral nerve injury exists on a spectrum that can be described by the 
Sunderland scale. This chapter also seeks to investigate the use of PNM across different categories 
of peripheral nerve injury, including crush, transection without a gap, as well as transection with 
a gap. 
While having significantly better outcomes, 2nd-4th degree injuries often do not reach full 
recovery and take weeks to months to recovery. Currently, there is no accepted treatment or aid 
for this type of peripheral nerve injury. An off the shelf product that has the potential to improve 
outcomes for serious nerve injuries and speed the return to function for less severe injuries is an 
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attractive solution. PNM hydrogel is an easily injectable material in an off the shelf formulation 
which promotes recruitment of alternately activated M2 macrophages, Schwann cell migration, 
and axon extension. We believe that PNM can positively impact both crush and gap nerve injuries. 
This study will expand our understanding of delivery techniques and therapeutic applications for 
the PNM hydrogel. 
In addition to the rat models of sciatic nerve injury, a pilot study was undertaken in a large 
animal model of recurrent laryngeal nerve transection. An illustration of the anatomy of the path 
of the recurrent laryngeal nerve which branches from the Vagus nerve (cranial nerve X) and 
innervates the intrinsic muscles of the larynx can be seen in Figure 22. Injury to the recurrent 
laryngeal nerve (RLn) results in vocal fold immobility, dysphonia, and potentially life-threatening 
airway obstruction with major consequences for speech, airway  coaptation or by nerve graft [197-
199]. The RLn branches off the vagus nerve in the chest and works its way back to the larynx 
(Figure 22). Injury to the RLn is a possible complication of thyroid surgery and other neck 
procedures. Despite advances in microsurgical technique and extensive studies on nerve repair, 
presently used surgical reinnervation methods produce only moderate results and full functional 
recovery after nerve injury is seldom achieved [200-203]. Therefore, methods that accelerate or 
improve reinnervation following reconstruction of the RLn are of significant clinical interest. 
In this chapter the effect of PNM on functional recovery through numerous animal 
peripheral nerve injury models, including crush, transection, and nerve defect injuries was 
investigated. Two pilot studies using rat models of sciatic and common peroneal nerve gap defect 
injuries was used to establish the sciatic functional index (SFI) experiment. These were also used 
to get initial functional results on a critical and non-critical length defect injury. Two large studies  
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investigated a non-critical gap defect and crush injury of the rat sciatic nerve. Finally, a canine 
model of recurrent laryngeal nerve transection was used to test PNM in a transection and 
coaptation model of peripheral nerve injury.  
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4.2 Methods 
Five studies were used to test PNM across several animal and injury models. The 
experiments used in these pre-clinical studies are summaries in Table 9. 
 
 
 
Table 9: Diagram of Pre-clinical studies and experiments used 
 
 Study 
Experiments Pilot study of 
rat critical-
length sciatic 
nerve defect 
Pilot non-
critical 
defect of rat 
common 
peroneal 
nerve 
1cm rat 
sciatic nerve 
gap defect 
model 
Rat sciatic 
nerve 
crush 
model 
Large animal 
recurrent 
laryngeal 
nerve 
transection 
Nerve histology      
Muscle histology      
SFI/PFI      
Walking track 
analysis 
     
Von Frey      
Electrophysiology      
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4.2.1 Pilot Study of Critical-length Gap Defect of Rat Sciatic Nerve Surgical Procedure 
After a brief isolation period, the rats underwent behavior testing using the sciatic function 
index. After the animals’ hind legs were dipped in ink, they were persuaded to walk across a paper 
thereby demonstrating specific gait patterns and documenting toe spread at baseline.  
The surgery was performed under ketamine (2-10 mg/Kg, intramuscularly) and 
acepromazine (1-2 mg/kg, intramuscularly) sedation. Buprenex (0.1-0.25 mg/kg) and gentamicin 
(2-4 mg/kg) were also administered subcutaneously immediately post induction. An incision using 
the scalpel was carried out longitudinally along the leg exposing the underlying muscle. Dissection 
around the muscle exposed the underlying sciatic nerve. The nerve is then cut with a scalpel blade 
to avoid crush injury. A 5 mm non-branching segment will be removed. Next, a 15 mm collagen 
conduit will be placed in the gap between the nerve ends. The nerve ends sat in the lumen of the 
conduit and was sutured in place with two 10-0 nylon sutures. In the experimental groups, the 
conduit was filled with a 10 mg/mL PNM hydrogel. For the control group the nerve segment was 
flipped and sutured back as an analog to the nerve autograft. Two animals with nerve defects were 
not repaired and kept as negative controls. The skin was closed with the 4-0 suture in an interrupted 
fashion.  
The animals were followed for 180 days. Every 14 days, the animals underwent the 
behavioral testing of the sciatic function test to document progress as well as toe spreading. At the 
end of the 180 days the animals were euthanized using CO2 until they ceased to breath and heart 
function had stopped. As a secondary method of euthanasia, cervical dislocation was used.  
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4.2.2 Pilot Non-critical Gap Defect of Rat Common Peroneal Nerve Surgical Procedure 
To evaluate the effects of PSECM on functional recovery, a non-critical 8 mm gap defect 
was created in the common peroneal nerve using a 10 mm conduit in the left hind limb of Sprague 
Dawley rats (females, 200–250 g). Conduits were filled with PNM or left empty (control, n = 
6/group). All surgeries were block randomized and anesthetic and surgical procedures were 
performed as described above.  
4.2.3 Surgical Model of a 1cm Gap Defect Injury of Rat Sciatic Nerve 
The sciatic nerve with its three major branches were exposed through the hamstring 
through a splitting incision. A 5-10 mm section of the sciatic nerve approximately 5 mm proximal 
from the main branching point was excised. This segment was either removed and the resultant 
gap repaired using a conduit or flipped and sutured in place. Afterwards the various treatment and 
control procedures were performed, and the muscle and skin were closed using 3-0 and 4-0 sutures. 
Five groups specific to the nerve defect model were used: the autograft repair alone, conduit alone, 
or conduit with PNM lumen filler at concentrations 10, 20, and 40 mg/mL ( 20). 
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Figure 20: Representative surgical images of sciatic nerve defect model 
Representative images showing the three major surgical repairs (A) autograft, (B) silicone 
conduit repair, and (C) silicone conduit repair with PNM lumen filler are varying concentrations. 
 
 
 
4.2.4 Surgical Model of Sciatic Nerve Crush Injury 
A rat model of sciatic nerve crush resulting in a third degree axonotmesis injury was used. 
A segment of the sciatic nerve 5 mm proximal to the tibial and common peroneal nerve split was 
exposed and crushed for 60 seconds using a bulldog clamp calibrated to produce 500 g of force. 
The nerve was then injected with 25-30 µg of PMN hydrogel using a 25G needle. Controls 
included a crushed sciatic nerve without additional treatment, an uninjured sciatic nerve with 
injection of PMN hydrogel, a transection and ligation of the nerve at the same location, as well as 
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sham and uninjured controls (Figure 21). Animals were sacrificed after 90 days at which time their 
nerves and gastrocnemius were excised. The general procedure of crushing the sciatic nerve as 
well injected the PNM hydrogel can be seen in Figure 21. 
 
 
 
 
Figure 21: Representative surgical images of sciatic nerve crush model 
(A) Normal, uninjured nerve was injected with 25-30 µg of PMN hydrogel using a 25G needle 
(DO-PNMI). (B) Sciatic nerve crushed with a bulldog clamp calibrated to 500g of force (C-NT). 
(C) Sciatic nerve crushed with same bulldog clamp and then injected with 25-30 µg of PMN 
hydrogel using a 25G needle (C-PNM). Other controls (sham procedure, SHAM; no injury, NI; 
transection and ligation, T-NT) not shown. 
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4.2.5 Large Animal Model of Recurrent Laryngeal Nerve Reconstruction 
4.2.5.1 Animals and Instrumentation 
This study was performed in accordance with the PHS Policy on Humane Care and Use 
of Laboratory Animals, the NIH guide for Care and Use of Laboratory Animals, federal and state 
regulations, and was approved by the Cornell University Institutional Animal Care and Use 
Committee (IACUC). Animals were brought into the research unit and given a 7-day 
acclimatization period prior to any procedure. Daily record logs of medical procedures were 
maintained. Cages with elevated floors were cleaned daily and disinfected biweekly. The animals 
were fed twice a day to maintain proper body condition and allowed water ad libitum. Group 
housing provided socialization and ample space for exercise.  
Eleven female Beagle dogs (age 5-7 years, body weight 6.8 ± 0.7 kg, range 6.4-8.7kg) 
with no history of upper airway disease and normal laryngeal function, determined 
endoscopically, were used. Dogs were chosen at random and fasted for at least six hours before 
anesthesthetic procedures. At the end of each procedure, dogs were monitored for one hour 
before returning to their group housing. 
After fasting overnight, each dog was anesthetized with dexmedetomidine (2 mcg/kg IV 
followed by 2 mcg/kg/hour) and maintained under anesthesia at a constant expired isoflurane 
concentration (approximately 1MAC, 1.3%). Monitoring consisted of continuous 
electrocardiogram, pulse oximetry, non-invasive blood pressure, capnography and temperature. 
Analgesia was provided with pre-operative Meloxicam (0.2 mg/kg body weight) 
subcutaneously (SQ), followed by meloxicam given as an oral suspension (0.1 mg/kg body 
weight), daily for four additional days. 
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Figure 22: Anatomy of the recurrent laryngeal nerve 
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4.2.5.2 Surgical Method for Canine Model of RLn 
Animals were placed in left lateral recumbency and a lateral approach to the larynx was 
made in a standard fashion anterior to the right linguofacial vein, the subcutaneous fascia was 
divided and the main trunk of the right Recurrent Laryngeal nerve (RLn) identified ( 22). The RLn 
was identified and transected 15 mm inferior to the cricoid. We performed these experiments on 
the right side of the larynx as there is some evidence for reduced functional recovery of left RLn 
injury compared to right, although the mechanism for this difference is unclear [204]. Endoscopy 
using a rigid endoscope (2.7 mm diameter, Olympus) was performed to verify right sided paralysis 
immediately after surgery. 
Animals were randomly (computer generated code) divided into three groups. In the 
control group RLn transection was immediately followed by end-end RLn-RLn anastomosis 
performed using 3 epineural stitches of nylon 9-0 suture. Care was taken to avoid driving the 
needle or suture through the nerve fascicles. The anastomosis was surrounded by a preplaced 
empty 7 mm silicone conduit (3.5 mm internal diameter, Silastic; Dow Corning, Midland, MI) 
tagged to the perineurium at either end. In the two treatment groups the conduit was filled with 
either ECM derived from equine motor nerve (PNM); or with ECM derived from Urinary Bladder 
Matrix (UBM) and introduced into the conduit lumen via an 18-gauge needle. Hydrogels were 
brought to room temperature 5 minutes prior to injection into the conduit. The incision was then 
closed in layers. 
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Animals were euthanized at 6 months following implantation and laryngeal muscles and 
nerves harvested bilaterally for histology and immunohistochemistry. 
Endoscopy using a rigid endoscope (2.7 mm diameter, Olympus) was performed 
immediately following surgery, and at 2 and 6 months to assess arytenoid movement under light 
sedation (dexmedetomidine (1 mcg/kg IV)) [205, 206]. 
 
4.2.6 Common Peroneal Functional Index and Sciatic Functional Index 
Walking track analysis was used to determine hind limb function using a modified peroneal 
functional index (PFI) before injury (week 0) and 2, 4, 8, 12 and 16 weeks after repair [207]. 
Briefly, a minimum of three walking track assessments were obtained by inking the rat’s feet, 
using an oversized inking pad (Ranger Industries, Tinton, NJ), and then permitting them to run 
across a single 43 cm long by 10 cm wide piece of plain white paper within a clear Perspex 
corridor. Three trials for each rat at each time point were retained for analysis, and rejection of a 
trial occurred if the rat paused or stopped in the middle of the trial or otherwise did not maintain a 
relatively constant velocity or if the prints made were unusable due to poor inking. Walking tracks 
were scanned into digital images (CanoScan LiDE 110, Canon USA, Inc, Melville, NY), and 
measurements for print length (PL, the distance between cranial extent of digit III and caudal extent 
of the print); total spread (TS, the distance between the centers of paw pad I and paw pad V); 
intermediate toe spread (IT, the distance between the centers of paw pad II and paw pad IV); 
distance to the opposite foot (TOF, the vertical distance between the cranial aspects of contralateral 
prints) and deviation angle (DA, the angle of the foot with respect to the direction of travel; 
destination = 180°) obtained, with concealment of group allocation, using Photoshop CS6® 
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software (Adobe Systems, Inc., San Jose, CA). All measurements for all prints were recorded for 
each trial (usually 2 prints per limb) and mean measurements determined from all ipsilateral prints. 
Factors contributing to PFI (PL, IT and DA) were calculated as a percentage of baseline 
(preinjury) value rather than as a percentage of the contralateral limb. Modified PFI was calculated 
as PFI = (-55.47×PL) + (74.87×IT) + (163.43×DA) - 2.18. A mixed effect model was fitted to the 
data with animal identity as a random effect. Time after injury (weeks) was treated as a categorical 
variable to allow for a non-linear effect of time and an interaction term (time*group) included. 
Tukey’s post hoc tests and linear contrasts were used as appropriate. Statistical analysis was 
performed using one-way ANOVA and Tukey post-hoc with SPSS (IBM Corporation, Armonk, 
NY, USA) or JMP (SAS Institute, Cary, North Carolina, USA). Significance was set at p < 0.05 
throughout. 
Standard metrics for Sciatic Functional Index (SFI) was captured at mid-stance phase ( 23). 
A custom MatLab program was written to collect the measure the data from video stills and to 
calculate the SFI measurement (Appendix B.1.1). Each measurement was captured 3 times per 
video.  
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Figure 23: SFI measurements in a rat model of sciatic nerve defect injury 
(A-C) Measurements for injured side including (A) print length from middle finger to heel, 
(B) outer toe spread from 1st and 5th digits, and (C) the inner toe spread from 2nd and 4th digits. (D-
F) Contralateral side measurements including (A) print length, (B) outer toe spread, and (F) inner 
toe spread. 
 
 
 
4.2.7 Kinematics Collection and Analysis 
Functional assessment was performed using MotoRater (TSE systems), a semi-automated 
system for rodent kinematic gait analysis. Animals were evaluated at weeks 0, 1, 2, 3, 4, and every 
even week following, out to 24 weeks. Three videos were captured per rat per timepoint. Simi 
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Motion movement analysis software was used to place tracking dots at various joints of the body 
and at key phases of gait. Ankle angle was captured at toe-off to assess the function of the 
gastrocnemius muscle. Tracking dots were placed on the forefoot, ankle, and knee of the rat. These 
locations were tattooed onto the rat before surgery ( 24). 
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Figure 24: Representative still of kinematic analysis videos from TSE MotoRater 
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4.2.8 Nociception Testing with Von Frey Fibers 
Nociception, or the perception and processing of noxious stimuli was assessed by using a 
series of von Frey fibers. A custom cage was created with metal mesh screen floor (#14, 1.41 mm). 
Animals were evaluated at weeks 0, 1, 2, 3, 4, and every even week following out to 24 weeks. 
Animals were placed into the custom cage and both injured and uninjured rear paws were tested 
for nociception response. Briefly, starting with a 10 g von Frey fiber the paw was test four times. 
If the animal responded to at least two of the four tests the next smallest von Frey was used 
otherwise the next larger fiber was used. The process is repeated until the direction is changed 
from decreasing size to increasing size three times [208]. 
4.2.9 Electrophysiologic Analysis of Evoked CMAP 
Electrical conduction of the sciatic nerve was assessed using invoked compound muscle 
action potential of the tibialis anterior muscle. Briefly, the sciatic nerve was exposed using the 
same surgical approach as the original intervention. A stimulating probe was hooked around the 
sciatic nerve proximal to the injury and two recording hook electrodes were embedded into the 
center body of the tibialis anterior. The sciatic nerve was tested at increasing stimulating 
amplitudes (0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, and 1.0 mA). 
At each test, the nerve was stimulated twenty times for 200 us and at 10 V. The average root mean 
square (RMS) value for each stimulating amplitude was calculated using MatLab. The minimal 
amplitude that achieved motor neuron activation saturation was selected and used for statistical 
comparisons. 
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For canine study of the recurrent laryngeal nerve transection a different method was used. 
Immediately prior to euthanasia, animals were anesthetized, and anesthesia was maintained with 
isoflurane in O2 via an endotracheal tube capable of detecting evoked compound motor action 
potentials (CMAP) from the vocalis muscle following proximal stimulation of the recurrent 
laryngeal nerve (NIM EMG Endotracheal tube, (inner diameter 7.0 mm, outer diameter 10.5 mm) 
Medtronic) [209]. Endoscopy was performed during the same anesthetic episode and the degree 
of arytenoid abduction at peak inspiration determined under light sedation. 
The right RLn was exposed by dissection in the mid cervical region and a single monopolar 
needle (Neuroline monopolar, AMBO Inc.) placed adjacent to the RLn 10 cm caudal to the anterior 
ring of the cricoid cartilage. A supramaximal pulse (8-14 mA) was applied to the monopolar needle 
and the corresponding CMAP recorded at the vocalis muscle (Sierra Wave II, Caldwell 
Laboratories, Kennewick, WA). Presence/absence and peak amplitude of each CMAP was 
recorded for each of three repetitions. This procedure was repeated on the left side. 
Raw CMAP data was exported as a text file and analyzed using custom software written in 
MATLAB to determine peak amplitude and area of the CMAP. Mean values were determined 
from the three CMAPs recorded on each side. For each parameter, differences between left and 
right CMAPs was determined using Wilcoxon-signed rank tests 
 
4.2.10 Staining of NF200 to Analysis Axon Growth Across Injury 
Nerve tissue was subjected to a series of increasing sucrose washes, cut cross-sectionally 
at the half-way point across the conduit or graft, and then embedded in OCT. For the gap injury, 
cross sections 10 µm thick were taken every 2mm, collecting samples from the midpoint, and then 
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±2mm, and ±4mm from the midpoint. Crush injury nerves were only sampled at the distal portion 
of the sciatic nerve. The slides were then stained for neurofilament heavy chain (NF200) for axons. 
Consecutive sections were incubated with NF200 antibody (1:300, Sigma) overnight. 
Corresponding secondary antibodies (1:300, Alexafluor) were given for 1 hour. Sections were then 
washed with PBS (1X) and cover-slipped. Crush sections were also stained for S-100 for Schwann 
cells and Fluoromyelin. Consecutive sections were incubated with Fluoromyelin (1:400, Life 
Technologies) and anti-S-100 antibody (1:200, Sigma) overnight. Corresponding secondary 
antibodies (1:100, Alexafluor) were given for 1 hour. 
 
4.2.11 Histologic Analysis of Downstream Muscles 
The gastrocnemius muscle collected from both legs at 12 weeks post-surgery was fixed in 
10% neutral buffered formalin. The tissue was cut cross sectionally across the thickest region of 
the muscle. Tissue was paraffin embedded and 8um thick slides were produced for histology. 
Hematoxylin and Eosin (H&E) staining was performed to visualize the muscle structure and five 
10X images per slide were taken and assessed for fiber diameter. The minor diameter of twenty 
fibers were measured per image using ImageJ. Macroscopic images of the cross-sectional muscle 
were also taken, and total cross-sectional area was measured using ImageJ. 
For canine study of the recurrent laryngeal nerve transection a different method was used. 
Posterior cricoarytenoid (PCA) and lateral cricoarytenoid (LCA) muscles were harvested from 
explanted larynges and weighed. Collagen V immunohistochemistry was performed on mid 
sections of left and right PCA and LCA muscles and minimum fiber (Feret’s) diameters 
determined using custom semi-automated software written in MatLab. 8 μm thick cryosections of 
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acetone-fixed muscle were used for immunohistochemical analysis. Cryosections were washed 
with phosphate buffered saline containing 0.05% Tween 20 (PBST) for 3 times (5 min each). 
Nonspecific staining was blocked with a mixture of 10% rabbit serum and 2xcasein for 30 minutes 
at room temperature. The primary antibody goat anti-type V collagen antibody (SouthernBiotech, 
Birmingham, AL) was diluted to 1:1,000 in PBS containing 1xcasein, and the sections were 
incubated for 1.5 hr at 37o C. Biotinylated rabbit anti-goat IgG (Vector Laboratories, Burlingame, 
CA) was diluted to 1:200 in PBS and incubated for 30 min at room temperature. Finally, 
streptavidin-Texas Red (Molecular Probe, Life Technologies, Grand Island, NY) was used to 
visualize positive staining (used at 1:200 in PBS), and then the sections were mounted in 
Vectashield containing Dapi (Vector Laboratories). PBST was used for washing throughout the 
procedure. Goat IgG was diluted to the same final concentration as primary antibody was used as 
a negative control. IHC results were examined and photographed using Olympus AX 70 compound 
microscope. 
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4.3 Results 
4.3.1 Improvement of Function with a Sciatic Nerve Defect Model 
SFI from a rat model of critical-length sciatic nerve defect. Groups include a 17 mm 
silicone conduit with PNM 10 mg/mL lumen filler (PNM10), flipped and replaced nerve section 
repair (Autograft), and complete resection of the nerve without repair (No Repair, not shown). 
PNM was used in a critical length defect model test return of function. The equation described by 
Bain et al. was used (Figure 25A). Abbreviations shown within the equation are E (experimental 
side), N (contralateral side), PL (print length), TS (outer toe spread), and IT (intermediate toe 
spread) (Figure 25A). As previously described, this equation uses the paw lengths and the paw 
widths between the 1st and 5th digits, and the 2nd and 4th digits from each paw. Representation of 
the six measurements taken for SFI as well as representative ink prints from weeks 0, 2, 4, and 6 
are shown in (Figure 25B, C). Ink was applied the hind feet of the rat and each rat was subsequently 
allowed to traverse across a platform with a paper lining, leaving their hind paw prints behind 
(Figure 25C). The prints were photographed and a MatLab code was written to analyze the images 
(Appendix B.1.1). SFI from this study showed similar outcomes between a conduit with PNM10 
as lumen filler and autograft. Functional outcomes trended towards being better for the PNM10 
treatment as well (Figure 26A). A trend towards increasing values was observed for all groups 
including the negative control. This was controlled for by normalizing to the negative control 
which was an injury without repair (Figure 26A).  
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Figure 25: Representation of SFI walking track analysis using inked paw prints 
(A) Equation used for deriving SFI. Abbreviations used are E (experimental side), N (contralateral 
side), PL (print length), TS (outer toe spread), and IT (intermediate toe spread). (B) Location of 
the SFI measurement on a rat paw print. (C) Example of collected prints from a rat sciatic nerve 
gap defect injury at weeks 0, 2, 4, and 6. 
 
 
 
However, a limitation to this comparison is the amount of contracture that formed in the 
autograft group (Figure 26B). At 20 weeks, all autograft animals had developed some form of 
contracture. Contracture can signify an imbalance in functional return or the presence of synkinetic 
innervation. Regardless of cause, paw contracture negatively impacts SFI and is a possible 
explanation for why the autograft appears to have performed poorly.  
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Figure 26: SFI for PNM in a pilot rat critical length sciatic nerve defect 
(A) SFI collected over 22 weeks and normalized to no repair group to remove variability in 
collection and analysis or non-recovery related adaptations. (B) Paw contractures that limit the 
reliability of the SFI measurement was tracked. All autograft animals developed contractures while 
no PNM treated animals did. 
 
 
 
4.3.2 Improvement of Function with a Common Peroneal Defect 
As anticipated, modified peroneal functional index decreased significantly after injury in 
both control and PNM groups (p < 0.001,  27). Partial recovery was observed in the PNM group 
with significantly improved PFI 8 and 16 weeks after nerve repair compared to the control group 
(linear contrasts p = 0.004 and p = 0.006 respectively, n = 6). Overall the interaction term (week x 
group) was significant (p = 0.03) as were fixed effects for group (p = 0.01) and week (p < 0.001). 
Model fit was good (Adjusted R2 =0.87) and model assumptions were met. While some autophagy 
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was observed in the previous study of sciatic nerve transection and gap, autophagy was not 
observed in any of the rats for this study. The most obvious difference is the severity of the injury 
involved here was not as great. 
 
 
 
 
Figure 27: Common Peroneal Nerve Functional Index (PFI) 
PNM improves hind limb function determined by walking track analysis and modified 
peroneal functional index. PFI was significantly higher in the PNM group 8 and 16 weeks after 
nerve repair compared to the control group (linear contrasts p=0.004 and p=0.006 respectively, 
n=6 / group). 
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4.3.3 Assessment of Functional Recovery in a Rodent Sciatic Nerve Gap Defect Model 
4.3.3.1 Functional Assessment Using Walking Track Analysis 
SFI and ankle angle at toe-off (end of stance phase) were collected from MotoRater (TSE 
Systems, Chesterfield, MO) videos. PNM had been previously shown to enhance cellular response 
to peripheral nerve injury including macrophages and Schwann cells. This study focused on 
electrophysiology and downstream function. Four metrics of regeneration were collected SFI, 
ankle angle at toe-off, nociception, and compound motor action potential (CMAP) ( 28). Walking 
track analysis showed an approximately 30-point improvement in SFI after 24 weeks for all three 
treatment groups (PNM10, PNM20, and PNM40) ( 28A). No dose dependent effect was observed 
between the three groups. Autograft treated animals recovered by 40-point by the end of the study. 
The autograft was significantly different (Two-way ANOVA, p < 0.01) from all groups except for 
PNM40 (p = 0.057). 
Ankle angle was taken at the end of the stance phase during toe-off ( 28B). This is a direct 
measure of gastrocnemius muscle function during normal locomotion. All treatment groups saw a 
200% improvement in ankle angle by the end of study but did not differ from conduit control. By 
24 weeks, only autograft is significantly different then conduit control (p < 0.001). Ankle angle 
was the metric most susceptible to the effects of weight change. Over 24 weeks, animals gained 
weight especially male rats who over doubled in weight.  
Nociception, or the response to noxious stimuli was tested using graded von Frey fibers ( 
28C). This graph also includes controls from a separate study that followed the same methods 
including dissection only without injury (DO-NT), no injury or surgery (NI-NT), and transection 
and ligation to prevent recovery (T-NT). Von Frey testing was expected to be a rigorous test of 
both sensory and motor function of the affected limb, however controls that were expected not to 
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recovery (T-NT) began to respond to stimuli. Though the response was not equivalent with 
dissection only or no injury. This could have been a product of the tester or learned behavior of an 
unrelated stimulus. Whatever the cause, the controls showed that the experiment did not provide 
as reliable of testing for sensory recovery. 
 
 
 
 
Figure 28: Functional metrics for a rat model of sciatic nerve defect  
Abbreviations used: PNM10, conduit repair with 10 mg/mL PNM hydrogel as lumen filler; 
PNM20, conduit repair with 20 mg/mL PNM hydrogel as lumen filler; PNM40, conduit repair 
with 40 mg/mL PNM hydrogel as lumen filler; DO-NT, dissection down to nerve only with no 
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nerve injury; NI-NT, no surgery; T-NT, transected and ligated nerve to prevent regrowth (A) SFI 
and (B) ankle angle at toe-off (end of stance phase) collected from MotoRater (TSE Systems, 
Chesterfield, MO) videos. (B) Ankle angle is shown as a ratio of injured extremity over uninjured. 
(C) Nociception tested using von Frey fibers and results show the raw withdrawal thresholds (g). 
 
 
 
While differences were not observed at the 24 week timepoint ( 29B), earlier in the study 
animals showed improvements that resembled more the autograft than the negative control ( 29A, 
C). SFI at 4 weeks for PNM10 treated animals showed significant differences from negative 
control (*, p < 0.05,  29A). At this timepoint, the autograft was already significantly different from 
the negative control as well (****, p < 0.0001,  29A). Ankle angle also showed early improvements 
at the 4-week timepoint ( 29C). Both PNM10 and PNM20 were significantly better than the 
negative control (**, p < 0.01, ***, p < 0.001,  29C). Both were not significantly different from 
the autograft control. 
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Figure 29: Assessment of SFI and ankle angle at 4 and 24 weeks 
SFI at 4 weeks (A) and 24 weeks (B) as well as ankle angle at 4 weeks (C) and 24 weeks 
(D). Difference between conduit and PNM treatment groups are significantly larger after the first 
month. (*, p < 0.05, **, p < 0.01, ***, p < 0.001, ****, p < 0.0001, n = 4-8).  
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4.3.3.2 Electrophysiologic Function of Sciatic Nerve at the Tibialis Anterior Muscle 
The sciatic nerve was stimulated above the graft site and the stimulus response was 
measured at the tibialis anterior muscle by hook electrodes. Stimulus responses were collected 
across a range of stimulus currents. At each stimulus current, 20 response curves were collected. 
These were overlaid using MatLab before analyzing ( 30).  The 20 response curves for each 
stimulus current remained consistent and a current. A stimulus current of 0.8 mA was chosen based 
on stimulus curves ( 31B) to reduce signal clipping at higher intensities. CMAP amplitude analysis 
was not performed because some clipping was still present and response curves were not simple 
single peak CMAPs, therefore a different analysis method was used. Analysis was done by taking 
the root mean square (RMS) of the curves using a MatLab code. Furthermore, response curve 
complexity was assessed by taking the derivative of the curves. Only conduit differed significantly 
in the population of stimulus responses at the selected stimulation curve ( 31A). The CMAP RMS 
after 6 months for the treatment groups were statistically similar to the autograft group and were 
significantly different than the transection and ligation negative control (T-NT) ( 31C). The 
autograft was statistically similar to PNM groups but had not returned to a normal CMAP response 
although was also similar to the dissection only, sham procedure. 
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Figure 30: Representative compound motor action potential traces of the sciatic nerve 
measured at the tibialis anterior 
Abbreviations used: PNM10, conduit repair with 10 mg/mL PNM hydrogel as lumen filler; 
PNM20, conduit repair with 20 mg/mL PNM hydrogel as lumen filler; PNM40, conduit repair 
with 40 mg/mL PNM hydrogel as lumen filler; Sample traces collected at 0.8 mA. 
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Figure 31: Compound motor action potential of the sciatic nerve at the tibialis anterior 
muscle 
(A) Number of unique CMAP responses possibly denoting separate axon populations responding 
to the stimulus. (B) Response curves were taken from an increasing range of stimulation currents. 
The mean CMAP RMS is plotted for each stimulation current. Further readings shown at 0.8mA. 
(C) Mean CMAP RMS of the groups collected at 0.8 mA. Differing letters denote statistical 
significance (p < 0.05) and error bars show standard error. 
 
 
 
4.3.3.3 Assessment of Axons Crossing the Nerve Defect Injury 
The number of axons across the defect injury was quantified through immunofluorescent 
imaging and image analysis using Cell Profiler. Representative images show staining of NF200 of 
the distal (-4mm from midline injury) segment ( 32A). Qualitatively, the bridge formed in the 
PNM10 treatment group produced was similar to that of the autograft, while the PNM20, PNM40, 
and conduit were smaller in size ( 32A). All groups except for PNM10 showed a slight decrease 
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from proximal to distal portions of the defect ( 32B-F). Overall, both PNM10 and PNM20 showed 
a significantly greater number of axons at the distal portion of the defect than the negative control 
(conduit) and all three PNM treatment groups were similar to the autograft control ( 32G). Error 
bars show standard error and different letters denote statistical significance (p < 0.05). 
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Figure 32: Axon count across sciatic nerve defect injury 
 (A) Representative immunofluorescent images of nerve cross-sections stained with NF200 at 
distal segment. (B-F) Axon counts for each group across the conduit or graft. Zero denotes the 
center of the graft or conduit with -4 being proximal and +4 being distal. (G) Average axon counts 
for the distal segment. Differing letters denote statistical significance (p < 0.05) and error bars 
show standard error. 
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4.3.4 Assessing Functional Recovery in a Rat Model of Sciatic Nerve Crush 
The sciatic nerve was crushed using a bulldog clamp with a calibrated force of 500 g. This 
force deformed 2 mm of nerve tissue, flattening it ( 21B) and causing a complete disruption of 
signal conduction across the injury. Intraneural injection of the PNM hydrogel caused a slight 
bulging of the epineurium in the dissection only ( 21A) while the crushed nerve was swelled back 
to normal dimensions ( 21C). 
4.3.4.1 Safety of Direct PNM Hydrogel Injection into Nervous Tissue 
Intraneural injection is generally considered to be safe for anesthesia reasons, with very 
low risk of peripheral nerve injury complication. However, intraneural injection is not a common 
practice as a treatment for traumatic nerve injuries. Our test of the safety of PNM injection directly 
into the nerve (dissection only with PNM injection, DO-PNM), found little to no change in SFI ( 
33A) and ankle angle ( 33). Nociception shows no difference between groups whether in 
withdrawal threshold (g) ( 33C) or normalized to the positive control ( 33D).  
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Figure 33: Safety of PNM hydrogel injection into nervous tissue 
Abbreviations used: NI, no injury or surgery; DO-PNM, dissection down to nerve and 
PNM injection into healthy nerve; DO, dissection down to nerve without injury. (A) SFI and (B) 
ankle angle at toe-off (end of stance phase) collected from MotoRater (TSE Systems, Chesterfield, 
MO) videos. (B) Ankle angle is shown as a ratio of injured extremity over uninjured. (C) 
Nociception tested using von Frey fibers and results show the raw withdrawal thresholds (g) as 
well as values normalized to both contralateral side and positive control (D)  
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4.3.4.2 Intraneural Injection of PNM as a Treatment for Peripheral Nerve Injury 
SFI is a well cited metric for measuring function after sciatic nerve injury. Our controls 
matched expectations of this metric with the transection and ligation (T-NT) showing no recovery 
and no injury (NI) remaining at normal. SFI showed that the crush injury returns to normal by 6 to 
8 weeks regardless of treatment (Figure 34A). PNM scored significantly higher than crush alone 
at weeks 2 and 3 (p < 0.05). Ankle angle at toe-off is representative of gastrocnemius function 
during normal gait. This metric also shows a return to normal function of the gastrocnemius by 6-
8 weeks (Figure 34B). Function was significantly enhanced for C-PNM over C-NT for weeks 3 
and 4. Nociception shows a development of a transient hypersensitivity to noxious stimulus during 
the first month after the injury (Figure 34C, D). This response is resolved for both crush groups 
(C-NT, C-PNM) by 6-8 weeks. Transection and ligation group has a steady reduction in sensitivity. 
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Figure 34: Intraneural injection of PNM as a treatment for peripheral nerve injury 
Abbreviations used: C-NT, crush with no treatment; C-PNM, crush with PNM injection; 
T-NT, transection and ligation to prevent regrowth; NI, no injury or surgery. (A) SFI and (B) ankle 
angle at toe-off (end of stance phase) collected from MotoRater (TSE Systems, Chesterfield, MO) 
videos. (B) Ankle angle is shown as a ratio of injured extremity over uninjured. (C) Nociception 
tested using von Frey fibers and results show the raw withdrawal thresholds (g) as well as values 
normalized to both contralateral side and positive control (D) 
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4.3.4.3 Axon Growth Across Injury in Sciatic Nerve Crush Injury 
The number of axons distal to the injury was quantified through immunofluorescent 
imaging and image analysis using Cell Profiler. Representative images show staining of 
fluoromyelin, NF200, and combined of the tibial, sural, and cutaneous branch portion of the sciatic 
nerve. Qualitatively, a greater number of large, myelinated axons are present in the crush with 
PNM similar to the normal sciatic nerve fiber when compared to the crush injury without treatment 
( 35A). Myelin appears disrupted in both crush with and without treatment and fewer axons were 
observed in crush without treatment. All four branches, tibial, sural, cutaneous, and peroneal were 
imaged and analyzed. Axon counts were normalized to the no injury group. and axon counts of the 
sciatic nerve distal to the injury show an increased in the number of axons crossing the injury. 
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Figure 35: Axon growth across injury in sciatic nerve crush injury 
(A) Representative cross section immunofluorescent images of NF200 and fluoromyelin staining 
for axons and myelin for no injury, crush with and without PNM treatment. (B) Axon count taken 
distal to the crush injury and processed using ImageJ (n=8). 
 
 
 
4.3.4.4 Atrophy of Downstream Muscle 
The gastrocnemius muscle is a 50:50 mixed fast and slow twitch muscle innervated by 
tibial branch of the sciatic nerve. Both muscle fiber diameter and total cross-sectioned area was 
taken for both the injured and uninjured sides. We discovered that this level of nerve injury either 
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was not sufficient to produce muscle atrophy or that muscle atrophy recovered by the end of the 
90-day timepoint. The negative control (T-NT) demonstrated the maximal atrophy possible within 
the 90-day timeframe. Transection and ligation (T-NT) produced a significant shrinking of both 
muscle fiber diameter and muscle size by 30% and 60% (p < 0.05, n=8), respectively (Figure 36A, 
B). Representative images of the injured side muscle show a slight effect of the crush injury but 
not a significant difference between crush with and without treatment (Figure 36C). 
 
Figure 36: Atrophy of gastrocnemius muscle after sciatic nerve crush injury 
Abbreviations used: C-NT, crush with no treatment; C-PNM, crush with PNM injection; 
T-NT, transection and ligation to prevent regrowth; NI, no injury or surgery; DO-PNM, dissection 
down to nerve and PNM injection into healthy nerve; Sham/DO, dissection down to nerve without 
injury. (A) Minimum fiber diameter of the gastrocnemius as a ratio of injured over uninjured 
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muscle. T-NT is significantly different from all other groups (p < 0.001). (B) Gastrocnemius cross-
sectional area as a ratio of injured over uninjured muscle. T-NT is significantly different from all 
other groups (p < 0.001). (C) Representative cross-sectional images of injured gastrocnemius 
muscle stained with H&E. 
 
 
 
4.3.5 Electrophysiology of Downstream Muscle 
Evoked CMAP of the tibialis anterior performed healthy nerve and immediately after 
injury shows that the crush model achieves complete disruption in conduction ( 37A). The sciatic 
nerve proximal to the crush site was excited with an increasing range of stimulation amplitudes. 
Complete stimulation range included 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 
0.7, 0.8, 0.9, and 1.0 mA and further results shown, and comparisons were made from the 0.8mA 
reading (Figure 37B).  
Average RMS was taken from 20 trances at each stimulation amplitude and overall 
averages are showed (Figure 37B). Both raw traces and average RMS was assessed for a 
stimulation amplitude that produced a supramaximal excitation. A stimulation amplitude of 0.8 
mA was selected, and those results shown (Figure 37C). Direct injection into nerve did not have a 
significant impact on electrical conduction (Figure 37C). Application of PNM (C-PNM) 
significantly increased CMAP over crush alone (C-NT) (p < 0.05) and was similar to no injury  
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(Figure  37D). These results show roughly a 50% increase in conduction for the treatment group 
over crush alone. PNM injected into a sham control did not significantly affect evoked CMAP and 
both C-PNM and DO-PNM were not significantly different from no injury or sham groups. 
 
Figure 37: Electrophysiology of tibialis anterior muscle after sciatic nerve crush injury 
(A) Mean CMAP RMS of normal, no injury and immediately post-crush. 
Electrophysiologic response shows a complete ablation of signal after crush. (B) Response curves 
were taken from an increasing range of stimulation currents. The mean CMAP RMS is plotted for 
each stimulation current. Further readings shown at 0.8mA. (C) Mean CMAP RMS of the groups 
investigating the safety of intraneural injection of PNM. No significant differences between PNM 
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injection and controls. (D) PNM enhanced CMAP over crush injury without treatment (p<0.05, 
n=8) and not different than no injury group (p=0.08, n=8). Differing letters denote statistical 
significance (p < 0.05) and error bars show standard error. 
 
 
 
4.3.6 Sex Base Variance in Compound Motor Action Potential Measures of Recovery 
A mix of female and male Lewis rats were used in this study to better represent the normal 
population. Several groups showed favorable recovery in females over males including the crush 
with PNM injection (Figure 38). However, these differences were only pronounced in the 
Compound motor action potential (CMAP) divided by sex for crush study (Figure 38A). No 
significant differences between sexes were observed in the nerve gap defect study (Figure 38B).  
While significance was not found due to small sample size between sexes, the trend still 
suggests there could be some sex-based variance in peripheral nerve recovery. Earlier studies in 
the literature have shown that sexually dimorphic hormones and steroids such as testosterone and 
progesterone, play an active role in nerve regeneration. Concentrations of these neuroactive 
steroids differ between male and female rats and could lead to this difference seen in this study 
between male and female rats [210-212]. 
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Figure 38: Sex base variance in compound motor action potential measures of recovery 
(A) Mean CMAP RMS for the crush injury model divided by sex. PNM treated crush injuries show 
a trend towards more favorable outcomes in females compared to male rodents. (B) The same 
division shown for the gap defect model. Unlike the crush model, no differences are seen between 
the male and female animals. 
 
 
 
4.3.7 Restoration of Nerve Function Following Reconstruction of the RLn in Canine 
Model 
No laryngeal movement was observed in any animal at 4 weeks. 24 weeks after 
implantation, laryngeal endoscopy revealed arytenoid movement but ineffective abduction in 
animals implanted with UBM and PNM but no movement in the animals with coaptation without 
hydrogel support or transection only CMAP amplitudes for animals at the 24 week time point were 
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(mean ±se) PNM (0.68 ±0.32 mV, n = 2); UBM (0.71 ±0.019 mV, n = 2); conduit (0.34 mV, n = 
1); transection (0.09 ±0.016 mV, n = 2) with no significant differences between groups (p = 0.24, 
ANOVA). CMAP amplitudes at the 4 week time point were all 0 mV (conduit only, n = 2; UBM, 
n = 2; PNM, n = 2) (Figure 39B). Peak CMAP amplitude at the TA complex was strongly and 
significantly correlated with explanted PCA muscle weight across all animals with a 0.19 ±0.011 
mV increases in CMAP amplitude for every 1-gram increase in PCA weight (R2 = 0.80, p = 0.001, 
Figure 33E). The relationship between TA complex peak CMAP amplitude and LCA muscle 
weight was less strong with a 0.05 ±0.02mV increase in CMAP amplitude for every 1 gram 
increase in LCA weight (R2 = 0.40, p = 0.02) (Figure 39E). 
Significant differences were observed between the 4- and 24-week time points in right PCA 
(12.6 ±2.5 g, 20.7 ±2.3 g, p = 0.037, t-test) and LCA (7.9 ±1.8 g, 12.0 ±2.7 g, p = 0.007, t-test) 
muscle weights, although no differences were observed between treatment groups at any time 
point. Similarly, a significant reduction in right PCA muscle weight (denervated) relative to left 
PCA (control) at 4 weeks across all groups (right 12.6 ±0.5 g; left 19.0 ±1.8 g, p = 0.007, paired t-
test) but not at 24 weeks (right 23.0 ±0.96 g; left 20.7 ±8 g, p = 0.43). A similar pattern was 
observed in LCA muscle weights at 4 weeks (right 7.9 ±0.7 g; left 12.4 ±0.8 g, p = 0.0007) and 24 
weeks (right 12.0 ±1.0 g; left 14.5 ±1.0 g, p = 0.43) after denervation and repair. 
No significant differences were observed between PCA or LCA minimum fiber diameters 
between groups at 24 weeks after repair: PCA-PNM, 66.9±4.0 µm; UBM 72.4±6.8 µm; conduit 
only 58.5 µm; transection 60.0 ±7.6 µm (p = 0.54); LCA-PNM, 57.9±4.4 µm; UBM 64.6±1.67 
µm; transection 62.8±9.2 µm (p = 0.69) (Figure 39D). Similarly, no differences were observed 4  
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weeks after repair, PCA- PNM, 49.7±0.65 µm; UBM 62.6±7.4 µm; conduit only 52.4 µm (p = 
0.24); LCA-PNM, 54.7±13.4 µm; UBM 55.4±8.67 µm; conduit only 65.7 ±3.1 µm (p = 0.68) 
(Figure 39B, E).  
Combining treatment groups, right PCA weights were significantly reduced at 4 weeks 
(54.9 ±3.2 µm) compared to 24 weeks (65.3 ±3.3 µm, p = 0.04). Right LCA weights were not 
significantly different at 4 weeks (58.6 ±4.8 µm) compared to 24 weeks (61.8 ±2.7 µm, p = 0.57) 
(Figure 39D, E). 
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Figure 39: Functional recovery of RLn in a canine model  
(A) Intraoperative photo of silicone conduit placement after anastomosis of transected RLN. (B) 
Compound muscle action potential amplitude measured at the vocalis muscle after super-
stimulation of the RLN. (C) Duration between stimulation of the RLN and recorded action 
potential at the vocalis muscle. (D) Muscle fiber diameter of the posterior cricoarytenoid muscle. 
All three measurements were taken after 6 months of recovery, post-surgery. (E) Relationship 
between right cricoarytenoid muscle mass and vocalis CMAP amplitude (R2 = 0.80, p =0.001) 
Statistic are not shown because of the limited group sizes used (n = 2). 
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4.4 Discussion 
The most prevalent rodent model for testing the functional return of a sciatic nerve injury 
is the walking track analysis using the sciatic functional index (SFI). In the late 1970s, Hruska, et 
al. demonstrated that walking tracks made by rats have consistent and reliably quantified 
characteristics and proposed the measurement of changes in print morphology as a marker of 
functional recovery [213]. Generally, this method involves the application of some ink-like media 
to the hind feet of the rat and subsequently allowing them to traverse a substrate upon which they 
leave their hind paw prints. De Medinaceli et al. developed specific measurements and a formula 
to provide an index of nerve function between 0 and -100 in 1982 [214]. This first equation 
incorporated four parameters that were directly measured from the rodent’s footprints: distance to 
opposite foot, print length, outer toe spread, and inner toe spread ( 40A). Later versions of the SFI 
described by Carlton and Goldberg simplified the equation to just three metrics ( 40B). However, 
these early SFI formulas weighted parameters equally and were poorly indices of function. Bain 
et al. drastically improved the SFI by incorporating coefficients derived from multiple linear 
regression analysis ( 40C).  
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Figure 40: Equations for calculating Sciatic Functional Index 
(A) SFI equation described by De Medinaceli, Freed and Wyatt in 1982. (B) SFI equation 
described by Carlton and Goldberg in 1986. (C) SFI equation described by Bain, Machinnon, and 
Hunter in 1989. Abbreviations are E (experimental side), N (contralateral side), TOF (distance to 
opposite foot), PL (print length), TS (outer toe spread), and ITS (intermediate toe spread). 
 
 
 
The SFI is determined by comparing various geometric parameters of the affected hind 
paw from an injured rat and comparing it to the contralateral paw. The equation described by Bain 
et al. produces a value of function, between 0 and -100. There are several equations that are present 
in the current research community, however each usually provides nearly the same values. The 
calculations have been most often based on the lengths and widths of the inked impressions of the 
paws left on a piece of paper during normal locomotion. The simplest equation is based on three 
A. De Medinaceli, Freed and Wyatt, 1982 
𝑆𝐹𝐼 =   
𝐸𝑇𝑂𝐹 − 𝑁𝑇𝑂𝐹
𝑁𝑇𝑂𝐹
 +  
𝑁𝑃𝐿 − 𝐸𝑃𝐿
𝐸𝑃𝐿
 +  
𝐸𝑇𝑆 − 𝑁𝑇𝑆
𝑁𝑇𝑆
 +  
𝐸𝐼𝑇 − 𝑁𝐼𝑇
𝑁𝐼𝑇
  
220
4
 
B. Carlton and Goldberg, 1986 
𝑆𝐹𝐼 =   
𝑁𝑃𝐿 − 𝐸𝑃𝐿
𝐸𝑃𝐿
 +  
𝐸𝑇𝑆 − 𝑁𝑇𝑆
𝑁𝑇𝑆
 +  
𝐸𝐼𝑇 − 𝑁𝐼𝑇
𝑁𝐼𝑇
  
220
3
 
C. Bain, Machinnon, and Hunter, 1989 
𝑆𝐹𝐼 = −38.3  
𝐸𝑃𝐿 − 𝑁𝑃𝐿
𝑁𝑃𝐿
 + 109.5  
𝐸𝑇𝑆 − 𝑁𝑇𝑆
𝑁𝑇𝑆
 + 13.3  
𝐸𝐼𝑇 − 𝑁𝐼𝑇
𝑁𝐼𝑇
 − 8.8 
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measurements: the paw lengths and the paw widths between the 1st and 5th digits, and the 2nd and 
4th digits. Paw length is the largest driver of SFI followed by the 1st-5th toe spread and then the 2nd-
4th toe spread.  
SFI is an extremely well published method with a strong correlation with functional 
recovery when employed correctly but is not immune from issues. Several difficulties can prevent 
researchers from obtaining usable print marks. Print length is the most influential parameter within 
the SFI equation but is negatively affected by a static position. If the rodent does not cross the 
track continuously, SFI can be artificially lowered. This behavior can be avoided by ample 
conditioning trials. Autotomy presents a permanent problem to gathering SFI data. After 
transection of the sciatic nerve, rodents may scratch or bite their anaesthetized foot. This behavior 
can result in autotomy, or the amputation of one or more toes. When this occurs, the rodent can no 
longer be assessed with SFI. This behavior can be curbed by applying foul-tasting substances upon 
the foot [215] or starting with a breed, such as Lewis rats that have demonstrated minimal autotomy 
[216]. Sciatic nerve injuries often cause joint contractures caused by either a faster or more 
complete reinnervation of the flexor muscles in comparison with the extensor muscle group [217, 
218]. While a sign of reinnervation, flexor contracture of the foot can decrease SFI readings and 
overall make data collection difficult. Physical therapy can mitigate this development [219]. 
Sciatic nerve transection models have consistently shown a relatively small degree of 
observable functional recovery when estimated using SFI, limiting its usefulness in peripheral 
nerve studies [201]. This is the result of two distinct problems: 1) axonal misdirection in the 
regenerative process and 2) the mixed grouping of fascicles that contribute to the tibial and 
common peroneal branches of the sciatic nerve. Ultimately, non-selective reinnervation of the 
distal stump fascicles causing a mixture of tibial and common peroneal tributaries entering the 
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distal stump results in altered activation patterns of opposing muscle groups during locomotion 
[49]. One alternative to minimize the effect of synkinetic regrowth in our first look at function 
recovery is to use a model of common peroneal nerve injury. A peroneal nerve functional index 
(PFI) equation was described by Bain, Machinnon, and Hunter in 1989 [207]. Using PFI mitigates 
the limitation imposed on SFI because of non-selective cross-innervation, since the motor units of 
the common peroneal nerve have related muscular functions, rather than opposing.  
The use of PFI is less common than SFI, and SFI and the sciatic nerve injury model still 
represents a gold standard in current literature. With possible issues that could reduce the power 
of the standard SFI measurement, it is logical to employ multiple metrics of functional recovery. 
Further studies that employ sciatic nerve injury models in this chapter include metrics that measure 
gastrocnemius muscle recovery during walking or score the sensory and pain reflex function. 
Combining the SFI score with biomechanical measures (kinematics) and measures of sensory and 
reflex recovery allows for a more holistic picture of functional recovery. 
However, for both PFI[220-223] and SFI [129, 220-234], several problems with walking 
tracks are apparent in the literature, such as contracture, related to loss of function of tarsal 
flexor/digital extensor muscles[220, 221, 223], or other causes of poor print quality[235, 236]. 
Other problems have been suggested, but not investigated, such as alteration of contralateral limb 
prints as a result of compensatory strategies during locomotion[223], and the effect of velocity on 
walking track analysis [237-239].  
One remaining limitation of most metrics used in the chapter is the use of the contralateral 
limb as a control or normalizing factor. It is very likely that compensatory limb loading would 
result in altered foot placement or gait in the uninjured contralateral limb. By comparing 
measurements from all time points for the contralateral limb to pre-injury prints, it has been shown 
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that there are significant differences in the contralateral limb’s SFI post-injury. Therefore, it is 
possible that results could be muted or exaggerated by compensatory changes in the contralateral 
limb.  
In studies that include both functional metrics (SFI, PFI, ankle angle, etc.) and CMAP, it 
is observed that electrophysiologic results do not always translate to similar changes in function. 
For example, PNM10 treatments as lumen fillers in a non-critical sciatic nerve defect significantly 
increased CMAP amplitude by 70% over conduit control (p < 0.05) and provided conduction 
comparable to the autograft. However, PNM10 did not perform any better than the conduit control 
in function assays. One possible source for this disparity is the presence of synkinetic growth. For 
large injuries that disrupt normal axon channels, axonal misdirection in the regenerative process 
can significantly affect function, particularly in the case of the mixed grouping of fascicles that 
contribute to the tibial and common peroneal branches of the sciatic nerve. Axonal misdirection, 
or synkinetic growth can cause a mixture of tibial and common peroneal tributaries entering the 
distal stump results in altered activation patterns of opposing muscle groups during locomotion 
[49]. This could lead to positive CMAP readings when evoked in isolation but poor overall 
function during voluntary locomotion. 
CMAP done in the rat gap and crush models experienced signal clipping at higher currents, 
limiting our confidence that we were accurately comparing groups. This was limited by the 
equipment used to collect the stimulus curves which was designed for smaller electrophysiologic 
measurements. Instead of collecting amplitude measurements that would be strongly impacted by 
recording clipping, the area under the curve was collected by root mean squared (RMS) 
assessment. The area under of the curve was collected from multiple stimulus curves at different 
stimulus currents and plotted over stimulus current. The stimulus traces were consulted and a 
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current that minimized the clipping while still being at a plateau of RMS results. For crush injuries, 
this current was able to be selected within a response plateau but for the gap injury a plateau was 
not able to be reached with the protocol being performed. Under normal conditions, CMAP 
represents a strong test of nerve regeneration. While there are a number of limitations with the 
current studies using electrophysiology, the CMAP results match closely with axon counts at the 
distal portion. This could suggest that while the CMAP results for the gap study are not 
supramaximal, they still represent a relative comparison between groups. In addition to RMS 
CMAP results, CMAP traces showed multiple peaks at different peak latencies rather the typical 
biphasic CMAP response curve at a single peak patency. These multiple waveform components 
suggests that there were multiple populations of axons with different conduction velocities that 
were contributing to the overall CMAP recorded from the tibialis anterior muscle. This waveform 
complexity was scored and compared but no significant differences was found between autograft 
and treatment groups. Only conduit alone different and this was possibly because of animals that 
did displayed little to no recovery. 
The functional tests, in design also represent a limitation of the present study. SFI is a well 
described measure [129, 220-234], but conditions that effect the foot can greatly affect the test 
because the index relies heavy on measures of the toes. These conditions include autophagy (self-
amputation of toes) or chronic foot flexion contractures [228, 240]. In our studies, autophagy was 
extremely rare, with an incidence of <1%. However, we observed a high occurrence of chronic 
flexion contractures in the sciatic defect injuries, especially in the autograft groups. The prevailing 
theory is that these flexion contractures symbolize regrowth of the injured nerve but represent 
either synkinetic reinnervation of opposing muscle groups or a preferential reinnervation of the 
flexion muscle groups [228, 240]. 
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The von Frey fiber nociception test was added to test the nociceptive sensory component 
of the sciatic nerve afferent fibers that contribute to the generation of the withdrawal reflex. This 
was the first sensory test incorporated into the study but was highly variable and limited 
conclusions were drawn from this experiment. This experiment was also not a pure test of sensory 
function, instead required a reinnervation of a reflex arc, arc, including the regeneration of both 
motor and sensory neurons. These limitations combined caused this assay to be a very ineffective 
test of sensory function return. Future study could use other reflex tests with stimulations generated 
by heat, cold, or electrical shock that may have less variability. However, this still does not resolve 
the complexity necessary to recover a full reflex arc. Overall, the reflex test used in this study was 
a weak measure of functional recovery. 
A rat sciatic nerve crush model was used to assess both the safety and efficacy of an 
intraneural injection of PNM to the site of injury. While both groups returned to full functional 
recovery by the end of 12 weeks, PNM injection sped return to function by one week, increased 
the number of axons crossing the injury and evoked CMAP across the injury. The use of PNM 
injection into the site of injury had a positive impact on peripheral nerve regeneration and could 
be a potent strategy upon further development. 
One limitation to this study is the possible variability of the degree of nerve injury induced. 
A third degree axonotmesis injury is associated with damage to the axons as well as the endoneurial 
linings. This can lead to endoneurial scaring, which can impede or misdirect axonal regeneration 
resulting in a variable functional recovery. Our goal was to achieve this more severe form of the 
axonotmesis injury. We were interested in an injury without full functional recovery with a more 
exaggerated inflammatory response. We observed that the crush injury resulted in a decrease in 
axons at the distal region and a similar decrease in evoked CMAP at the downstream muscle. 
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However, functional metrics showed a complete recovery after 6-8 weeks. It is possible that the 
nerve injury achieved was not a severe as intended and therefore provided a narrow window for 
the PNM to impact recovery. Some studies have highlighted the resistance of rat nerve tissue to 
higher levels of axonotmesis injury, showing that various methods consistently demonstrated only 
a second-degree axonotmesis injury with only minor features of third-degree injury. 
All intraneural injections were at one point considered to be a portent to nerve injury and 
were avoided in most medical practices. However, with advances in ultrasound guidance, it is 
possible to visualize the difference between perineurial space and intrafascular regions allowing 
for precise delivery of drugs and anesthetics. Current practices show only a 0.5-1.0% occurrence 
of peripheral nerve injury complication due to anesthesia injections into nerve tissue [241]. Even 
without advanced visualization techniques to guide injections, we wanted to show that the 
intraneural injection of our treatment was safe. We saw that PNM injection without nerve crush 
injury showed no deleterious effect on functional metrics. Small effects on evoked CMAP and 
axonal count distal to the injury could have been caused by an unintended needle injury to a portion 
of the nerve.  
We hypothesized that PNM would have a positive effect on nerve regeneration of a crush 
injury through the recruitment of Schwann cells and macrophages, a shift in macrophage 
polarization, and a reduction in inflammation. We confirmed in vitro that PNM degradation 
products produce an enhanced Schwann cell migratory response and neurite outgrowth. While this 
study did not investigate these possible mechanisms in vivo, previously published work did show 
that PNM did have an impact on recruitment of Schwann cells and macrophages and a shift in 
macrophage polarization both in vitro and in vivo. 
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For the large animal model of RLn transection, a minimal study design measured evoked 
CMAP from the laryngeal muscles and compared to muscle size. The approach to detect evoked 
CMAPs, generated by a supramaximal stimulus proximal to the site of nerve coaptation, was 
effective and evoked CMAPs were detected in all animals at the 24-week time point. There was a 
very close correlation between CMAP amplitude and the weight of the intrinsic laryngeal muscles 
reinnervated by the RLn, although the correlation was stronger for the PCA muscle than the LCA 
muscle. This difference may be due to the more intricate geometry of the LCA and in its intimate 
relationship with the TA complex, making precise explanation and subsequent determination of 
LCA muscle weight difficult. The reduction in PCA (34%) and LCA (37%) weight four weeks 
after denervation compared to the contralateral innervated muscles is anticipated and reflects the 
relatively slow atrophy and absence of necrosis found after denervation in other large animal [36-
38] rather than rodent models [39, 40]. 
Taken together, these data suggest that evoked CMAPs detected at the TA complex provide 
a useful minimally invasive approach to monitor the return of reinnervating axons to the end target 
organ. In future work, this approach could be combined with an implanted nerve cuff [41, 42] to 
provide repeated longitudinal assessment of reinnervation. Reinnervation of the thyroarytenoid 
complex is crucial to the restoration of vocal cord function and voice and this approach would 
allow ongoing evaluation of the effects of regenerative therapies on RLn reinnervation. 
Despite increases in PCA and LCA muscle weights, CMAP amplitudes and minimum fiber 
diameters at 24 compared to 4 weeks after direct RLn-RLn coaptation, no effective arytenoid 
movement was observed. This result is anticipated in the case of repair to the common RLn trunk 
in which abductor and adductor fibers are spatially intermingled [43, 44, 45] due to synkinetic 
reinnervation [46, 47].  
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The major limitation of this study was the small number of animals at each time point and 
within each treatment group in the canine study. The goal of this work was to determine the 
feasibility of the use of ECM hydrogels in RLn repair. While the results of the study clearly 
demonstrate the potential for the use of ECM hydrogels in this application, more extensive work 
is required to determine significant differences between treatment groups and to evaluate the 
benefits of using a tissue-specific ECM hydrogel for nerve repair [48, 49].  
Overall, this work showed that PNM enhanced CMAP conduction across the injury site of 
both nerve defect and nerve crush and that gross function recovered quicker than conduit control. 
These results were consistent across the three injury models (crush, transection, and gap defect). 
The smallest effects on CMAP were observed in the crush group with an increase by about 50%. 
Both the 1 cm gap defect model and large animal transection model saw large increases in CMAP 
of about 70% and 100% respectively.  
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5.0  PNM Increases the Effectiveness of an Engineered Nerve Guidance Conduit 
Containing Cell-secreted Neurotrophic Factors  
5.1 Introduction 
To this point, PNM has been investigated for its ability to improve peripheral nerve 
regeneration in isolation of any other therapies outside of standard surgical repair. For nerve defect 
models, an inert nerve guidance conduit made from silicone was selected and used. PNM was 
shown to improve outcomes when combined with this inert silicone conduit but did not exceed the 
nerve autograft in all studies. One limitation is that silicone conduits are not an accepted material 
for nerve guidance conduits and does not perform as well as accepted conduit materials such as 
collagen type 1 or PGA. Current data suggests that PNM can improve the outcomes of all nerve 
guidance conduits when used as a lumen filler. Studies that compare the autograft repair to the use 
of PNM as a lumen filler for FDA approved conduits are needed. While not a clinically available 
conduit, PNM is used as a lumen filler for an engineering conduit that incorporates cell-secreted 
neurotrophic factors in this last chapter. 
In the pursuit of an effective nerve conduit, many physical and biological strategies have 
been employed during fabrication [193, 242-246]. On the physical side, nanofibers obtained from 
electrospinning hold great promise due to their ability to be fabricated with aligned arrangements 
closely resembling native nerve ECM, and they have demonstrated the ability to guide neurite 
extensions [242, 247-249]. On the biological side, neurotrophic factors (NTFs) such as brain 
derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF) have been 
shown to play an important role in facilitating axonal growth, guidance, and survival. In addition, 
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chemokine gradients are instrumental in driving Schwann cell migration into the regenerating 
nerve bridge and axon elongation [9, 42, 250-257]. Current methods of sustained delivery of 
growth factors by microparticles, along with other technologies, have demonstrated utility in 
experimental models of nerve repair, but these technologies have not yet addressed the dynamic 
time course of growth factor production, the use of anti-inflammatory cytokines, or the capability 
to supply a multitude of growth factors simultaneously [243, 244, 258, 259].  
A potential route toward addressing these issues lies in the use of stem cells. Mesenchymal 
stem cells (MSCs) are multipotent cells that have the ability to differentiate into many lineages, 
including neural-like lineages [260, 261]. Early transplantation experiments involving these stem 
cells demonstrated that they supported nerve regeneration (originally believed to be due to 
transdifferentiation to neural lineages but more recently thought to be through production of 
NTFs), and they have also been shown to possess immunoregulatory functions, which could 
potentially decrease scar tissue infiltration into conduits and neuroma formation [193, 253, 262, 
263]. Indeed, studies utilizing nerve conduits seeded with MSCs reported both larger axons as well 
as greater amounts of myelination per axon [193].  
This chapter investigates the combination of PNM with an engineered nerve conduit as 
well as the addition of a cell-secreted neurotrophic gradient. The effect of the regenerative response 
of peripheral nerve was examined through a 1 cm sciatic nerve transection model in rats. Basic 
histologic and function metrics were used to examine the effect that each component had on nerve 
regeneration. 
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5.2 Materials and Methods 
All chemicals were purchased from Sigma Aldrich (St. Louis, MO, USA) unless otherwise 
specified. All procedures were performed according to the guidelines of the Institutional Animal 
Care and Use Committee at the University of Pittsburgh, protocol number 16036308. 
5.2.1 Fabrication of Cell-seeded PCL/GelMA Nerve Conduits  
The composite PCL/GelMA scaffold was produced as previously described [264]. Briefly, 
a dual spinning setup with 14.0% w/v PCL (80 kDa) in 2,2,2-trifluoroethanol and 18% 
methacrylated-gelatin (GelMA) in 95% 2,2,2-triflurorethanol in water was used to produce random 
and aligned scaffolds. A 2.0 x 5.5 cm sheet of aligned scaffold and a 2.2 x 5.5 cm sheet of random 
scaffold was cut for each group and subsequently exposed to UV irradiation for 30 minutes to 
sterilize. The aligned scaffold was then overlapped on top of the random scaffold by 2 mm, and 
approximately 20 μL of photoinitiator solution (8% methacrylated gelatin, 0.3% photoinitiator 
lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) in HBSS (Gibco, Waltham, MA, USA) 
was applied to the overlapped region. This area was then irradiated with a visible light source 
supplying wavelength of 395 nm (7202UV395, LEDWholesalers) for 40 seconds to cure the 
gelatin and bond the two sheets together. Following this, approximately 300 µL of photoinitiator 
solution was used to wet both scaffolds. 50 uL of photoinitiator solution was then used to resuspend 
6 million cells, which were then pipetted in three vertical stripes 1.2 cm apart equidistant from the 
horizontal edges of the scaffold. This completed sheet was then rolled up around a hypodermic 
needle of 1.5 mm diameter, and subsequently photopolymerized with visible light for 2 minutes 
while rotating on the needle. The construct was then removed, and 0.95 cm was removed from 
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each end of the tube followed by cutting the remaining 3.6 cm into three 1.2 cm tubes such that 
the cell stripes fell into the central third of each conduit (2 million cells/conduit). These wall-
encapsulated cellular conduits were then placed in culture medium (10% fetal bovine serum (FBS) 
[Invitrogen, Carlsbad, CA, USA], 1x PSF [Gibco] in Dulbecco’s Minimal Essential Medium 
(DMEM) [ThermoFisher, Waltham, MA, USA]) until surgical implantation.  
5.2.2 ECM Hydrogel Preparation 
Peripheral nerve ECM was prepared from sciatic nerves collected from market-weight pigs 
(Tissue Source; LLC, Lafayette, IN, USA). The tissue was then frozen for at least 16 h at -80° C. 
The tissue was quartered longitudinally and cut into sections of less than 5 cm. Decellularization 
is performed as previously described [162]. Enzymatic degradation products were produced from 
solid ECM scaffold material as previously described [162]. Enzymatic degradation products were 
aliquoted and lyophilized. Immediately before use, lyophilized degradation products were 
rehydrated using sterile water. Gelation was then initiated by adjusting the pH of the digest to 7.4 
and 0.5X PBS concentration through the addition of 0.2 M NaOH and 10X PBS. A concentration 
of 20 mg/mL was tested in this study. 
 
5.2.3 Scaffold Implantation 
Nerve conduits with wall-encapsulated rat ASCs (DiI-labeled with Vibrant CM solution 
(Invitrogen) for 1 to 6 week experiments according to manufacturer’s protocol) or cell-free 
conduits were prepared for implantation. The sciatic nerves in Lewis rats were exposed and a 10 
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mm segment was removed using microscissors. Nerve stumps were sutured 1 mm into each end 
of the 12 mm conduit (for a gap of 10 mm) using 8-0 nylon suture. The conduit was either unseeded 
and left empty (Figure 41A), unseeded and filled with PNM20 (Figure 41B), seeded with MSCs 
and left empty (Figure 41C), or seeded with MSCs and filled with PNM20 as a lumen filler (Figure 
41D). A total of n = 6 rats was used for each group at each timepoint.  
 
 
 
 
Figure 41: Diagram of groups used to test engineered conduit with PNM as lumen filler 
 
 
 
  162 
5.2.4 Explanation and Immunohistochemical Analysis 
Scaffolds were explanted at their specified timepoints (either 1, 2, 4, 6, or 16 weeks). 
Scaffolds were then fixed in 10% buffered formalin phosphate for 2 days at 4° C. These were then 
passed through a series of solutions: 10% sucrose for 4h at room temperature, 20% sucrose 
overnight at 4° C, and lastly 30% sucrose overnight at 4° C. Samples were then placed in optimal 
cutting temperature gel (OCT) (Sakura Finetek USA, Torrance, CA, USA) for 2 h to equilibrate. 
Following this, 3 samples were transversely cut through the middle of the conduit and frozen in 
new OCT cut side down. Sections were collected at every millimeter with a thickness of 16 μm 
starting from the center to study cellular distributions. The other 3 samples were embedded 
longitudinally in fresh OCT for longitudinal sections to assess continuity of nerve growth. Samples 
were subsequently stored at -80° C until sectioning.  
5.2.5 Rat Sciatic Functional Index Testing 
Rats were placed in the MotoRater System (TSE GmbH, Chesterfield, MO, USA) and 
acclimated for two days prior to testing. Videos were then recorded videos for rats walking across 
the length of the MotoRater System. Simi Motion 9.2.1 software (Simi Reality Motion Systems 
GmbH, Unterschleissheim, Germany) was used to measure toe spread distances from acquired 
videos. SFI measurements from 4 steps were averaged for each rat.  
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5.2.6 Statistical Analysis 
All data were expressed as mean ± standard error of measurement (SEM). Statistical 
analysis was performed in Prism 7. Statistical analysis was performed using ANOVA with Tukey’s 
HSD post-hoc testing unless specified otherwise. One-tailed Mann-Whitney testing was used to 
determine differences in distributions, and non-linear fitting was used to determine Gaussian and 
quadratic fitting. One-way ANOVA followed by Fishers LSD post-hoc testing against wall or 
control was used for Week 6 Schwann and myelin thickness/ratio, respectively. A threshold of p 
< 0.05 was used to determine statistical significance. 
5.2.7 Immunohistochemistry of Nerve Conduit Sections and Analysis 
Sections were equilibrated in PBS for 10 minutes to remove OCT compound. They were 
then blocked for one 1 h at room temperature with 0.1% Tween-20, 4% Goat Serum (Gibco) in 
Tris buffered saline (TBS). Following this, primary antibody was applied in block solution and left 
on overnight. Slides were subsequently washed 3x with 0.1% Tween-20 in TBS wash buffer, and 
secondary was applied in 0.5% Triton X-100 in TBS for 1h at room temperature. Slides were then 
washed 3x with wash buffer. Lastly, DAPI stain mixed in 0.5% Triton X-100 in TBS was applied 
for 10 minutes. After drying, slides were mounted and coverslipped with Vectashield hardset 
aqueous mounting medium (Vector Laboratories, Burlingame, CA, USA). The following primary 
antibodies were used:  NF160 (1:250, mouse IgG1; Sigma), S100 (1:250, rabbit IgG; 
DakoCytomation), and Fluoromyelin Red (1:300, Invitrogen). The following secondary antibodies 
were used: goat anti-rabbit IgG Alexa 488/594/647 (1:220; Invitrogen) and goat anti-mouse IgG1 
Alexa 488/594/647 (1:220; Invitrogen). Slides were imaged with an Olympus inverted microscope 
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(IX81). To quantify Schwann cells and ASCs within cross-sections, aggregate fluorescent intensity 
or area was used as a surrogate. Within and between groups, exposure times and thresholding were 
kept consistent. Fluorescent channels were then analyzed using Fiji (ImageJ) applying over/under 
thresholding to limit analysis to the positive-staining areas. Myelin thickness and percent 
myelination was calculated using custom python code reported by Mokarram et al (56). Briefly, 
the algorithm designates myelination status if 40% or more of an axon is encircled by Fluoromyelin 
positive tissue. Myelin thickness is computed using a rotating vector that measures the thickness 
of the Fluoromyelin positive tissue. 
In addition to immunohistochemical analysis, 6-week explants were also analyzed 
qualitatively for cell infiltration and collagen production using Masson Trichrome stain (American 
Master Tech, Lodi, CA, USA) following the manufacturer protocols. Collagen stains blue and 
nuclei stains red.  
5.3 Results 
5.3.1 Multilayered Nanofibrous Nerve Conduits Possess Suitable Physical Properties for 
in Vivo Implantation 
A nerve guidance conduit had been previously engineered to possess suitable physical and 
biological properties for in vivo implantation [265]. The conduit had showed physical suitability 
for surgical manipulation and implantation. This included the ability to flex around physiologically 
relevant curvatures, retain patency after full compression, and adequate tensile suture retention 
strength. Lastly, as expected, conduits have a faster degrading GelMA component and slower-
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degrading PCL component to avoid conduit collapse during the regeneration process [265]. The 
conduit was also previously tested for biocompatibility. Cells implanted into the conduit increase 
metabolic activity over the course of 28 days, indicating proliferation and biocompatibility [265]. 
Given the importance of neurotrophic factors in nerve regeneration, it was found that the 3D 
scaffold design increased gene expression levels of BDNF and VEGF (two NTFs known to be 
produced by MSCs in abundance [247, 264]) and seeded cells produced neurotrophic factors that 
permeated through the scaffold.  
 
 
 
  
Figure 42: Implant and explant of nerve conduits 
(A) 1 cm of sciatic nerve was removed and (B) a 1.2 cm long nerve conduit was placed in 
the gap. (C) Proximal and distal ends of the nerve were sutured 1 mm into each end of the tube. 
(D) Gross morphology of conduit attached to nerve at 6 weeks. (E) Gross morphology of nerve 
conduit explant at 6 weeks. 
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5.3.2 Conduits with Wall-encapsulated Cells Improve Peripheral Nerve Regeneration 
The ability of the nerve conduit with PNM to effect functional recovery in sciatic nerve defect 
model was analyzed. Conduits were implanted allogeneically into Lewis rats in a 1 cm sciatic 
nerve defect model (Figure 42). Briefly, 1 cm of sciatic nerve was removed ( 42A) and a 1.2 cm 
long nerve conduit was placed in the gap ( 42B) Proximal and distal ends of the nerve were sutured 
1 mm into each end of the tube ( 42C). Gross morphology of conduit attached to nerve at 6 weeks  
42D). Gross morphology of nerve conduit explant at 6 weeks ( 42E). 
 Four groups were tested: conduits with or without wall-encapsulated cells in the central third of 
the conduit and with or without PNM10 hydrogel filler. Implanted conduits did not elicit a foreign 
body reaction, and at 6 weeks PNM10 plus cells produced a robust connective tissue bridge (Figure 
43).  
Longitudinal and transverse sections of conduits at the center, respectively. Blue stains for 
collagen while red stains nuclei. Note: the conduit itself also stains lightly blue. Control groups 
display a thin regenerating bridge through the conduit while cell and hydrogel + cell (combo) 
groups demonstrate much thicker regenerating bridges. Control and hydrogel conduits possess 
much less collagen production in their walls when compared to cell-containing groups, and it can 
be seen that cells do not infiltrate into the inner aligned layers of the conduit (evidenced by red 
staining only in the outer portion of the conduit walls) ( 43).  
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At 16 weeks post-surgery, the wall-encapsulated cell group (cell) and combination of wall-
encapsulated cells with PNM10 (combo) both presented with significantly higher sciatic functional 
index (SFI) when compared to control (p < 0.001) (Figure 44). In addition, the cell group also 
significantly increased SFI compared to the no-cell with hydrogel filler group (hydrogel) (p < 
0.05). The hydrogel vs. control and combo vs. hydrogel were both at the border of significance (p 
= 0.0627 and p = 0.0505, respectively).  
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Figure 43: Masson Trichrome staining of 6-week nerve conduit explants. (Top, Bottom) 
Longitudinal and transverse sections of conduits at the center, respectively. Blue stains for 
collagen while red stains nuclei. Note: the conduit itself also stains lightly blue. Control groups 
display a thin regenerating bridge through the conduit while cell and PNM + cell (combo) groups 
demonstrate much thicker regenerating bridges. Control and PNM conduits possess much less  
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collagen production in their walls when compared to cell-containing groups, and it can be seen 
that cells do not infiltrate into the inner aligned layers of the conduit (evidenced by red staining 
only in the outer portion of the conduit walls). 
 
 
 
 
Figure 44: Combination of centrally located wall-encapsulated ASCs and PNM improve 
functional return 
Sciatic functional index at 16 weeks for cell-free control (control), nerve conduits with 
ECM hydrogel lumen filler (hydrogel), nerve conduit with wall-encapsulated cells (cell), or nerve 
conduit with wall-encapsulated cells plus PNM hydrogel lumen filler groups (combo). *, p < 0.05. 
***, p < 0.001 compared to Control.  
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Lastly, axon myelination at 16 weeks was also assessed to correlate with functional 
outcomes (Figure 45). MSCs have been shown to increase myelination when applied in nerve 
conduits [193]. Figure 45A depicts representative images of neurofilament, myelin, and DAPI 
staining while Figure 45B displays the same images with only the myelin channel for better 
visualization (Scale: bar = 15 μm). Representative images of nuclear, axon, and myelin staining at 
distal end of conduit for cell-free control (control), nerve conduit with ECM hydrogel lumen filler 
(hydrogel), nerve conduit with wall-encapsulated cells (cell), or nerve conduit with wall-
encapsulated cells plus ECM hydrogel lumen filler groups (combo) are shown with NF-160 stain 
(green), Fluoromyelin (red), and DAPI (blue). At both the center of the conduit and 2 mm from 
the distal end of the transected nerve (Wallerian degeneration mainly affects the distal end of the 
nerve), the cell group possessed thicker axon myelination compared to control (p < 0.05) (Figure 
45C, D). The hydrogel group also exhibited increased myelination compared to control (*, p < 
0.05 compared to Control) (Figure 45C, D). Looking at percentage of myelinated axons, the 
hydrogel group displayed a significantly higher percentage over control (p < 0.05) (Figure 45E). 
The cell and combo group both had higher average myelination than control, but failed to reach 
statistical significance likely due to lack of power (p = 0.1361 and p = 0.0896, respectively) (Figure 
45E). Overall, nerve conduits with wall-encapsulated cells significantly enhance functional return 
and axon myelination in rats 16 weeks post-repair. 
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Figure 45: Conduits with centrally located wall-encapsulated ASCs improve axon 
myelination 
Representative images of nuclear, axon, and myelin staining at distal end of conduit for 
cell-free control (control), nerve conduit with ECM hydrogel lumen filler (hydrogel), nerve 
conduit with wall-encapsulated cells (cell), or nerve conduit with wall-encapsulated cells plus 
ECM hydrogel lumen filler groups (combo). Green channel is NF-160 stain, red is Fluoromyelin, 
and blue is DAPI. (B) Myelin staining from images in A for better visualization of myelin. (C) 
Myelin width at center of conduit. (D) Myelin width at distal end of conduit. (E) Percent 
myelinated axons in distal end of conduit. *, p<0.05 compared to Control. Scale bar = 15 μm. 
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5.4 Discussion 
In this study, PNM was combined with a nerve conduit harnessing cell-secreted 
neurotrophic gradient and its effect on the regenerative response of peripheral nerves was 
examined. A 1 cm sciatic nerve transection model in rats, implants with cells wall-encapsulated 
along the central third of the conduit length directed a stronger migration of Schwann cells into 
the center of the conduit compared to their counterparts with lumen-injected cells. This led to 
complete bridging of the conduit at 6 weeks by Schwann cells, and a significantly higher Schwann 
cell area in the center of the conduit compared to both cell-free conduits and conduits with lumen-
injected cells. At 16 weeks, rats with these wall-encapsulated cellular conduits presented with 
significantly increased sciatic functional index and axon myelination over controls. Furthermore, 
PNM increased the robustness of the connective tissue bridge and increased myelination over cell-
alone groups. Thus, the use of spatially controlled cell seeding to produce neurotrophic gradients 
presents a powerful strategy to maximize the potential of cell application in improving peripheral 
nerve regeneration.  
There have been many descriptions of neurotrophic factors in the MSC secretome that 
enhance nerve growth [193, 266]. This is further supported by observations that VEGF and BDNF, 
two growth factors found in high levels with these cell types, have been shown to significantly aid 
axonal extension [11, 192, 247, 264, 267]. In addition, our observations are in accordance with 
previous findings and suggest that wall-encapsulated cells exert their effects through neurotrophic 
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factor secretion rather than other processes such as transdifferentiation [268]. Utilizing a cell-
seeded conduit with cells located only in the walls along only the central third of the conduit, we 
sought to create a biomolecular gradient [250] of cell-secreted NTFs with the highest concentration 
in the center that decreased towards the ends of the conduit due to diffusion of NTFs (Figure 5). 
This pattern of cellular seeding led to a Gaussian distribution instead of the quadratic distribution 
observed with cell injection (Figure 5D, E). This gradient was enough to drive Schwann cells into 
the center of the regenerating nerve bridge.  
At week 16, conduits with both PNM alone and wall-encapsulated cells displayed enhanced 
functional return and axon myelination (Figure 45C). This increase in myelination is in accordance 
with observations that injected or seeded MSCs promote axon myelination [193]. Surprisingly, the 
presence of PNM lumen filler derived from decellularized peripheral nerve did not synergistically 
add to the capabilities of the cellular conduit. We hypothesize that this is because the hydrogel and 
cells both act through neurotrophic factor enhancement of nerve regeneration, such that the cell-
secretome induced migration of Schwann cells is not further augmented by the NTFs found in 
PNM.  
Through this study, we sought to examine the use of PNM hydrogel as a lumen filler for a 
nerve guidance conduit that was engineered for peripheral nerve repair. Results matched previous 
studies where PNM hydrogel was able to support the use of a conduit. Again, PNM enhanced 
morphologic, histologic, and functional aspects of peripheral nerve regeneration. In this study, 
PNM hydrogel alone did not outperform the conduit with seeded MSCs. However, the combination 
of the MSC-seeded conduits and PNM hydrogel produced interesting results and could be worth 
investigating further. Furthermore, PNM still represents an accessible and off-the-shelf 
augmentation to peripheral nerve repair. 
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6.0  Overall Summary and Conclusions 
Macrophages and Schwann cells play a key role in the conducting the early events after 
peripheral nerve injury. Throughout this dissertation we have investigated one strategy for 
improved functional improvement by utilizing the PNM to manipulate the microenvironment at 
the site of nerve repair to promote modulation of the host inflammatory response and promote 
Schwann cell (SC) migration and axon extension across the repair site (Figure 46). We have shown 
that this is an effective approach. Here we determined the effects of the PNM hydrogel on 
macrophage gene expression, phenotype and migration using a combination of Nanostring 
technology and immunohistochemistry. We also evaluate effects on SC migration, numbers of 
motor neurons reaching their target and axon extension using rat models of sciatic and common 
peroneal nerve injuries. Finally, functional recovery was determined after both sciatic crush injury 
and common peroneal and sciatic nerve transection associated with a short gap. Control groups 
including uninjured animals, exposure of the nerve without injury, transection and ligation without 
repair and injection of hydrogel in uninjured nerves were also performed (n = 8/group). Animals 
were followed for 12 weeks and assessed longitudinally using multiple measures of sensory and 
functional recovery. Metrics included von Frey nociception assay, sciatic functional index, and 
kinematic analysis. At 12 weeks animals were subjected to electrophysiologic assessment of 
evoked compound motor action potential prior to euthanasia for tissue collection and subsequent 
histologic analysis.  
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Figure 46: Graphical abstract of the use of PNM in augmenting peripheral nerve injury 
response 
 
 
 
PNM promoted expression of Platelet Derived Growth Factor and M2 (regenerative) genes 
including Chi313, Retnla and IL4ra. Macrophage, particularly M2, recruitment to the injury site 
was increased in rats (p < 0.05). PMN promoted SC migration both in vitro and in vivo (p < 0.05). 
Axon extension determined by extension of axons in a crush model and across an 8mm gap was 
increased in the presence of PNM compared with an empty conduit (p < 0.05).  
The amplitude of CMAP across the sciatic crush injury site, demonstrating axonal regrowth 
to the terminal muscle was increased by 50% compared to control following intraneural injection 
of PNM 12 weeks after nerve crush. Furthermore, CMAP amplitude was increased by 70% in an 
8 mm gap in the presence of PNM compared with an empty conduit (p < 0.05).  
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These results demonstrate that an injectable, peripheral nerve matrix hydrogel derived from 
porcine sciatic nerve can modulate the response of two key cell types which conduct the early 
response to nerve injury. The present dissertation does not attempt to investigate the mechanisms 
by which the injectable ECM promote these phenomena; however, a recent study has described 
M2 macrophage mediated angiogenesis as a mechanism leading to Schwann cell chemotaxis and 
downstream regeneration [181]. However, though the exact mechanisms are not clear, these results 
link these phenomena to functional improvements downstream and suggest that PNM has the 
possibility to be used as a tool for improving nerve repair.  
However, this dissertation was not without limitations, including the limited comparison 
to non-nerve specific ECM, several underpowered animal studies, and weakness of functional 
metrics assessed. In composition and in vitro assays, PNM was compared to UBM and SIS. 
Differences were observed in many of these experiments and these differences suggested that PNM 
would perform better in an animal model of peripheral nerve injury. However, this dissertation did 
not include either SIS or UBM in the majority of subsequent animal studies. UBM was only 
included with a large animal pilot study of recurrent laryngeal nerve transection and re-
anastomosis repair. In this study, both PNM and UBM showed a similar trend towards improved 
recovery but little to no difference was observed between the two ECM sources. Future work could 
examine the use of non-nerve specific ECM hydrogels in nerve defect repair further. This work 
could elucidate the effect of nerve specific components from the general effect of having any 
extracellular matrix present. Furthermore, the inclusion of a simple collagen type I hydrogel as a 
control would further provide evidence that PNM provides a specific benefit. 
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Chapter 4 of this dissertation focused on measuring return to function after peripheral nerve 
injuries. The studies incorporated several different measures of function including functional 
indexes, nociceptive withdrawal reflex testing, gait kinematics, and electrophysiology. This was 
meant to capture a full picture of nerve function while covering for limitations of single 
measurements. While we were able to make some conclusions from these experiments, we found 
that the indexes, nociceptive withdrawal reflex testing, gait kinematic measures of function were 
limited by a number of factors that limited the utility of these tests. We still found the motor 
function test valuable to understand the impact that the PNM treatment had on downstream 
function but do not believe that these tests were indicative of the full effect that PNM had on the 
regeneration after injury. The most accurate measures of regeneration are the histology and axon 
counts of the regenerating axons and secondly the electrical conduction of the nerve axons to the 
downstream muscles measured through CMAP electrophysiology. 
To this point, PNM has yet to be combined with an FDA approved conduit and has only 
been investigated minimally in combination with other regeneration strategies. For the majority of 
nerve defect models, an inert nerve guidance conduit made from silicone was used. PNM was 
shown to improve outcomes when combined with this inert silicone conduit but did not exceed the 
nerve autograft in all studies. Current data suggests that PNM can improve the outcomes of all 
nerve guidance conduits when used as a lumen filler. Studies that compare the autograft repair to 
the use of PNM as a lumen filler for FDA approved conduits are needed. Furthermore, present 
studies showed an increased rate of regeneration during the first month after crush and transection 
injuries. Evidence suggests that this ECM hydrogel might only remain within the conduit for the 
first 1-2 weeks [97, 162, 269]. One possible future direction could be the additional 
supplementation of PNM to the injury site after the first month to boost regeneration. This process 
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would use already established techniques as well as developing new practices for using image-
guided injection of the PNM hydrogel through the skin to refill the nerve guidance conduit. In 
addition, these techniques could be used to further investigate the injection of PNM directly into 
the nerve tissue to lead the nature regeneration as it regrows back through the distal end of the 
nerve. 
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Appendix A. Abbreviations Used 
A 
B 
BDNF (brain derived neurotrophic factor) 
bFGF (basic fibroblast growth factor) 
BM (Bone Marrow) 
BMSC (Bone Marrow Stromal Cells) 
BSA (Bovine serum albumin) 
C 
cm (Centimeter) 
CNS (Central Nervous System) 
C-NT (crush without treatment) 
C-PNM (crush with PNM injection) 
D 
DNA (Deoxyribonucleic acid) 
DNAse (Deoxyribonuclease) 
DO-PNM (dissection down to nerve and 
PNM injection into healthy nerve) 
DRG (Dorsal Root Ganglion) 
E 
ECM (Extra Cellular Matrix) 
EMG (Electromyography) 
EVA (Ethylene-vinyl acetate) 
F 
FDA (Food and Drug Administration) 
G 
GAG (glycosaminoglycans) 
GDNF (Glial derived neurotrophic factor) 
GFAP (Glial Fibrillary Acidic Protein) 
H 
h (Hours) 
HCT/P (Human Cellular and Tissue-based 
Product) 
I 
IL-1 (Protein) 
K 
kg (Kilograms) 
L 
M 
mg (Milligram) 
min (Minute) 
mm (Millimeter) 
MMP (metalloproteinases) 
MSC (Mesenchymal Stem Cells) 
N 
NFs (Neurotrophic Factors) 
NGF (Nerve Growth Factor) 
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NI (No injury or surgery) 
NIH (National Institutes of Health) 
NT-3 (Neurotrophin-3) 
NT-4 (Neurotrophin-4) 
P 
p (P-Value) 
PCL (Poly(DL-Lactide-E-Caprolactone)) 
PDGF-β (Platelet derive growth factor β)  
PGA (Polyglycolic Acid) 
PHB (polyhydroxybutyrate) 
PhD (Doctorate) 
PHEMA-MMA 
(Polyhydroxyethylmethacrylate) 
PI (Principle Investigator) 
PLGA (Polylactic-co-glycolic acid) 
PNM (Peripheral nerve matrix) 
PNM10 (PNM hydrogel at 10 mg/mL 
concentration) 
PNM20 (PNM hydrogel at 20 mg/mL 
concentration) 
PNM40 (PNM hydrogel at 40 mg/mL 
concentration) 
PNS (Peripheral Nervous System) 
R 
R&D (Research and Development) 
RNA (Ribonucleic acid) 
S 
s (Second) 
S-100 (low molecular weight Protein) 
SC (Schwann Cells) 
SD (Sodium deoxycholate) 
SDS (sodiumdodecyle sulfate) 
Sham/DO (dissection down to nerve without 
injury) 
SIS (Porcine Small Intestinal Submucosa) 
T 
T-NT (transection and ligation) 
TS (Toe-spread Test) 
U 
UBM (Urinary bladder matrix) 
V 
VEGF (Vascular Endothelial Growth Factor) 
μm (Micrometer) 
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Appendix B. Programing Code 
B.1 Matlab Code 
B.1.1 MatLab Code Used to Process SFI from Photographs of Ink Footprint Impressions. 
 
cont=1; 
    if exist('sciaticfunctionalindex')==0 
    sciaticfunctionalindex=zeros(40,9); 
    sciaticfunctionalindex=double(sciaticfunctionalindex); 
    count=1; 
    end 
r=0; 
timepoint=input('Please input timepoint week: ','s'); 
filename= strcat('SFI_rodentfunction_wk',timepoint) 
timepoint=str2num(timepoint); 
while cont==1; 
    
imagename = uigetfile('.jpg'); 
  
  
    
  
  
A = imread(imagename); 
  
image(A) 
    number=input('Please input animal number: '); 
standardlength=1; 
  
disp('Please measure experimental 3rd toe to heel'); 
EPL=imdistline(); 
pause; 
centertoeheeldistance = getDistance(EPL); 
centertoeheeldistance = centertoeheeldistance/standardlength; 
  
disp('Please measure normal 3rd toe to heel'); 
NPL=imdistline(); 
pause; 
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ncentertoeheeldistance = getDistance(NPL); 
ncentertoeheeldistance = ncentertoeheeldistance/standardlength; 
delete(EPL); 
delete(NPL); 
  
  
disp('Please measure experimental first to 5th toe'); 
ETS=imdistline(); 
pause; 
outertoedistance = getDistance(ETS); 
outertoedistance = outertoedistance/standardlength; 
  
disp('Please measure normal first to 5th toe'); 
NTS=imdistline(); 
pause; 
  
noutertoedistance = getDistance(NTS); 
noutertoedistance = noutertoedistance/standardlength; 
delete(ETS); 
delete(NTS); 
  
  
disp('Please measure experimental 2nd to 4th toe'); 
EIT=imdistline(); 
pause; 
innertoedistance = getDistance(EIT); 
innertoedistance = innertoedistance/standardlength; 
  
disp('Please measure normal 2nd to 4th toe'); 
NIT=imdistline(); 
pause; 
ninnertoedistance = getDistance(NIT); 
ninnertoedistance = ninnertoedistance/standardlength; 
delete(EIT); 
delete(NIT); 
  
% disp('Please measure direction of travel (first heel to last heel of one foot)'); 
% wa=imdistline(); 
% pause; 
% walkingangle=getAngleFromHorizontal(wa); 
%  
% disp('Please measure experimental deviation angle'); 
% efa = imdistline(); 
% pause; 
% EDA=getAngleFromHorizontal(efa) 
% EDA=abs(abs(walkingangle)-abs(EDA)) 
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%  
%  
% disp('Please measure normal deviation angle'); 
% nfa = imdistline(); 
% pause; 
% NDA=getAngleFromHorizontal(nfa) 
% NDA=abs(abs(walkingangle)-abs(NDA)) 
%             if NDA>90 
%                 NDA=180-NDA 
%             end 
%             if EDA>90 
%                 EDA=180-EDA 
%             end 
%              
%             EDA=EDA*0.0174533 
%             NDA=NDA*0.0174533 
SFI=38.3*((centertoeheeldistance-
ncentertoeheeldistance)/ncentertoeheeldistance)+109.5*((outertoedistance-
noutertoedistance)/noutertoedistance)+13.3*((innertoedistance-
ninnertoedistance)/ninnertoedistance)-8.8 
% PFI=-
63.58*(centertoeheeldistance)+88.98*outertoedistance+26.55*ncentertoeheeldistance+(328.34*(
EDA)-265.02*NDA)-7.95 
question=input('Do you want to continue (y/n): ','s'); 
if strcmp(question,'n'); 
    cont=0; 
end 
  
sciaticfunctionalindex(count,:) = 
[number,timepoint,SFI,centertoeheeldistance,ncentertoeheeldistance,outertoedistance,noutertoedi
stance,innertoedistance,ninnertoedistance] 
count=count+1; 
end 
  
  
save (filename,'sciaticfunctionalindex'); 
B.1.2 MS Amplitude from CMAP Analysis RMS Amplitude from CMAP Analysis 
addpath 'C:\TDT\OpenEx\Examples\TTankX_Example\Matlab\'; 
  
tank = 'C:\TDTData\Travis'; 
block_prefix = '2017_09_12_R6'; 
blocks = {'-1', '-2','-3','-4','-5','-6','-7','-8','-9','-10','-11','-12','-13','-14','-15','-16','-17','-18','-19'}; 
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stim_amp = [0.04 0.05 0.06 0.07 0.08 0.09 0.1 0.5 0.6 0.7 0.8 0.9 1 0.2 0.3 0.4]; 
  
emg_blocks = []; 
for j=1:length(blocks) 
    block = [block_prefix blocks{j}]; 
  
    data = TDT2mat(tank,block); 
  
    estim = data.streams.EWav.data; 
    emg_wav = data.streams.EMG_.data(1,:)*1000/20; 
  
    fs = data.streams.EMG_.fs; 
    t = (0:length(estim)-1)/fs; 
  
    stimon = diff(estim)>1; 
    stiminds = find(stimon); 
  
    pre_t = 0; 
    post_t = 5000; 
  
    emg_snip = []; 
    emg_rms = []; 
    for i=1:length(stiminds) 
        emg_snip(i,:) = emg_wav(1,stiminds(i)-pre_t:stiminds(i)+post_t); 
        emg_rms(i) = sqrt(mean(emg_wav(1,stiminds(i)-pre_t:stiminds(i)+post_t).^2)); 
    end 
    emg_blocks(j).emg_snip = emg_snip; 
    emg_blocks(j).emg_rms = emg_rms; 
    emg_blocks(j).emg_wav = emg_wav; 
    emg_blocks(j).estim = estim; 
    emg_blocks(j).fs = fs; 
    emg_blocks(j).t = t; 
    emg_blocks(j).mean_emg_rms = mean(emg_rms); 
  
    snip_t = (-pre_t:post_t)/fs; 
    figure;plot(snip_t,emg_snip') 
    title(['EMG Snippets, ' num2str(stim_amp(j)) ' mA']) 
    xlabel('Time (s)') 
    ylabel('EMG (mV)') 
end 
 Figure;plot(stim_amp,[emg_blocks.mean_emg_rms],'bo') 
title('Mean EMG RMS vs. Stim Amplitude') 
xlabel('Stim Amp (mA)') 
ylabel('EMG RMS (mV)'); 
  
save([block_prefix '.mat'], 'emg_blocks') 
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